Studies into Amphetamine-Induced Unconditioned Behaviour in the Rat. by McHale, Susan Lesley


LIBRARY STORE 
This copy of the thesis has been supplied on condition that anyone 
who consults it is understood to recognise that its copyright rests 
with its author and that no quotation from the thesis and no 
information derived from it may be published without the author's 
prior written consent. 

studies into Amphetamine-Induced Unconditioned Behaviour 
in the Rat. 
by 
Susan Lesley l\/icHale 
A thesis submitted to the University of Plymouth in partial fulfilment for the degree of 
DOCTOR OF PHILOSOPHY 
Department of Psychology 
Faculty of Human Sciences 
S e p t e m b e r 1994 ^ ' \ 
90 0219737 X j 
L- 1 tri,; i'ij,,?rirLri;;'';wr^i;v»r:r.i*wri'j^'™i 
UNiVERSITY OF PLYMOUTH 
LIBRARY SPVIOMS 
Item 
No. 
Class 
No. -r U S ' ? ? i^t^' 
Contl. 
No. 
Studies into Amphetamine-Induced Unconditioned 
Behaviour in the Rat. 
Susan Lesley McHale. 
Abstract. 
Previous worl< on the unconditioned effects of amphetamine in rats has 
examined qualitative changes in behaviours which become stereotyped and 
quantitative changes in locomotion. Stereotyped behaviours have been adopted as a 
model of raised caudate-putameri function whilst locomotion has been adopted as a 
model of raised mesolimbic dopamine function. These models have been used to study 
drugs which are effective in the treatment of schizophrenia. Only locomotion is 
reliably antagonised by all classes of antipsychotic drugs, although it has been 
hypothesised that, under some doses of amphetamine, locomotion may also become 
stereotyped. The Lyon-Robbins hypothesis of the behavioural effects of amphetamine 
predicts competition between the output of the mesolimbic and caudate-putamen, and 
would predict that stereotyped locomotion represents a 'blending' of mesolimbic and 
caudate-putamen behavioural output. 
An experiment was conducted to test the Lyon-Robbins hypothesis using 
contrast-based image analysis to determine the spatio-temporal characteristics of 
open-field locomotion. A further four experiments examined the effects of a classic 
antipsychotic (haloperidol), the atypical antipsychotics (clozapine and sulpiride) 
and a putative antipsychotic (a 5-HT3 antagonist, ondansetron) on open-field 
locomotor routes taken by rats following treatment with 3.5mg/kg amphetamine. 
Measures of stereotyped locomotion derived from image analysis were 
supported by a novel form of behavioural analysis based on multi-dimensional 
scaling which provided an integrated analysis of behavioural change following drug 
treatment. Haloperidol blocked locomotion and stereotyped behaviours including 
stereotyped locomotion, whereas clozapine, sulpiride and ondansetron blocked 
locomotion but not stereotyped locomotion and in some cases increased stereotyped 
behaviours. This suggests that stereotyped locomotion represents synergistic 
functioning of both mesolimbic and caudate-putamen systems, when the output from 
the caudate-putamen is insufficient to over-ride that of the mesolimbic system. 
Antagonism of a 5-HT3 enhancement of mesolimbic locomotor activity by ondansetron 
allowed latent 5-HT and dopamine mediated behaviours to be expressed. This 
effectively mimicked a leftwards shift of the amphetamine dose response curve, 
hypothesised as amplification of the caudate-putamen output. These findings lend 
support to the Lyon-Robbins hypothesis of the behavioural effects of amphetamine. 
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Chapter One 
Introduction 
Preface 
Animal experiments on the functional correlates of brain dopaminergic 
transmission have resulted in the rapidly growing area of psychopharmacology. 
The use of specific and selective chemical agents to manipulate normal brain 
function has provided the basis for research into dopamine and the changes in 
behaviour that result from this selective interference. Animal models based on 
these manipulations has been of great value in the development of new drugs for 
the treatment of Parkinsonism and schizophrenia. 
Studies into the treatment of schizophrenia have examined the antagonism 
of amphetamine-induced behaviours in animals as a model of raised striatal and 
mesolimbic dopamine function to study the underlying mechanisms of 
antipsychotic drug treatment, and to detect novel antipsychotic agents. 
In the past attention has focused on amphetamine-induced behaviours such, 
as sniffing, licking and gnawing because these behaviours are reliably antagonised 
by classic antipsychotics used in the treatment of schizophrenia, such as 
haloperidol and chlorpromazine (Szechtman et al. 1988). However, it is now 
clear that a group of clinically effective drugs - so-called atypical antipsychotics 
- do not antagonise all the components of the amphetamine syndrome. Both classic 
and atypical antipsychotics share the ability to antagonise amphetamine-Induced 
hyperactivity, and this rtiay form the basis of a more appropriate test for 
antipsychotic potential (Rebec and Bashore, 1984; Ljungberg and Ungerstedt, 
1 9 8 5 ) . 
The development of a model based on amphetamine-induced increases in 
locomotion (so-called hyperactivity) may not adequately address the problem of 
providing a clear, well defined animal model for antipsychotic drug screening, as 
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all aspects of this amphetamine-induced behaviour have not been adequately 
investigated. To date much of the characterisation of drug effects on locomotor 
activity in rats is based solely on quantitative increases and pays scant regard to 
the qualitative changes which occur. It has been known for some time that 
locomotion may have stereotyped characteristics under some doses of 
amphetamine therefore the development of a model which incorporates the spatio-
temporal changes in locomotion which occur following treatment With 
amphetamine may provide better insight into the underlying mechanisms of 
antipsychotic drug action, and the amphetamine response in rats. Such a model 
may also be better able to discriminate effective antipsychotic agents including 
those that may act via different mechanisms than the dopamine antagonists already 
identified. This research programme sets out to examine the nature of the 
qualitative changes which occur following administration of amphetamine and the 
way in which antipsychotic drugs acting via several different mechanisms behave 
within the model system. 
This introductory chapter considers amphetamine-induced behaviours 
from a broad historical perspective and discusses some of the unresolved problems 
which have led to the current series of experiments. Initially, I will describe the 
nature of schizophrenia and the dopamine hypothesis of this disease, which 
suggests that dopaminergic over-activity is an inherent feature of schizophrenia. I 
shall examine the role that amphetamine has played in this theory, which although 
by no means unequivocal, has dominated scientific enquiry since its formulation 
by Randrup and Munkvad in 1965. I will then turn to the role amphetamine has 
played in the formulation of animal models of this illness, a difficult task in view 
of the fact that the major manifestations of the disease are those related to 
dysfunction of thought and information processing. I will examine the nature of the 
behaviour exhibited by rats treated with amphetamine, and the manner in which 
these behaviours have helped to identify some of the underlying mechanisms 
relating to the biochemistry and morphology of dopamine neurotransmission in rat 
brain, whilst at the same time providing much of the paradox inherent in the 
dopamine theory of schizophrenia. In particular I shall examine stereotyped 
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behaviours, which in addition to being induced after centrally active stimulant 
drug administration, are also present in clinical conditions. I will propose that far 
from being a convenient way in which to categorise the effectiveness of stimulant 
drugs, stereotyped behaviours induced after drug administration - when 
adequately investigated - have the capacity to provide rich information with 
regard to. the function of brain systems and the organisation and manifestation of 
behaviour. Finally it is suggested that hyperlocomotion induced after amphetamine 
administration has stereotyped properties and the study of this behaviour in ' 
greater depth will provide a powerful model which will support and develop an 
understanding of the theoretical issues arising from the effects of stimulant drugs 
on behaviour, and in addition provide a better model for selecting new drugs for 
the treatment of schizophrenia, perhaps acting via different mechanisms from 
those drugs already in use. 
1.1 Schizophrenia: Disease and Treatment 
The diagnosis of schizophrenia has existed for over a century and the 
massive and extreme disruptions of thoughts, perceptions, emotions and behaviour 
manifest in this disease are the epitome of what we perceive to be 'madness'. Of ajl 
the psychiatric disorders it is perhaps the most interesting and elusive in terms 
of gaining an understanding of the underlying mechanisms of this extremely 
complex disorder. 
Schizophrenia is the most common of the psychoses, afflicting 
approximately 1 percent of the population. The concept of schizophrenia proposed 
by Kraeplin (1913), which he termed dementia praecox, had at its core psychotic 
symptoms such as delusions and hallucinations. Since this original definition the 
concept has gradually broadened. Bleuler (1911), in contrast to Kraeplin's 
emphasis on a deteriorating course of the illness, emphasised the importance of a 
variety of symptoms and stressed those that were on a spectrum with normality, 
such as ambivalence in thoughts and emotions, and abnormalities of affect. Bleuler 
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reduced the emphasis on psychotic symptonis and expanded the definition to include 
latent and non-psychotic forms. The resulting over-diagnosis of schizophrenia in 
the United States led to an attempt to redefine the concept of schizophrenia in the 
DSM IIIR (1987) classification which removed schizoaffective disorder and latent 
and non-psychotic forms from the definition, in addition to requiring the 
symptoms to persist for longer than 6 months, with a deterioration in 
functioning. 
At our current level of understanding, schizophrenia is characterised by a 
multiplicity of symptoms that represent a broad range of cognitive dysfunctions. 
Patients with schizophrenia suffer from dysfunction of perception, attention, 
communication, affect, cognition and motor function. The clinical 'perspective' can 
be very different over a broad range of patients, and the disease Is characterised 
by a clustering of symptoms, none of which are specific to the disorder, or 
necessarily all present in any one patient, or any one time or indeed over the 
course of the illness (see Andreasen, 1987). 
In an attempt to define schizophrenic symptoms in a more coherent manner 
several attempts have been made to group symptoms together in a logical and 
meaningful manner and currently the classification which has gained most support 
is to place the symptoms into two major groups: positive symptoms which include 
abnormality, distortion or exaggeration of normal functioning and include 
delusions and hallucinations and abnormalities in language and behaviour, and 
negative symptoms which represent a deficit or loss of function and include such 
features as poverty of speech and content (alogia), affective blunting, anhedonia 
and loss of will (Andreasen, 1983, 1985). There is some evidence to suggest that 
positive symptoms occur more frequently in the early stages of schizophrenia, 
whereas negative symptoms are more prevalent in the later stages and are 
persistent (Pfoh and Winokur, 1982, 1983). 
The discovery of the antipsychotic effect of chlorpromazine (Delay et al, 
1952) heralded the beginning of modem psychopharmacology and a new 
understanding of the mechanisms and aetiology of schizophrenia. Antipsychotic 
drugs are primarily effective against the positive symptoms and are much less 
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effective against the negative symptoms of schizophrenia (see Tamminga and 
Gerlach, 1987). There are also some patients with positive symptoms who are 
refractory to treatment with these drugs. The greatest problem posed by long-
term treatment with antipsychotic drugs is the induction of unwanted side-effects. 
Many of the antipsychotics produce sedation, but this effect does not account for 
the symptom remission they produce, as other sedative drugs eg the 
benzodiazepiries, barbiturates and antidepressants, are not clinically effective 
antipsychotic agents. 
Other side effects are collectively called the extrapyramidal syndrome 
(EPS) as they are similar to symptoms seen with dysfunctions in the 
extrapyramidal system of the brain (the caudate nucleus, the putamen and the 
globus pallidus). The symptoms include motor restlessness, rigidity and tremor 
similar to that seen in Parkinson's disease, as well as muscle spasms and loss of 
muscle tone. These side effects occur in approximately 50% of patients and like 
Parkinson's disease can be treated with anticholinergic agents, which do not reduce 
the clinical effectiveness of antipsychotic drugs. During long term treatment a 
chronic, disfiguring and often permanent movement disorder known as tardive 
dyskinesia may develop in 10-15% of patients (see Casey 1987). 
A newer class of antipsychotic drugs have been classified as 'atypical' as 
they retain antipsychotic action with a relative absence of E P S . These include the 
substituted benzamides eg sulpiride and the dibenzazepines eg clozapine which 
despite having a low incidence of EPS has many side-effects, notably sedation, 
cardiovascular effects and in some patients a pathological state in which there is a 
marked decrease in the number of granulocytes in the blood known as 
agranulocytosis (see Levinson and Simpson 1987). 
The dopamine hypothesis of schizophrenia came into existence primarily as 
a result of increased understanding of the mechanisms of action of antipsychotic 
drugs. 
1.2 The Dopamine Hypothesis of Schizophrenia 
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The dopamine hypothesis of schizophrenia is based almost entirely on 
pharmacological evidence, and a disturbed dopamine function has not yet been 
established beyond doubt in schizophrenia. It is hypothesised that enhanced 
cerebral dopaminergic activity exacerbates the symptoms of schizophrenia whilst 
a reduction in dopaminergic activity is associated with an amelioration of the 
illness. The hypothesis is supported by two lines of pharmacological evidence; 
dopamine receptor antagonists are often effective antipsychotics whereas dopamine 
agonists induce psychosis in non-psychotic subjects and are known to exacerbate 
psychosis in schizophrenic patients (Youngs and Scoville, 1938). 
Psychosis associated with the use of amphetamine, an indirect dopamine 
agonist, was first describied by Youngs and Scoville (1,938). With increasing 
recreational use of amphetamine in the 1950s cases of amphetamine psychosis 
increased and Connell (1958) proposed that the clinical features of amphetamine 
psychosis were indistinguishable from acute or chronic schizophrenia. Ellinwood 
(1967) provided a detailed behavioural description of amphetamine psychosis in 
humans. In addition amphetamine was shown to induce paranoid delusions in an 
experimental setting (Griffith et al, 1968) and large doses were able to induce 
hallucinations and thought disorder in addition to paranoia (Angrist et al, 1974) 
This work provides the most convincing parallel of the two conditions. Further 
evidence was provided by the fact that small doses, which failed to induce psychotic 
symptoms in normal volunteers, intensified existing psychotic symptoms in 
patients with schizophrenia (Davis, 1974; Segal and Janowsky, 1978). Although 
a major premise of the dopamine hypothesis of schizophrenia is that dopamine 
agonists induce psychotic states which resemble schizophrenia, the evidence is not 
conclusive. There are reports that some volunteers given high doses of 
amphetamine do not develop psychotic symptoms (Kornetsky, 1976), and 
paradoxically, chronic schizophrenics maintained on neuroleptics may show 
additional improvement if L-dopa is administered concurrently (Flemming et al, 
1970), such a response to L-dopa seems incompatible with the dopamine 
hypothesis of schizophrenia. The preponderance of delusions and hallucinations in 
amphetamine psychosis are visual and tactile, whereas In schizophrenia, auditory 
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hallucinations seem to be more common. As visual hallucinations are prevalent in 
unrelated drug states and fever this has led some researchers to suggest that 
amphetamine psychosis is merely a toxic drug response (see Jenner et al, 1989). 
Slater (1959) and Bell (1965) put forward the view that amphetamine psychosis 
can be distinguished from schizophrenia on three criteria: a lack of thought 
disorder; frequency of visual hallucinations; and quick affective response, 
although Angrist and Gershon (1970) describe auditory hallucinations and formal 
thought disorder in some of their amphetamine treated volunteers. Despite 
reservations, these observations and experimental findings have provided one of 
the major foundations for the dopamine theory of schizophrenia and encouraged the 
study of amphetamine in laboratory animals. 
Amphetamine is known to release the catecholamines dopamine and 
noradrenalin from nerve terminals and to inhibit reuptake processes. Biochemical 
tools (eg. alpha-methyl-para-tyrosine and dopamine B-hydroxylase) have lacked 
the sensitivity to examine the relative action of dopamine or noradrenalin in the 
behavioural effects of amphetamine (see review by Moore, 1978). Observation of 
the uptake of the d- and l-isomers of amphetamine in the cerebral cortex 
synaptosomes, rich in noradrenalin compared with striatal synaptosomes 
predominantly dopamine initially suggested that the d-isomer was 10 times more 
potent than the l-isomer in blocking catecholamine uptake into cerebral cortex 
synaptosomes (Taylor and Snyder, 1971), indicating that behaviours mediated by 
noradrenalin should be more affected by the d-isomer. Failure to replicate these 
findings (Harris and Baldessarini, 1973; Holmes and Ruttledge, 1976) eroded 
what originally seemed to be a clear pharmacological tool for determining the 
catecholamine system responsible for mediating certain behaviours. Lesion studies 
have played an important role in defining the roles of dopamine and noradrenalin 
in the amphetamine response. Results from lesion studies examining the'running 
behaviours' following administration of low doses of amphetamine and the 
stereotyped motor responses seen following higher doses have indicated that there 
is strong evidence that dopamine rather than noradrenalin is involved (see 
Iversen, 1986). These studies implicating the role of dopamine in both locomotor 
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and stereotyped behaviours will be discussed later in greater detail (see section 
1.4). 
The second line of evidence to support the dopamine hypothesis of 
schizophrenia is the action of dopamine antagonists. The mechanism of action 
common to effective antipsychotic drug action is thought to be dopamine receptor 
blockade, usually at the post-synaptic receptor sites (Carlsson and Lindquist, 
1963). It is now accepted that there are several dopamine receptor subtypes, a 
distinction being made between DI 'type' linked to adenylate cyclase and D2 'type' 
Inhibitory or not coupled to adenylate cyclase (Kebabian and Calne, 1979; Left and 
Creese, 1983). It is widely believed, but by no means universally accepted, that 
the effect of antipsychotic drugs result from D2 receptor blockade. This is based 
on evidence that a significant correlation exists between the therapeutic potency of 
antipsychotic drugs and their relative ability to inhibit dopamine release and 
displace radiolabelled haloperidol from dopamine receptor binding sites in vitro 
(Seeman et al, 1976) and specifically for the D2 receptor (Creese, Burt and 
Snyder, 1978). The majority of antipsychotic dopamine receptor antagonists show 
a higher affinity for D2 sites (Carlssdn, 1988). Recent positron emission 
tomography (PET) scan studies have demonstrated that a large number of 
antipsychotic agents with varying chemical structure, given to schizophrenic 
patients at therapeutic doses, caused displacement of the highly selective 
dopamine D2 receptor ligand raclopride from striatal binding sites (Farde et al , 
1988). The regional localisation of mRNA for the D2 receptor has been determined 
by histochemical methods and the areas of highest expression correspond to major 
dopamine projection areas such as the caudate-putamen, nucleus accumbens and 
the olfactory tubercle. D2 receptor mRNA is also found in the dopaminergic cell 
bodies within the substantia nigra and ventral tegmental areas, indicating a pre­
synaptic, as well as a post-synaptic, role for the D2 receptor. It is also clear that 
drugs interfering with the function of dopamine in other ways have antipsychotic 
properties. Drugs which cause depletion of dopamine from transmitter stores (eg 
reserpine) are effective antipsychotic agents, and drugs which inhibit the rate-
limiting step in dopamine synthesis (eg alpha-methyl-para-tyrosine), have been 
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shown to potentiate the antipsychotic action of receptor blocking antipsychotic 
drugs (Carlsson, 1987). 
Until the introduction of specific DI agonists and antagonists it was thought 
that the DI receptor had no behavioural function (Laduron, 1983; Seeman, 1980; 
Creese et al, 1983). This is no longer thought to be the case, there is now 
convincing evidence that the two receptor types cooperate and that a 'complete' 
behavioural dopaminergic response requires activation of both receptor types (see 
Longini et al , 1987). 
Although pharmacological evidence for a role of dopamine in schizophrenia 
is convincing, the evidence for dopamine dysfunction in this disease has not been 
shown. Post-mortem analysis of brains of patients suffering from chronic 
schizophrenia have shown an increased number of D2 receptors. It is unclear 
whether this increase is the result of antipsychotic drug treatment, or a primary 
effect of the disease (Henn, 1987). The data from PET scan studies has provided 
contradictory evidence. Farde et al, (1987) found no difference in D2 density 
between drug-naive schizophrenics and age-matched controls, whilst Wong et al, 
(1986) claim to have observed an increase in D2 receptors in drug naive 
schizophrenics. 
It has been established that changes in the firing rates of dopamine 
neurons, either electrochemically or pharmacologically, are correlated with local 
changes in the major extracellular dopamine metabolite, homovanilic acid (HVA) 
(Post et al , 1975). Attempts to discover differences in cerebrospinal fluid (CSF) 
HVA levels between groups of schizophrenia patients and normal control subjects 
have largely resulted in negative findings (Berger et al, 1980; Bowers 1973; 
Post et al, 1975) although, high C S F HVA has been found in schizophrenics with a 
family history of schizophrenia (Sedvall and Wode-Helgodt, 1980). As the 
majority of centrally produced HVA appears to originate in the nigrostriatum, 
especially the caudate (Portig and Vogt 1968; Wood 1980), this method may be 
unable to detect overactivity of dopamine systems in other areas of the brain. 
Another source of information concerning dopamine activity is measures of plasma 
HVA (pHVA) levels. Administration of dopamine receptor agonists or antagonists 
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produce parallel changes in brain HVA and pHVA in primates and rodents (Kendler 
et al, 1981, 1982). Unmedicated severely ill schizophrenic patients have been 
shown to, have higher pHVA concentrations than less severely ill patients (Davis et 
a l , 1985). 
Currently dopamine is the main target for both typical and atypical 
antipsychotic treatment, although dysfunction of other neurotransmitter systems 
is postulated as taking a role in schizophrenia. The majority of these suggestions 
have evolved from the dopamine theory of schizophrenia which has provided, over 
the last thirty years, a useful working hypothesis to explain the symptoms of the 
disease but has not fulfilled its promise in providing convincing explanations of 
the aetiology of schizophrenia. Because the cost of drug development remains high 
it remains all the more difficult to test drugs dependent on novel non-
dopaminergic principles. 
Amphetamine is known to release noradrenalin as well as dopamine, 
although lesions to the forebrain noradrenalin pathway did not block the motor 
effects of amphetamine (Creese and Iversen 1975). Iversen herself claims that 
'one cannot feel entirely confident in ruling out a component of noradrenalin 
dysfunction in schizophrenia' (Iversen 1986, p 91).' 
Serotonin (5HT) is found in high concentrations in dopamine terminal 
areas of the brain. Cell bodies containing 5HT are found clustered in the midline 
region of the pons and upper brain stem and the raphe nuclei, from where they 
ascend to innen/ate the basal ganglia, hypothalamus, thalamus, hippocampus, 
limbic forebrain and neocortex, and also the cerebellum. Prior to the dopamine 
hypothesis, serious consideration was given to the possibility that abnormal 5HT 
activity was involved in schizophrenia (Gaddum 1954, Woolley and Shaw 1954).. 
More recent evidence suggests that serotonin may indeed be involved, as raised 
5HT turnover has been found in familial schizophrenia (Sedvall 1980). "In 
addition, Leysen et al, (1978) reported that some antipsychotics act as 
antagonists at 5-HT receptors as well as dopamine receptors. Clozapine, for 
example, is a potent 5-HT2 antagonist, but a weak D2 antagonist, a profile which 
is claimed lowers E P S liability (see Meltzer, 1988). It has also been shown that 
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5-HT3 antagonists inliibit dopamine release in the nucleus accumbens (Imperato 
and Angelucci, 1989, Carboni et al, 1989a), and block nicotinic or morphine-
induced place preference which has been shown to depend on mesolimbic dopamine 
systems (Carboni et al, 1989b), since these systems may be involved in 
psychosis, it is speculated that 5-HT3 antagonists may have antipsychotic 
potential. Recent studies in rats and marmosets show that 5-HT3 antagonists are 
effective at antagonising behaviours thought to be mediated by dopaminergic 
systems (Brittain et al, 1987, Costall et al, 1987). Drugs such as ondansetron 
(GR 38032F), a potent selective antagonist at 5-HT3 receptors may represent a 
new class of antipsychotic agents, with the absence of side effects normally 
associated with antipsychotic drug treatment. 
Cortical glutamatergic neurons project to presynaptic dopamine terminals 
and exhibit modulatory effect on dopamine release (Maura et al, 1988). It has 
been suggested that glutamate antagonism has potential as an antipsychotic 
treatment (see Neilsen and Andersen 1991). Glutamate receptors exist in several 
subtypes which include NMDA, quisqualate, kainate (Honore 1989), and a 
modulatory site to NMDA sensitive to glycine (White et al, 1989). In addition 
there are suggestions that glutamate antagonists may provide protection against 
the putative ischemic process in schizophrenia (Deakin 1988). 
The interactions between dopamine systems and sigma receptors is 
complex, and to date it has been difficult to evaluate to what extent sigma 
antagonism is a valid therapy in the treatment of psychosis (see Tamminga and 
Gerlach 1987; van Kammen and Gelernster 1987). 
Recently there has been considerable interest in the role of peptides as 
neurotransmitters or neuromodulators. Cholecystokinin (CCK) is found to co­
exist with dopamine neurons in the mesencephalon, and for this reason it is 
suggested that it may take a role in schizophrenia (see Nair et al, 1985). C C K has 
been suggested as having an antagonistic effect on dopamine mediated 
neurotransmission and thus may prove to have therapeutic effects in the treatment 
of schizophrenia (Fuxe et al, 1986). Neurotensin (NT) is another peptide which 
has been linked to modulation of dopamine activity (see Nemeroff, 1983), with 
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preference for the mesolimbic system. Several researchers have suggested that NT 
possesses a pharmacological profile resembling antipsychotic drugs (Quirian, 
1983, Nemeroff et al, 1984, Nemeroff and Cain 1985). 
Some antipsychotic drugs are potent antagonists of calcium (Ca2+) 
channels (Deutsch et al, 1988). Meltzer et al, (1986) have speculated that this 
may relate to antipsychotic potential, particularly on negative symptoms. Reports 
by Pilebald and Carlsson (1978) Fadda et al, (1989) suggest that Ca2+ blockade 
may lead'to a decreiase in dopamine synthesis. 
These varied and interesting approaches to antipsychotic drug treatment 
have largely been developed from pharmacological discoveries made using animal 
models. 
1.3 Animal Models of Schizophrenia 
Animal models are one of the most important tools for studying disease 
processes. The development of animal models for psychiatric disorders is by 
necessity a compromise between experimental simplicity and the complexity of 
the disorder. Lack of understanding of the process underlying the disease leads to 
an inability to develop good animal models, which in turn leads to an inability to 
fully elucidate the underlying mechanisms of the disease. Despite these 
limitations, animal models have proved to be of great value in elucidating 
dopaminergic mechanisms, and evaluating novel treatments. The ideal animal 
model should resemble the disease it models in its symptomology, aetiology, 
biochemistry and treatment (McKinney and Bunney, 1969). No such ideal model 
exists of course, and although there are numerous ways in which animal models 
can be categorised eg drug-induced versus non-drug-induced models or 
categorisation by neurotransmitter, a more theoretical approach to describe 
animal models of psychiatric disorder is appealing as it possibly leads to a more 
appropriate set of validating criteria and ultimately to a better way of evaluating 
the various models. The theoretical approach of examining the validity of a model 
was introduced for models of depression by Willner (1984). Such an approach can 
be directly applied to animal models of schizophrenia (Ellenbroek and Cools 
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1990), which of ail the psychiatric disorders has proved the most difficult to 
model. 
If the validity of a model is taken in terms of an increasing hierarchy from 
predictive to face to construct validity, then those models with predictive validity 
have the lowest level of validity, as the actual behaviour displayed in the model is 
generally totally unrelated to the symptoms of the disease. In the study of 
schizophrenia such models are based on the effectiveness of antipsychotic drugs, 
and are therefore unlikely to uncover drugs with a mechanism of action completely 
different from that of the current antipsychotics, but such models, have value as a 
screening technique for developing more effective antipsychotic drugs and to give 
insight into the neuronal mechanisms underlying the effects of existing 
antipsychotic treatments. Drugs such, as haloperidol, a butyrophenone, clozapine, 
a dibenzazepine and sulpiride, a benzamide, all differ greatly in their chemical 
structure but share antipsychotic action and should act similarly in a good animal 
model. Thus, an animal model with predictive validity should satisfy the following 
criteria: antipsychotic drugs of various chemical classes should be effective, and 
there should be no false negative or false positive drugs. 
All drugs have multiple effects. One of these effects may be a beneficial 
reduction of symptoms of a disorder that defines a particular class of drugs eg 
antipsychotic action or anxiolytic action. The other effects are secondary to this 
activity, often unwanted and termed 'side effects'. Those drugs which reduce 
symptoms can be classified as type I. Those drugs which do not produce symptom 
reduction but can produce the same secondary effects as the type I drugs are 
termed type II drugs whilst a further category of drugs, type III, have effects of 
their own which include neither symptom reduction nor the secondary effects seen 
in type I and type II drugs. An effective model should therefore select type I drugs 
as being effective and should not select either type II or type III drugs. The model 
should discriminate drugs in the same way that the clinical response (symptom 
reduction) differentiates them. The difference between type I and type II drugs lies 
in their ability to reduce symptoms not in their secondary effects. Therefore the 
model should select drugs on the basis of their symptom reduction and not on the 
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basis of their secondary effects (see Table 1). This is essentially a restatement of 
the term power, in which the cell in the upper right is the probability of 
rejecting HO when it is actually false (p=1-B); the upper left cell constitutes a 
type II error (p=B), and the lower right cell a type I error (p=a). 
Tablel .1 Effects of various classes of drugs tested in an animal model. 
Clinical Change No Response Response 
YES (Type 1 drug) False Negative Effective Drug 
NO (Type II and Type III Correct Rejection False Positive 
drug) 
Adapted from Carlton 1983. 
In addition, anticholinergic drugs should not reduce the therapeutic effects 
of antipsychotic drugs, although anticholinergic drugs reduce the extrapyramidal 
side effects of antipsychotic treatment. The same effect occurs with chronic 
antipsychotic therapy. The effects of anticholinergic drugs and chronic 
antipsychotic treatment indicate that the EPS and therapeutic effects of a 
treatment can be separated pharmacologically. 
There should also be a relationship between the clinical potency of the drug 
and its potency in the model. A confounding factor is that the potency of the drug 
depends on a number of non-disease-related but species-specific phenomena (eg 
ability to penetrate the blood brain barrier) so that a perfect correlation between 
potencies in the model and in treatment would not necessarily be expected, but a 
general agreement between potencies of disease control and efficacy in the model 
should exist. Animal models of schizophrenia which satisfy the criteria for 
predictive validity are the conditioned avoidance response (Arnt 1982), intra­
cranial self stimulation (Wanquier, 1979) and catalepsy (Janssen et al , 1965). 
The second category of animal models are those with face validity. These 
models exhibit a phenomenological similarity between the disease and the animal 
model. As these models are hierarchically higher than models with predictive 
validity, models with face validity should also obey the criteria for predictive 
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validity. In addition the animal model should resemble schizophrenia in a number 
of respects, which should be specific to the disease. The similarities should coexist 
in a specific subtype of schizophrenia, but not show features unrelated to 
schizophrenia. Animal models of schizophrenia which have face validity are 
difficult to develop as most symptoms are related to thought disorder and 
perception and are therefore very difficult to model in an animal. In addition, 
symptoms which appear phenomenologically similar need not necessarily result 
from similar underlying mechanisms. For these reasons the number of animal 
models with face validity is small. These include amphetamine and apomorphine-
induced stereotypy (Jansseri et al, 1967). As amphetamine-induced hyperactivity 
and stereotyped behaviours are the main subject of this study an evaluation oi 
these animal models is not appropriate at this point and will be discussed in detail 
throughout the remainder of the introduction although a discussion of the 
relevance of stereotypy to schizophrenia is relevant to the face validity of this 
model. 
Stereotypy in schizophrenic patients and following amphetamine use in 
humans has been well documented. Bleuler considered that motor stereotypy was a 
fundamental symptom of schizophrenia (see Iversen 1986). A form of stereotyped 
behaviour frequently reported in amphetamine addicts is a repetitive scratching of 
the skin (Sudilovsky 1975), similar to the repetitive grooming behaviours seen 
in amphetamine treated rhesus monkeys (Ellinwood et al, 1973). Complex 
patterns of stereotyped behaviours following amphetamine have been variously 
described as 'punding' (Rylander 1971), obsessive compulsive tendencies 
(Ellinwood -1967; Kramer et al, 1972) and 'hung up activity' (Scher 1966). 
There is strong evidence that behavioural stereotypy is a characteristic feature of 
the response to amphetamine both in experimental animals and humans. 
The highest level of validating criteria for animal models are those models 
which possess construct validity. These are models which attempt to model the 
psychopathological construct underlying the disease process. In order to develop 
models of schizophrenia which reflect accurately the hypothetical constructs 
underlying the disease it is important to understand the pathological constructs 
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relevant to this disorder. At the present time there is no clear consensus, and the 
constructs underlying schizophrenia are the subject of much debate. Many 
researchers have argued that a dysfunction in information processing lies at the 
core of schizophrenia, and have sought to interpret deficits in terms of the 
information processing theory of Broadbent (1971). Indeed, many studies have 
shown that schizophrenic patients are more easily distracted than normal controls 
(Green and Walker 1984; Cornblatt et al, 1985, 1989; Walker and Harvey 
1986; Harvey and Pedley 1989). Therefore it is hypothesised that schizophrenic 
patients suffer from disruptive selective attention (Nuechterlein and Dawson, 
1984; Ellenbroek and Cools 1990). 
Animal models which have been suggested as relevant to the study of 
attehtional processes in relation to schizophrenia are amphetamine-induced 
disruption of latent inhibition and blocking (Solomon et al, 1981, Lubow et al, 
1987, Crider et al, 1982), and phencyclidine-induced disturbances of the startle 
response (Braff et al, 1978). Schizophrenic patients have been shown to perform 
differently from normal control subjects in a latent inhibition task, with 
schizophrenia patients pre-exposed to a stimulus performing better than the pre-
exposed control subjects, thus for schizophrenic patients pre-exposure to the 
stimuli did not interfere with subsequent learning, as is normally the case. Animal 
models have examined the role of dopamine agonists on latent inhibition. Several 
studies, using a variety of methods have shown that amphetamine disrupts latent 
inhibition in a similar manner to that seen in schizophrenic patients (Solomon et 
al, 1981, Weiner et al, 1988, Crider et al, 1982). The majority of these studies 
showed that chronic rather than acute injections of amphetamine disrupt latent 
inhibition. In addition several studies have examined the effects of antipsychotic 
drugs on latent inhibition. Solomon et al, (1981) and Crider et al, (1982) 
showed that acute doses of chlorpromazine and haloperidol prevented 
amphetamine-induced disruption of blocking, whilst several studies have shown 
that chronic rather than acute administration of both classical and atypical 
antipsychotic drugs improved latent inhibition. Interestingly, clozapine was found 
to exhibit no influence on amphetamine-induced latent inhibition and as such 
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would represent a false negative in this model (Dunn et al, 1989). As the ability 
to prevent amphetamine disruption of latent inhibition by the majority of 
antipsychotic drugs occurs after chronic rather than acute treatment, this 
mirrors treatment in clinical settings and the validating criteria for assessing the 
predictive validity of the model. Amphetamine injected into the nucleus 
accumbens, but not neostriatum can disrupt latent inhibition (Solomon and 
Statton, 1982). Furthermore, lesions to the hippocampus disrupt latent 
inhibition (Ackil et al, 1969, Kaye and Pearce 1987) and blocking (Solomon 
1977, Richert et al, 1978), whilst lesions to the 5HT innervation of the 
hippocampus disrupt latent inhibition (Cassaday et al, 1990). Further studies 
into the neuronal mechanisms underlying latent inhibition are required before the 
construct validity for latent inhibition and blocking are fully established. 
The second model which has been suggested as having construct validity for 
schizophrenia is phencyclidine-induced disturbance of the startle response. The 
startle response is a reaction to a novel intense stimulus. The most commonly used 
are either acoustic (about lOOdB burst of white noise) or tactile (usually a puff 
of air directed at the head of the animal). The response is measured as either a 
whole body response, or an increase in EMG activity in certain muscles. It has 
been suggested that the startle response is a useful model for studying 
sensorimotor integration and as such it may well represent an animal model with 
construct validity for schizophrenia. The startle response occurs if the stimulus 
reaches a certain intensity, therefore if the subjects threshold for external 
stimuli is lowered subjects should show a response to a lower intensity stimulus 
or an increased response to the normal startle stimulus. In addition, habituation 
occurs to a repeatedly occurring startle stimulus and the startle response is 
subject to prepulse inhibition, whereby the response is reduced if the stimulus is 
preceded by a comparable stimulus of lower intensity. Schizophrenic patients have 
been shown not to have a lowered threshold for external stimuli but to exhibit a 
reduced rate of habituation (Geyer and Braff 1982). In addition, unlike control 
subjects, schizophrenic patients did not show a diminished response when an 
acoustic stimuli was preceded by a less intense stimulus (Braff et al, 1978). 
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Several explanations have been put forward to explain the changes in the startle 
response, habituation and prepulse inhibition in schizophrenic patients. The 
disruption of pre-pulse inhibition has been explained as a loss of inhibitory 
control (AdIer et al, 1982), whilst the decrease in the rate of habituation is 
suggested to result from a general slowness in information processing (Geyer and 
Braff, 1987). Many drugs have been shown to effect the acoustic startle response 
(see Davis 1980, 1984), very few induce the same deficits as those observed in 
schizophrenic patients. (Mansbach et al, 1988, Geyer and Braff, 1987). 
Phencyclidine retards habituation and prepulse inhibition without lowering the 
threshold of responding (Geyer et al, 1984, Mansbach and Geyer 1989), 
suggesting that phencyclidine-induced changes in the startle response exhibit face 
validity for schizophrenia. There have been few studies on the effects of 
antipsychotic drugs on this animal model. 
Haloperidol has been shown to block the effects of phencyclidine on 
prepulse inhibition (AdIer et al, 1986). Ellenbroek and Cools (1990) suggest 
that the morphology of the startle response in humans and animals is very similar 
and consequently models of the startle response In animals relate to the constructs 
underlying the deficits in schizophrenia. Whilst the neuronal mechanism 
underlying the startle response has been partly elucidated, in particular the 
primary startle circuitry (Davis 1984), further studies are required to assess 
the validity of the startle response as a model for schizophrenia, in particular the 
ability of antipsychotic drugs to antagonise the response within this model. 
Clearly, these two models are based on the hypothetical construct that 
schizophrenic patients have a diminished capacity to distinguish relevant from 
irrelevant stimuli, and as such these patients are easily distracted. Ellenbroek and 
Cools (1990) point out that these models do not account for the negative 
symptoms (anhedonia, flat effect and social isolation) seen in the chronic phase of 
the disease, and that the construct hypothesised to underlie latent inhibition and 
the startle response - disruption of selective attention, and an increased 
propensity for distractibility - does not apply to the negative symptoms of 
schizophrenia. Hemsley (1988) proposed a compensatory mechanism in 
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schizophrenic patients which protects them from "sensory flooding'. Chronic 
treatment with amphetamine or phencyclidine may lead to a comparable 
compensatory mechanism in animals. Certainly in rats (Gambill and Kornetsky 
1976) and monkeys (Haber et al, 1977; Ridley et al , 1979) chronic 
administration of amphetamine leads to social withdrawal and isolation. In 
addition, amphetamine treatment induces stereotyped behaviour in monkeys, often 
with more individual variability than that seen in rodents (Ellenbroek et al, 
1989) and as such has face validity for the positive symptoms of schizophrenia, 
since stereotypy of movement, speech and thought occur in schizophrenia patients 
(Bleuler, 1911). It would appear that the validity of all these models is not 
without attendant problems, nevertheless they represent a more systematic and 
focused approach to the development of animal models for schizophrenia enabling 
an Increase in understanding of the neuronal structures underlying information 
processing dysfunction. 
1.4 Amphetamine-Induced Behaviours as an Animal Model of 
Schizophrenia 
Angrist and Gershon (1970) claim that amphetamine psychosis mirrors 
important aspects of paranoid schizophrenia including such conditions as thought 
disorder, delusions, paranoia and auditory hallucinations. Amphetamine psychosis 
- like schizophrenia - can be treated with antipsychotic drugs, reinforcing the 
view that amphetamine psychosis and schizophrenia have some common 
neurobiological element. In addition amphetamine worsens schizophrenic 
symptoms regardless of the subtype of schizophrenia. In view of these facts, 
amphetamine-induced behaviours in animals after chronic and acute exposure to 
the drug have been used to study the underlying mechanisms , and also the effects 
of antipsychotic drug treatment. 
Amphetamine produces dose-dependent changes in the expression of 
individual types of behaviour in the rat (Rebec and Bashore, 1984). 
D-amphetamine sulphate injected subcutaneously in the range of 0.3 - 1.5 mg/kg 
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produces an increase in fonward locomotion accompanied by sniffing and head 
bobbing. The locomotion persists for 40 - 90 minutes, depending on the dose, and 
is followed by a period of sleep. Higher doses ( 2 - 1 0 mg/kg) produce a 
multiphasic response that consists of early and late phases of locomotion and an 
intermediate phase of focused stereotyped behaviours during which locomotion is 
absent. Stereotypy describes the characteristics of a behaviour rather than a 
specific response. Ellinwood (1967) defined stereotyped behaviour as the 
performance of an invariant sequence of movements repetitively which is 
inappropriate with respect to its environmental context. The focused stereotypy 
phase is characterised by sniffing, repetitive head and limb movements and oral 
behaviours, which include licking, biting and gnawing; all expressed in a small 
area of the open field. These behaviours, although mainly restricted to the focused 
stereotypy stage, can also be observed intermittently during the other phases. The 
time course for each phase is dose-dependent, and with increasing doses the animal 
spends less time in forward locomotion and more time in focused stereotypy. 
Lyon and Robbins (1975) put fonvard a hypothesis to explain the 
behavioural effects seen following amphetamine treatment which states that: 
'amphetamine with increasing dose produces an increasing response rate within a 
progressively narrowing response repertoire'. Amphetamine stimulation leads 
initially to reductions in pausing, and at higher doses to enhanced behavioural 
competition among the different response sequences. The performance of 
behaviour, especially complete sequences is hindered by competition, even 
amongst the elements constituting a behavioural sequence. Behaviour as a 
consequence becomes dominated by elements, which are performed irrespective of 
sequence and the animal becomes immobilised as a result of over-stimulation. The 
resulting behavioural stereotypy is the culmination of a process of increased 
activation, mediated by dopamine release in the basal ganglia, whereby responses 
are elicited at an increasing rate. 
Many of the behaviours in the animal's response repertoire compete for 
expression. Evidence for behavioural competition is derived from three lines of 
evidence: particular responses take place over a shorter time with the occurrence 
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of abortive beiiavioural sequences; there is enhanced switching between 
behavioural elements; there is an enhanced rate of performance when competing 
behavioural responses are blocked. The most striking example of behavioural 
competition is that seen between the locomotor effects of amphetamine and the 
intense head movements and sniffing stereotypies (see Robbins et al, 1990). 
The Lyon-Robbins hypothesis would predict that amphetamine will not 
induce any form of behaviour not already present in the animals behavioural 
repertoire, and that those behaviours which occur at high rates have peak effects 
at much lower doses than those behaviours occurring at low rates. Robbins et al, 
(1990) state that this is essentially a representatiori of the Yerkes-Dodson 
(1908) principle relating the optimal performance of tasks to different levels of 
arousal, such that difficult tasks are performed optimally at lower levels of 
arousal than easy ones. The Lyon-Robbins hypothesis also postulates that animals 
under amphetamine do not suffer from deficits of sensory input In fact, 
environmental influences can either disrupt the behavioural response, lead to 
behavioural competition resulting in a blending of behavioural patterns, or lead to 
stereotyped responses of learned or conditioned behaviours. For example, novel 
stimuli can disrupt amphetamine stereotypy (Sahakian and Robbins 1975), and 
escape behaviour from a water maze is sufficiently strong to overcome stereotypy, 
at least temporarily (Mittleman as quoted in Robbins et al, 1990). 
Chronic treatment with amphetamine can cause sensitisation of certain 
behaviours (increased response output), whilst producing apparent tolerance to 
others (Eichler et al, 1980, Segal and Schuckit, 1983, Mittleman et al, 1985). 
Sniffing, head and limb movements tend to increase following repeated treatment, 
licking and gnawing decline in frequency. It is not clear whether the sensitisation 
effects following repeated administration of amphetamine result from 
neuropharmacological factors or the influence of conditioning. The basic, premise 
of Lyon and Robbins to account for acute effects of increasing doses of stimulants 
would appear to account for the cumulative effects of repeated treatment (Robbins 
et al , 1990). 
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It is now clear that stereotyped behaviours are mediated by the caudate-
putamen whilst hyperactivity is mediated by the mesolimbic system, in particular 
the nucleus accumbens. Creese and Iversen (1975) showed that selective 
dopamine depletion from the caudate-putamen in the rat reduced the stereotyped 
head movements produced by amphetamine, and subsequently Kelly et al, (1975) 
showed that locomotor responses following treatment with amphetamine resulted 
from the mesencephalic dopamine projection from the ventral tegmental dopamine 
pathway to the nucleus accumbens. Pjinenburg et al, (1976) demonstrated that 
infusions of amphetamine into the nucleus accumbens and also into the olfactory 
tubercle, elicited hyperactivity in the rat. The caudate-putamen and nucleus 
accumbens can be considered as part of the dorsal and ventral striatum 
respectively, with independent outputs through the dorsal and ventral palladium. 
As a consequence of the neuroanatomical relationship of these two structures the 
nucleus accumbens is in a position to alter functioning in the nigrostriatal 
projection, whereas the reciprocal interaction is not possible. Thus there is a 
possibility of competition between parallel independent output pathways and direct 
interactions whereby interruption of nigrostriatal activity may occur, or of 
boosting or amplifying the nigrostriatal output. The locomotor and overtly 
stereotyped effects following amphetamine do appear to compete for expression, 
and it would appear that stereotypy masks further dose-dependent increases in 
locomotion. The hypothesis put forward by Lyon and Robbins predicts this 
competition between the two systems. 
Mogenson et al, (1984) have suggested that the nucleus accumbens 
represents a functional interface between the limbic system and the motor system 
and as such provides a link between motivational and motor processes. This view 
is supported by (Cools et al, 1991). In addition. Cools (1980) suggested that 
striatal dopamine is involved in the sequencing and selection of behavioural 
responses. Dopamine in the striatum and accumbens has been implicated in the 
perseveration and switching of behaviour (Evenden and Robbins, 1983, Koob et 
al, 1978, Cades 1985). 
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Rotation seen following amphetamine administration and unilateral 
depletion of dopamine in the caudate can be suggested as a form of stereotyped 
locomotion with evidence that both structures participate. Kelly and Moore 
(1976) showed that unilateral depletion of dopamine from the head of the caudate 
determined the direction of rotation, whilst additional depletion of dopamine from 
the nucleus accumbens determined its rate. This led to the proposal that the 
accumbens projection "gain amplified' the bias produced by the caudate imbalance. 
This hypothesis is compatible with the suggestion that the intensity of stereotyped 
behaviour is determined by dopamine projections throughout the striatum, 
including the nucleus accumbens itself. Fink and Smith (1980) and Winn and 
Robbins (1985) have shown that amphetamine hyperactivity depends on dopamine 
projections to the anteroventral head of the caudate nucleus as well as in the 
nucleus accumbens, and that amphetamine locomotor response depends on the 
combined action of the central dopamine systems (Fink and Smith, 1980). 
In summary, stereotypy is a complex pattern of behaviour which when 
analysed at the behavioural and neural level can provide much information about 
CNS mechanisms of behaviour and psychological process. The induction of 
stereotypy in animals can be seen as a convincing model of psychopathology, 
including aspects of schizophrenia, and that models with greater face and construct 
validity (as stated earlier) will emerge when the full complexity of this 
behavioural response is taken into account. 
1.5 Locomotion as a More Appropriate Measure of ttie Amphetamine 
Syndrome 
Considerable attention has been placed on amphetamine-induced focused 
stereotyped behaviours because they are reliably antagonised by classic 
antipsychotics such as haloperidol or chlorpromazine (Szechtman et al, 1988). 
This observation was the foundation for an important preclinical screening 
technique for putative antipsychotic drugs. It is now clear that a group of 
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clinically effective drugs, so called 'atypical' antipsychotics do not antagonise all 
the components of amphetamine-induced stereotyped behaviour. 
Atypical antipsychotics are not a homogeneous class of compounds. They 
show a wide spectrum of biochemical effects on dopaminergic mechanisms and the 
incidence of E P S are claimed to be less with atypical antipsychotic drugs 
(Tamminga and Gerlach, 1987). In addition, they vary in their ability to 
antagonise specific amphetamine-induced stereotyped behaviours (Tschanz and 
Rebec, 1989). Ljungberg and Ungerstedt (1978) reported that sulpiride, 
clozapine and thioridazine predominantly antagonised apomorphine-induced 
hyperactivity without antagonising the stereotyped gnawing induced under this 
drug, and that clozapine and sulpiride antagonised only the locomotion induced by 
amphetamine (Ljungberg and Ungerstedt, 1985). There are several problems 
relevant to these studies. The holeboard apparatus did not adequately measure 
gnawing, and this is probably responsible for the anomalous results obtained for 
the largest dose of clozapine tested (50mg/kg). In addition, the 2.5 cm holes are 
sensitive to all parts of the rat's body, including limbs and tail, which may enter 
and break the photobeam, thus locomotor activity may artificially inflate gnawing 
measures. The measures 'of activity used were ill-defined and unnecessarily 
complex, relying on a predetermined distance, and locomotion in two 'arms' of the 
apparatus as a definition of forward locomotion. The use of visible light for the 
photobeams could act as a confounding factor, changing the characteristic nature of 
the locomotor behaviour. As stated earlier, amphetamine- induced behaviour is 
sensitive to sensory input, and high levels of illumination are known to induce 
lower levels of activity in the rat (Montenaro and Babbini, 1965). In studies 
with apomorphine (Ljungberg and Ungerstedt, 1978) and amphetamine 
(Ljungberg and Ungerstedt,1985) the number of animals tested in each condition 
was extremely small (4-6 at each dose) The variability of these data are'not 
quoted, but in view of the fact that the antipsychotic drugs were administered in 
large volume (5ml/kg body weight), it would be expected that the variability 
between individual rats would be high. Locomotion and gnawing are mutually 
exclusive behavioural categories and cannot be exhibited at the same time within 
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this apparatus. Ljungberg and Ungerstedt (1978) report that the pealc activity 
for both behaviours occur at different times following administration of 
apomorphine (0-30min for locomotion and 30-60min for gnawing), yet in a 
later study (Ljungberg and Ungerstedt, 1985) animals were tested for a short 10 
minute period 50-60 min following amphetamine and 90 minutes following 
antipsychotic pre-treatment, this timing would allow for a sensitive test of the 
effects of drugs on gnawing behaviour but would be less sensitive to effects on 
locomotor behaviours. In addition this short test period would maximise the effects 
of handling stress and habituation procedures. The description of gnawing 
behaviour following treatment with apomorphine by Ljungberg and Ungerstedt 
(1978) implies that pre-treatment with clozapine actually potentiated this 
behaviour, although the apparatus appears to be unable to detect this. A 
paradoxical finding was reported by Robertson and MacDonald (1984, 1985) who 
found that the atypical antipsychotics, sulpiride, clozapine and thioridazine 
enhanced some stereotyped behaviours (repetitive head movements, sniffing and 
gnawing). 
The paradoxical effects of atypical antipsychotics on stereotyped 
behaviour, and the observation that atypical, antipsychotics are less likely to 
produce the Parkinson-like side effects which are associated with classic 
antipsychotic drugs (for review see Tamminga and Gerlach, 1987), has cast doubt 
on the utility of amphetamine antagonism as a screening technique for 
antipsychotic potential (Robertson and MacDonald, 1985, Tschanz and Rebec, 
1989), and led to the suggestion that antagonism of amphetamine-induced 
stereotypy predicts a compounds potential to produce unwanted extrapyramidal 
side effects In humans (Ljungberg and Ungerstedt, 1985). This suggestion means 
that a fundamental reassessment of antagonism of amphetamine - induced 
stereotyped behaviours as a preclinical screening test for antipsychotic potential 
is urgently needed. Recently it has been argued that the shared ability of classic 
and atypical antipsychotics to reduce amphetamine-induced hyperactivity may 
form the basis of a more satisfactory test of antipsychotic potential (Ljungberg 
and Ungerstedt, 1985; Rebec and Bashore, 1984). 
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It is important to recognise that hyperactivity, or a general increase in 
motor activity, is not a single class of behaviour, but depending on the recording 
technique may consist of many different forms of motor movement. This has often 
led to a reliance on measures of locomotor rather than motor behaviour (Geyer, 
1990). Locomotor activity can be defined as movement from place to place, and is 
a specific measure because with either observational or automated monitoring, 
movements can be defined in units, often termed 'crossings' or 'crossovers' and 
invariably require ambulation by the animal. A limited number of different 
measurement techniques have been applied to the detection of locomotor activity in 
rodents, in particular the use of photobeams which have the added advantage in 
that they can be used to detect rearings and to monitor holepokes as an explicit 
measure of exploratory behaviour. 
Although these provide an accurate quantification of locomotor activity they 
do not allow for the description of any patterns inherent in the ambulation. 
1.6 A Distinction Between Amptietamine-lnduced Locomotion and 
Stereotyped Locomotion 
Traditionally the view was held that at certain doses amphetamine produces 
a three phase behavioural response in rats consisting of an enhanced locomotor 
phase followed by a stereotypy phase followed by an afterphase of enhanced 
locomotion (Schiorring, 1971; Segal 1975), with a clear distinction drawn 
between amphetamine-induced locomotion and focused stereotyped behaviours 
(Szechman et al, 1988). Several authors have argued that amphetamine-induced 
forward locomotion has stereotyped properties. Lat (1965) described the 
repetition of a 8-shaped locomotor route restricted to only part of the cage 
following treatment with amphetamine whilst Segal (1975) observed 
perseveration in the pattern of locomotion with doses as low as 0.5 mg/kg d-
amphetamine. 
Schiorring (1979) used plots of locomotor movements to demonstrate the 
perseverative nature of routes taken by amphetamine treated rats in an open field 
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divided into a number of equal sized squares. He used the term 'trip' to define the 
distance moved by the rat between two turns. If the rat made a tour of the open 
field apparatus, without any turns, this was registered as a trip. Schiorring 
classified three different types of trip: a complete repetition whereby the rat 
entered exactly the same squares as it did on the trip before; a partial repetition, 
in which the rat entered some of the squares it did on the previous trip, without 
including any new squares; and finally a complete repetition of the previous trip 
but including new squares. Amphetamine increased the number of complete repeats 
by about 10% and this indirectly implies perseverative or stereotyped patterns of 
locomotion in the open field. Schiorring also noted that trips along the whole 
periphery of the open field were seen in over 50% of the amphetamine treated 
rats and termed this stereotyped locomotion. This work was hampered by the 
difficulty of quantifying locomotor stereotypy. Schiorring divided the locomotion 
into two phases: before and after the first complete tour of the perimeter; which 
seems an unnecessarily clumsy way of quantifying these data. As a consequence it 
is difficult to determine the number and proportion of trips around the periphery 
of the apparatus. The study also employed high illumination (2x100 w) which as 
already stated would be likely to reduce open-field hyperactivity. Despite these 
limitations, Schiorring's work is pivotal in laying the groundwork for more 
detailed studies into amphetamine-induced hyperactivity and the perseverative 
nature of open-field locomotion. The strength of this study lies in the large size of 
the test field (3 x 3.5 m^) which allowed him to observe the spatial pattern of 
amphetamine-induced locomotion in detail, and the long (3.5 hour) test session 
which enabled him to fully document the pre, stereotypy and after phase of the 
amphetamine response (Schiorring, 1971). 
Mueller et al, (1989a, 1989b) attempted to refine Schiorring's method 
and quantify the repetition of any given pattern by converting the animal's path 
through the open field into a series of trips. A trip started in the centre of the open 
field, was terminated when the animal changed direction or completed a tour of the 
perimeter, or entered the centre area. A statistic, "gamma", was calculated to 
quantify repetitive locomotor patterns or locomotor stereotypy. Gamma is the 
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maximum lil<eliiiood estimate of the probability that the animal would repeat the 
trip it had just exhibited, "If the second trip is the same as the first, a 'repeat' 
(R) is recorded; if the third trip is the same as the second, another 'repeat' is 
recorded and so on. If any trip is different from the preceding trip a 'change' (C) 
is recorded. Gamma is defined as the number of repeats divided by the number of 
repeats plus changes: Gamma= R/(R+C)" (Mueller et al, 1989a, p75). 
Using this method to quantify locomotor stereotypy, Mueller et. al, 
(1989a) report that amphetamine produced a dose-related increase in 'gamma', 
whilst caffeine, which produced dose-related Increases in locomotion, did not 
increase 'gamma'. In a second study (Mueller et al, 1989b) 'gamma' did not 
increase in a dose-related manrier. Interestingly, in both studies Mueller and 
colleagues, like Schiorring, reported that circling the perimeter of the open field 
was associated with the highest doses of amphetamine " a particular type of 
locomotor stereotypy (circling the perimeter of the open field) tended to be 
produced in the vast majority of animals." (Mueller et al, 1989a, p78), and; 
"after 1 and 2 mg/kg amphetamine trips of '1' were most frequent. But after 3 and 
4 mg/kg amphetamine, at some time periods trips of '4' were as frequent as trips 
of '1 ' . A subset of rats repeated trips of '4' exclusively." (Mueller et al, 1989b, 
p505). It should be noted that the open field used by Schiorring was exceptionally 
large, 3 x 3.5 metres divided into 42 0.5 x 0.5 metre squares, whereas the open 
field used by Mueller et al, was much smaller, a little under a square metre 
divided into four areas with a central portion. Like Schiorring, Mueller's work 
was hampered by difficulties in quantifying the exact nature of perseverative 
locomotor routes and gartima does not consistently measure the dose effects of 
amphetamine-induced locomotion. The study reported by Mueller et al, (1989a) 
is beset with methodological problems. The animals were not tested until 25 
minutes after the injection of amphetamine. As peak locomotor effects occur at 
different time periods for different doses, the peak drug effects of the higher doses 
may well have been missed. The spatial distribution of amphetamine-induced 
locomotion is likely to change with time, with animals displaying different trips at 
different times. This would not necessarily, and indeed would be unlikely, to take 
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an identical course for all doses. Tfius in this experiment measures of "gamma" 
were likely to be confounded by omitting to test during the first 25 minutes 
following drug administration. An additional confounding factor is that animals 
were not habituated to the open field prior to testing; rats and guinea pigs show 
reduced levels of amphetamine-induced stereotypy when tested in a novel 
environment (Einon and Sahakian, 1979; Sahakian and Robbins, 1975). 
In the later study (Mueller et al, 1989b), animals were habituated in the 
open field prior to treatment with 0, 1 ,2 , 3, or 4mg/kg amphetamine, and 
animals were observed for 100 minutes immediately following amphetamine 
administration. These refinements go some way towards addressing the faults of 
the earlier study. These authors report a high 'gamma' score for animals treated 
with 1 and 2 mg/kg amphetamine and a decrease in 'gamma' for 3mg/kg. 
Additionally, they were unable to calculate gamma for the most relevant time 
intervals following treatment with 4mg/kg. The results reported in this study 
appear to contradict the earlier findings which reported a dose-related increase in 
'gamma'. 
Work in our laboratory (Kenyon et al, 1992) has shown that 'gamma' 
correlates well with length 1 trips, and consequently high gamma scores reflect a 
high number of length 1 trips (eg saline and low dose amphetamine treated 
animals)and that a decline in 'gamma' reflects a decline in length 1 trips. Such a 
decline occurs in animals treated with higher doses of amphetamine when length 4 
trips emerge (Kenyon et al, 1992). These findings suggest that 'gamma' does not 
quantify stereotyped locomotion accurately. As locomotor patterns become more 
thigmotaxic, 'gamma' declines. The higher 'gamma' scores for amphetamine-
treated animals in the first study can perhaps be accounted for by the lack of 
habituation, which perhaps suppressed perseverative locomotor patterns in the 
novel surroundings, and by the short testing period (20 minutes). 
Geyer and colleagues have demonstrated perhaps the most convincing 
quantification of locomotor patterns in the open field using the behavioural pattern 
monitor (BPM), which is designed to combine the features of activity and 
holeboard chambers (Adams and Geyer, 1982; Flicker and Geyer, 1982; Geyer 
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1982). Each chamber consists of a 30.5 x 60 cm blaci< Plexiglas box connected to 
a metal 'home cage'. The chamber contains three floor and seven wall holes 
equipped with infra-red beams and a wall touch plate to detect rearings. Several 
experiments have demonstrated the sensitivity of this system in the study of 
locomotor and investigatory behaviour. The use of the BPM has revealed a 
remarkably consistent structure of the behaviour of untreated rats. There is a 
general tendency for virtually all untreated rats to avoid the centre region and to 
stay near a corner of the chamber. Untreated rats make short excursions from the 
home corner and back following their own particular preferred pattern of 
movement. 
Geyer (1982) and Geyer et al, (1986b) have developed, a measure 
termed 'spatial coefficient of variation (CV)'. Originally a measurement was made 
of the transitions between any five areas, subsequent applications of this 
approach have involved the calculation of transitions between any nine areas. 
Relative transition frequencies are calculated as percent of the total permissible 
cell entries, and the spatial coefficient of variation is derived from this set of 
numbers. To the extent that an animal repeated certain transitions, the spatial CV 
increases. A more random distribution of these spatial transitions produces a low 
spatial CV. 
The effects of drugs on locomotor patterns have been studied in the BPM. At 
low doses amphetamine disrupts the normal structure of locomotion by producing 
highly varied patterns of directional change (Geyer et al, 1986). At higher doses, 
perseverative locomotor routes are produced following treatment with 
amphetamine (Lat, 1965; Schiorring, 1979; Mueller et al , 1989a). Other 
stimulant drugs essentially replace the normal pattern of locomotion with new, 
even more highly structured patterns. For example apomorphine-treated rats 
make circular trips around the perimeter of the chamber consistently in one 
direction for most of the session. Scopolamine treated rats also circulate the 
perimeter of the chamber but in addition frequently change directions and pause to 
investigate holes, and rear against the walls (Geyer et al, 1986). Stimulants such 
as caffeine and nicotine do not disrupt the normal structural pattern of locomotion. 
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locomotor patterns under these stimulant drugs are similar to those exhibited by 
untreated or saline animals. Rats in an enclosed arena have a tendency to remain 
close to the walls, referred to as thigmotaxis (Barnett, 1963). This trait is 
thought to be related to the need to avoid predators and the importance of vibrissae 
contact for rodents. This behaviour is obviously potentiated under treatment with 
some stimulant drugs eg scopolamine and apomorphine (Geyer et al, 1986), and 
higher doses of amphetamine (Lat 1965; Schiorring 1979; Mueller et al, 
1989a ,1989b) . 
Measures of centre entries have proved to be extremely sensitive to the 
effects of drugs. For example hallucinogens decrease entries into the centre of the 
chamber (Adams and Geyer, 1985). These studies indicate there is much to be 
gained measuring both peripheral and central movements in the analysis of the 
behavioural effects of drugs, and endorses the fact that the open field should be 
large enough to elicit thigmotaxis and to enable the detection of peripheral and 
central movement. Drugs such as MDMA (Ecstasy) which combine hallucinogenic 
activity with the classical stimulant actions of amphetamine (Beck and Morgan, 
1986), and MDE (Eve) show a combination of the behavioural effects of 
traditional stimulants and those of hallucinogenic drugs such as LSD. MDMA and 
MDE are similar to the hallucinogens in producing an avoidance of the centre, 
unlike LSD, MDMA produces increases in perserverative and thigmotaxic patterns 
of locomotion reflected by increases in 'spatial CV '. 
In contrast to the methods described above the use of metrics derived from 
ergodic theory of dynamical systems have been applied to locomotor movements of 
rats in an enclosed arena (Paulus et al, 1990). Such an approach aims to describe 
the statistical behaviour of stochastic as well as deterministic systems and allows 
for a comparison that has not been specified a priori but is chosen relative to the 
data set in question and allows that the animal has constructed its own specific 
pattern of movement in space. Such an approach to quantifying locomotor patterns 
following drug treatment, although at an early stage of development, holds much 
promise. 
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Behaviours induced by stimulant drugs are inter-related, even those 
behaviours which seem independent such as sleeping and locomotion because they 
compete with each other for expression. In order to draw conclusions about any 
one aspect of behaviour other contributions to the measured behaviour must be 
excluded, controlled or monitored. Changes in an unmeasured behavioural 
category could be responsible for an observed change in the measured behavioural 
category. Many behavioural actions are mutually exclusive and therefore will 
compete with each other for expression, thus the characterisation of drug-effects 
on behaviour will require the measurement of all behaviours that are induced 
under the drug as well as those behaviours that are in the normal repertoire of the 
animal in the test situation: This is particularly relevant in the use of measures of 
locomotion as indicators of constructs such as arousal and exploration. In many 
instances, the correct interpretation of the data obtained from automated measures 
of locomotor behaviour will depend on the use of direct observational techniques 
and the utility of a behavioural inventory. For example, under amphetamine, 
stereotypy interferes with the manifestation of locomotor activity. An 
interpretation of the possible underlying mechanisms requires measurement of 
both locomotor and the stereotyped behaviours. Using a multivariate approach to 
assess drug-induced unconditioned behaviour provides an opportunity to assess the 
validity of hypothetical constructs proposed to underly the behaviour, to make 
comparisons with findings reported in the literature, to examine the generality or 
specificity of the observations, and to identify the role of response competition as 
well as to detect and eliminate artefacts. 
A totally different approach has been adopted by Szechtman et al, (1985) 
who have measured behaviour following apomorphine by decomposing the observed 
motor activity into kinematic variables. Using the Eshkol-Wachmann movement 
notation (Eshkol and Wachmann,1958) which allows for the measurement of 
behaviour as a spatiotemporal process without defining behavioural acts a priori, 
they have identified three relevant variables - snout contact, progression and 
turning - and claim that seemingly unrelated acts such as sniffing, keeping the 
head down, forward locomotion, pivoting and head swaying are the result of an 
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interplay of these three independent processes, each with a unique time of peak 
action amplitude and rate of change. 
1.7 Studies into Amphetamine-Induced Stereotyped Locomotion 
The problem as defined above is to develop an effective animal model of 
schizophrenia with predictive, face and construct validity which can effectively 
discriminate antipsychotic drugs regardless of classification, and with the 
capability to evaluate novel antipsychotic drugs possibly acting via different 
mechanisms from those already identified. The characterisation of drug effects on 
locomotor activity in rodents which is based not only on quantitative increases in 
the amount of locomotion per se but also on the spatiotemporal characteristics of 
the hyperactivity seems to be one model which presents itself as worthy of 
investigation and further development. Clearly, models involving stimulant-
induced hyperactivity will become powerful tools only when the statistical 
assessment of behavioural sequences is adequately addressed. Certainly the 
measurement of 'spatial C V and 'trips' go someway towards quantifying the 
repetitive locomotor patterns, and could be most successful when used in 
conjunction with behavioural analysis using a rating scale specifically designed to 
assess behaviours-induced by the stimulant drug under study. For example, the 
method proposed by Fray et al, (1980) for the assessment of amphetamine-
induced stereotypy exemplifies this approach. Whilst novel approaches derived 
from non-linear dynanriics (Paulus et al, 1990) and movement notation 
(Szechtman et al, 1988) have provided interesting and novel approaches to the 
characterisation of drug effects In rodents. 
This research programme takes as its starting point the effective 
description and quantification of the spatial characteristics of amphetamine-
induced open field hyperactivity. Using computer assisted 'contrast' image analysis 
to describe the spatial distribution of amphetamine-induced movement in an open 
field, these studies set out to evaluate the utility of examining changes in the 
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nature and proportion of tiiigmotaxic locomotion as an effective quantification of 
amphetamine-induced changes in spatial patterns of locomotion. 
Recent work (Kenyon et al, 1992) has described the animals movements 
between quadrants in the open field as a series of 'trips'. The first 'trip' begins 
when the animal leaves the centre of the open field, and is completed when the 
animal reverses direction, completes a tour of the perimeter or moves back to the 
centre of the open field. Trips can be classified according to the number of 
quadrants entered. Thus a length 4 trip involves the animal entering each of the 
four quadrants in turn before returning to the quadrant from which it started; a 
length 1 trip takes the animal from one quadrant to an adjacent quadrant; whilst a 
length 2 trip and length 3 trip involve the animal entering 2 and 3 new quadrants 
respectively. Initial studies with the D2 receptor specific 'atypical' antipsychotic, 
sulpiride, have shown that a dose of 20 mg/kg reduced the total distance animals 
travelled in the test session, but failed to reduce the proportion of amphetamine-
induced thigmotaxic length 4 trips (Kenyon et al, 1992). The implication that 
hyperactivity and the stereotyped nature of locomotion can be dissociated by an 
'atypical' antipsychotic reflects an animal model worthy of further study. The 
initial aim is to examine the reliability and validity of 'trip length' as a quantifier 
of the spatial characteristics of amphetamine-induced hyperactivity in an open 
field. Further studies will examine the manner in which antipsychotic drugs (of 
various classes) change the spatial characteristics of amphetamine-induced 
behaviour within this model system. 
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Chapter Two 
Materials and Methods 
Preface 
Locomotor activity can be defined as movement from place to place, and the 
measurement of this behaviour in open field studies Is a much used technique in 
behavioural pharmacological research. Most of these measures rely on absolute 
values of locomotor activity such as distance moved, beam breaks, lines crossed 
and ignore the actual position of the animal in space. Although the history of 
examining the spatiotemporal characteristics of locomotion in an open field goes 
back to the work of Hall and Ballachey (1932) who reported tracings of the path 
taken by rats in a circular open field, and following drug administration to Lat 
(1965) and Schiorring (1979), the advent of new technologies such as video 
tracking systems and associated computer image analysis alongside the expanding 
knowledge of non-linear dynamics means that there is now considerable potential 
to gain an understanding of the effects of drugs on the spatiotemporal 
characteristics of spontaneous locomotor activity. 
This chapter discusses some of the methodological considerations related to 
this task, and sets out the methods that will be employed to examine 'trip length' 
as a quantifier of the spatial characteristics of amphetamine induced 
hyperlocomotion in an open field. 
2.1 Reliability of Open Field Measures 
The open field is a commonly used experimental tool for studying animal 
behaviour in a wide variety of settings and disciplines. Originally introduced by 
Hall (1932; 1934) for studying defecation and timidity, it has gained widespread 
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acceptance, because of the simplicity of the apparatus and the ease and rapidity of 
measurement of clearly defined behaviours. 
Behaviour in an open field represents an interaction of various factors 
including genetic background, maturation, biological rhythms, rearing, 
experience immediately prior to testing, stimulation by the test environment, 
previous experience of the test apparatus and method of measurement. Obviously 
this places limitations on the generalisations that can be made between 
experiments conducted in different laboratories. In addition it emphasises the 
importance that changes made at any stage of the experimental studies contribute 
to the findings. This led Henderson (1970) to pessimistically note that because of 
early environmental interactions with genotype were likely to limit the validity 
of findings uniquely to the laboratory of testing. 
The factors which influence the manifestation of behaviour in the open 
field can best be classed under the headings of environmental, experiential and 
internal factors. 
Environmental factors. Of all the environmental factors which influence 
behaviour the open field itself is perhaps of paramount importance. If the 
behaviour under study is locomotion, then the open field should be large enough to 
'elicit this behaviour. Generally open fields are either 0.75 -1 metre square or 
circular in nature, but some researchers (notably Schiorring, 1971) have used 
considerably larger open fields. Locomotion in rats is known to increase with 
increasing field size (Broadhurst, 1957; Montgomery, 1951), whilst a large 
open field size has been reported to produce a disproportionately large increase in 
locomotion under low levels of illumination (Blizard, 1971). There appears to be 
no reports in the literatuj-e of the effect of open field shape on behaviour, despite 
the fact that avoidance of the centre of the apparatus and thigmotaxis are an 
important aspect of the behavioural response in an open field. 
Testing animals in the light or dark portion of the day/night cycle is an 
important variable Influencing motor activity. Ivinskis (1970) has shown that 
open-field measures are influenced by the amount of illumination. High levels of 
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illumination produce low levels of activity, and stimulant drugs administered and 
tested in the dark produce a rate-dependent 'ceiling effect' of high control levels 
of activity (Montenaro and Babbini, 1965). Experiments should be designed to 
optimally test in the dark portion of the diurnal cycle with the use of red 
illumination, as the retina of the rat is relatively insensitive to this wavelength 
of light. 
Noise interference, extraneous to the test environment, can markedly 
affect activity levels in an open field (Ivinskis, 1970). High levels of noise have 
been shown to be aversive to the rat (Campbell and Bloom, 1965),, and abrupt 
loud noise has been shown to markedly inhibit locomotion and induce prolonged 
periods of immobility (Hofer, 1970; Walsh and Cummins, 1976). White noise 
has often been used to mask ambient noise, however its use has been noted to 
paradoxically reduce (Bindra and Spinner, 1958), or increase (Livesy and 
Egger, 1970), locomotion. 
Environmental odours are present in the test environment from both the 
previous test subject and the experimenter. Therefore it would seem to be a wise 
precaution to wash the open field between tests to exclude possible biasing effects 
of odour trails left by previous test subjects. The exclusion of the experimenter 
from the immediate test environment would also seem to be relevant. 
Experiential factors. Experiential factors refer to the experience of the animal 
in the same test situation, previous experience of the drug by the animal, and 
handling experience immediately prior to the experiment. 
The animal's prior experience with the test environment can exert a 
profound influence on the nature of open field locomotion. Experience with the 
test apparatus leads to habituation and a consequent decrease in levels of 
locomotion, in order to avoid masking drug-induced effects by a ceiling effect 
induced by a novel situation, animals should be habituated to the open field before 
treatment, though Battig (1969), claims that levels of activity were unaffected 
by exposure to the apparatus more than 2 hours before the experiment. 
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Previous experience with both apparatus and drug can affect behaviour 
over long periods (Rushton et al, 1963;1968). The studies to be outlined in the 
following chapters employed a 'single shot' method, thus there would seem to be 
little to be gained from an exhaustive discussion here of the interaction of 
previous experience with the test environment and drug, other than to record that 
it is highly significant. 
Details of the animal's removal from the home cage and transfer to the 
open field are seldom reported. Nevertheless, handling 'stress' is an important 
confounding factor in any test situation. Subjects which have been habituated to 
the transport procedure prior to testing show increased levels of locomotion at 
the beginning of an open field trial (Abel, 1971). Rats placed against a retaining 
wall have a tendency to remain on that side (Satinder, 1969). Therefore it would 
seem logical to standardise handling procedures, and to preferentially place 
animals in the centre of the open field at the start of a trial. 
The behaviour induced by a drug following injection varies as a function of 
the time preceding the test and the experience of the animal in this intervening 
period. Keeping the animal in its home cage for a period before testing produced 
different results on exploratory behaviour from those seen in animals placed in 
the experimental situation for the same period following methylphenidate 
(Hughes, 1972a), d-amphetamine and morphine (Sparber et al, 1973). In 
addition the route of drug administration will also effect behaviour, typically 
amphetamine is administered intra-peritoneally (IP) (see Dews 1972). 
Internal factors. The specjes and strain used in experimental studies places 
constraints on the extrapolation, generalisation and comparison with results 
reported in the literature, as strain differences in locomotor activity are well 
documented (Robbins, 1977). In addition to strain differences, age is-another 
factor which is known to influence open-field locomotor activity. In general, 
older animals are less responsive to both stimulant and depressant drugs. Both 
sex hormonal changes and circadian rhythms have been shown to influence drug-
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induced effects. Female rats are more active than males in a variety of situations 
including photobeam cages (Watzman et al, 1967). 
The nutritional state of the animal is also an important factor in 
influencing activity levels following drug treatment. Food deprivation is known to 
potentiate locomotor activity following treatment with d-amphetamine (Campbell 
and Fibinger, 1971., Simpson, 1974) and following treatment with apomorphine 
(Sahakian and Robbins, 1975) 
In some previous studies measuring locomotor activity in open fields along 
with concurrent, visual observation of behaviour, test sessions were as brief as 5 
to 10 minutes (eg Ljungberg and Ungerstedt, 1985). Such short test sessions 
maximise the influences of factors such as handling, familiarity with the test 
environment and escape related behaviour, all of which can be influenced by drug 
manipulation in a similar manner to the behaviour under study. The guidelines 
set out by the United States Environmental Protection Agency (EPA) indicate that 
the test session should be long enough for motor activity to reach asymptotic 
levels by the final 20 percent of the session for the majority of treatments and 
that activity measures should be collected in equal time periods not longer than 
10 minutes duration (Federal Register, 1986). These considerations suggest that 
sessions examining unconditioned amphetamine effects should be at least 30 and 
preferably longer than 60 minutes in duration (see Schiorring, 1971 and Rebec 
and Bashore, 1984). 
2.5 Validity of Open Field Measures 
So far the discussion of the open field and its relevance to behavioural 
pharmacological studies has hinged on the reliability of the methods employed and 
rigorous procedural constraints required to ensure inter- and intra- laboratory 
reliability of measurements. If the open field measure is examined in terms of 
its underlying constructs then the position is far from clear. The construct of 
"emotionality" has been widely represented in open field studies (Denenberg, 
1969). Ivinskis (1970), using a factor analytic design, attempted to test the 
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validity of a number of open field measures as indices of 'emotionality' in the rat: 
Of the seven parameters selected only defecation and latency to leave the starting 
area gave effective measures of 'emotionality', and then only as a consequence of 
changes in open field measures following changes in ambient auditory and visual 
stimuli. Clearly the evidence for any of the open field measures representing the 
intervening variable 'emotionality' is somewhat tenuous. In fact the term 
'emotionality' appears to be rooted in anthropomorphic interpretations. 
The act of placing a rodent in a novel open space from which it is 
prevented from escape by a surrounding wall can be viewed as a form of stress, 
rather than inducing emotionality. Several theorists have sought to emphasise the 
conflict between fear and exploration that occurs in rodents when placed in a 
novel environment (Hayes, 1960; McReynolds, 1962; Montgomery, 1955). The 
concept of a general stress response was developed by Selye (1950) and includes 
hormonal, metabolic and cytological changes which constitute the general 
response to environmental change, to this list of adaptive capability should be 
added behavioural change. Kinne (1964) considered the time course of adaptive 
responses in marine organisms to environmental change, and distinguished 
between the immediate response, the stabilisation of the response and the new 
steady state of performance. The immediate response to environmental change 
occurs over a time course of seconds to hours and may often involve 'overshoot or 
'undershoot' phenomena in altered rates of either behavioural or physiological 
processes. Such an approach can readily be applied to the open field situation. 
Antelman and Chiodo (1983) proposed that stress is an important factor 
in any model of schizophrenia, and went as far as to propose that the 
interchangeability of stress for amphetamine can account for a number of 
observations. Certainly acute psychosis can be induced by environmental 
stressors (Gardos and Cole, 1978), whilst stress can re-induce amphetamine 
psychosis in patients during remission (Utena, 1974). In addition the 
behavioural response to amphetamine is enhanced if the animal is exposed to 
unavoidable mild stress. Tail pinch has been studied as a non-specific arousing 
stimulus which activates dopamine neurones (Antleman et al, 1980), whilst rats 
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reared in isolation show both enhanced response to amphetamine and to tail 
pinch-induced oral behaviour (Sahakian et al, 1975; Sahakian and Robbins, 
1977). Whilst one of the major assumptions of Antleman and Chiodo (1983) is 
that the presence of a stressor should move the dose response curve for 
amphetamine-induced stereotypy to the left, this need not necessarily be the case. 
As Kinne (1964) has pointed out, the immediate response to a stressor may 
involve either 'overshoot' or 'undershoot' in altered responses such that 
movement in the dose response curve could be expected in either direction. In fact 
Robbins et al, (1990) state that 'Increments in "arousal" and "stress" do not 
always act in the same direction as increasing doses of amphetamine.' It is clearly 
over-simplistic to assert that environmental change acts upon a single 
hypothetical construct such as stress. The response of the organism to 
environmental change can readily be seen as falling into three broad categories: 
the components of a general response to stress; the specific behavioural and/or 
neuronal changes seen following individual stressors; and finally the change in 
'fitness' that results from these responses to environmental stimuli. These 
aspects of change to environmental stressors are inter-related and measurement 
of any or all of these aspects may contribute to the open field dependent measure, 
and thereby allow for a mixture of interoceptive and exteroceptive cues. 
Any behavioural test represents an interaction of the subject with the 
experimental situation, and exploration is defined as a broad category of 
behaviour which provides the animal with information about its external 
environment (Berlyne, 1960; Fowler, 1965), either by bringing the organism 
into contact with distant stimuli (inquisitive exploration) or by directed 
examination of proximal stimuli (inspective exploration) (Berlyne, 1960). 
Many behaviours are proposed to be indicative of exploration, including sniffing, 
rearing, and most commonly locomotion. Denenberg (1969) suggests that 
locomotion is both a measure of 'emotionality' in animals as well as indicative of 
exploratory behaviour, although the relationship between these two constructs 
remains unclear. Lat and Gollova-Hemon (1969) have described the behaviour in 
terms of arousal-habituation and constructs such as excitability, inhibition and 
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lability. Berlyne (1960) cites novelty and conriplexity of stimuli as eliciting 
exploratory behaviours, Robbins (1977) concludes that, of these, novelty is the 
more important. Lore (1968) proposes that in any particular test situation 
general activity levels consist of 'pure locomotor' behaviour alongside an 
exploratory component which is driven by the novelty and complexity of the test 
environment Leyland et al, (1976) claim that they were able to dissociate 'pure' 
locomotor activity and exploration using both novel and complex stimuli and 
amphetamine to obtain a double dissociation of the behavioural components. 
However, the use of visual stimuli seems somewhat incongruous in, an animal 
with poor visual acuity. 
Plots of locomotor routes taken by an animal in an open field 
following drug administration do not rely on specific exploratory variables and 
therefore any interpretation of these results in terms of exploratory behaviour 
must be viewed with caution. Such studies are useful for determining drug effects 
on general activity levels, but they do not distinguish between exploratory 
behaviour directed towards environmental stimuli and behaviour which is 
motivated by internal states or stimuli. These caveats should not deter or 
diminish the value of studying locomotor routes following drug administration but 
should provide the incentive to study this behaviour, not only in terms of its 
quantitative properties but also to gain an increasing level of understanding of the 
underlying constructs involved. 
In an attempt to comply with the above recommendations for the optimal 
testing of open-field locomotor behaviour, in particular with respect to its 
spatiotemporal characteristics, the procedures outlined below were adopted. 
Where these were not optimal, due to constraints placed on experimental design 
by factors outside the control of the experimenter, explanations are given. 
2.6 Method 
Apparatus. All experiments used an open field constructed from black perspex 
(30cm in height), which was either square (60 x 60cm) or circular (diameter 
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75cm). A closed circuit TV camera (Panasonic Colour WVP 200E), was mounted 
approximately five feet above each open field. In a separate room the camera 
picture was analysed by an HVS image systems VP112 unit which converted the 
video signal into a stream of X Y co-ordinate pairs, 3 per second. The digital 
tracking device used foreground/background contrast (white rat against black 
perspex) to determine the animal's position in the open field from the video 
image, by locating the first pixel group in the scanning pattern that met the pre­
set criterion for contrast (Renner et al, 1990). The apparatus was placed in a 
laboratory adjacent to the animal holding room which was devoid of ambient noise. 
Each apparatus was lit using dim red light, sufficient to allow for contrast-based 
image analysis (see figure 2.1). 
Subjects . Male Wistar rats (300-450g), the descendants of stock supplied by 
Olac, Bicester, Oxon. were used. Animals were bred in the University of Plymouth 
animal house facility and were available for use once they had reached the age of 6 
weeks. A minimum of 48 hours prior to an experiment, animals were moved to 
the experimental holding facility to acclimatise, where they were housed in 
groups of six with free access to food and water. Rats were maintained on a 12 
hour light/dark cycle with testing taking place in the light portion of the cycle. It 
would have been preferable to maintain animals on a 12 hour reverse light/dark 
cycle with testing taking place in the dark portion (Robbins, 1977; Geyer, 
1990), but as the animal house facilities were not exclusively for the use of the 
Department of Psychology this was not possible. The room temperature was 
maintained at 22 +- 3 degrees Celsius. 
Procedure. Animals were removed from the home cage, and if no pre-treatment 
drug was required, they were placed in the open field to habituate for 30 minutes. 
If a. pre-treatment drug was part of the experimental protocol, then animals were 
weighed, injected and then placed in the open field for the thirty minute 
habituatioh period. Immediately prior to injection animals were removed from 
the open field, weighed if this had not been done previously, and injected intra-
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peritoneally (IP) with stimulant drug. Animals were immediately replaced in the 
centre of the open field, for an experimental period of 105 minutes. The 
apparatus was washed with warm soapy water and dried with absorbent paper 
between test subjects. The open fields were not washed between the habituation 
period and the test session. 
Testing took place between 0900 - 1900 hours with the order of testing 
randomised for condition, time of day and cohort of animals. Weighing and 
injection took place in the animal holding facility, which was a room adjacent to 
the experimental laboratory. Both rooms were maintained at the same ambient 
temperature (22 +-3 degrees Celsius) and once the interconnecting door was 
closed were completely separated in terms of light, noise and odours. Analysis was 
conducted in a third room adjacent to the animal holding facility, where the 
experiment was monitored via video screens, enabling the experimenter to be 
absent from the test area for the entire experimental period. 
Behavioural observation . Animals were exposed to the open field for 30 minutes 
prior to injection of a psychostimulant drug (for exact details see individual 
experiments) and replaced immediately in the centre of the open field following 
injection of drug. The duration of each experimental trial was 105 minutes 
subdivided into 5 minute session intervals. This was deemed to be long enough to 
capture the entire preliminary locomotor phase (Schiorring 1971) for all doses 
of psychostimulants tested. 
Data Collection and Analysis . During the 105 minute test session the output from 
the camera and the HVS image analyser was monitored on a TV screen. The path 
taken by the subject was displayed on the computer screen by TRACKER software 
(Kenyon, 1990a), an IBM PC package written in Microsoft QuickBasic 2.0. The 
screen showed a representation of the floor of the open field divided into four 
equal-sized areas. The software tracked the animals movements between these 
quadrants. Horizontal movement was recorded as distance (in cm) moved by an 
animal in 5 minute time intervals. 
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The subjects sequence of movements between adjacent quadrants was 
subdivided into a series of trip lengths using S T E R E O software (Kenyon, 1991). A 
single trip consists of a sequence of movements between adjacent regions, and is 
terminated when the animal reverses direction, or completes a tour of the 
perimeter. Trip length is defined as the number of regions entered (lines 
crossed) during a period of forward locomotion without a turn (figure 2.2). 
S T E R E O assumes the floor of the open field has been divided into four regions 
(labelled 1,2,3,4), and that a complete trip in a clockwise direction around the 
field, starting and finishing in region 1, Would consist of the sequence: 1,2,4,3,1. 
This trip would be classified as a length 4 trip (figure 2.3). A centre trip is 
scored whenever the subject crosses between any of the regions of the open field 
that are diagonally opposite each other (eg from region 1 to region 4), and is 
classified as a length 1 trip. 
The program, written in Microsoft QuickBASIC 4.0, reads the sequence of 
region entries from DATA statements. This allows a word processor to prepare 
data for analysis. STEREO stores values for the number of trips, number of 
consecutive repeat trips for each subject in comma separated value (CSV) files. 
These files were then read into an Excel spreadsheet program and converted from 
IBM PC/XT (DOS) to Macintosh format. 
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Figure 2.1 
Components of the video image analysing system. 
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Figure 2.2 
Forward locomotion is divided into various 'trip lengths'. This 
sequence begins with a length 4 trip, the next trip is a length 3, 
this is followed by a length 2 trip, the last trip is length 1. 

Figure 2.3 
Example of length 4 trips. This sequence begins with a length 4 
trip, the next trip is also a length 4 trip. 

Chapter Three 
A Comparison between Caffeine- and Amphetamine-
Induced Hyperactivity and Stereotyped Locomotion in 
Open Fields with Different Shaped Perimeters. 
3.2 Introduction 
It is well documented that amphetamine not only Increases locomotion in 
rats, but also produces a qualitative change in the nature of open field 
hyperactivity (Lat, 1965; Segal , 1975; Schiorring, 1979; Mueller et al , 
1989a, 1989b). Several investigators have defined the perseverative nature of 
locomotor routes following administration of amphetamine as a form of 
stereotyped behaviour (eg Schiorring, 1979; Mueller et al, 1989a, 1989b). The 
work of Geyer and colleagues has indicated that quantification of the perseverative 
nature of open field locomotion following administration of a psychostimulant drug 
has the potential to discriminate drugs which would otherwise be 
indistinguishable when using conventional methods of quantifying open field 
locomotor behaviour (see Geyer, 1990). To date, quantification of locomotor 
patterns following stimulant drug administration remains only partially 
successful (see Chapter 1). The increasing sophistication of computer-based 
tracking and image analysis systems presents the opportunity to remedy this 
shortfall, and to develop novel techniques for the measurement of open field 
activity following drug administration, which will enable a more complete 
description of the amphetamine response in rats and ultimately lead to a more 
powerful tool at the disposal of behavioural pharmacologists. 
In our laboratory we have used a measure (termed 'trip length') as a 
means of quantifying perseverative patterns following amphetamine 
administration (Kenyon et al, 1992). For a complete description see Chapter 2. 
The purpose of the present study was to examine the reliability and validity of 
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'trip lengtii as a quantifier of locomotor patterns following amphetamine 
administration. Schiorring (1979) examined the locomotor patterns following a 
single (5mg/kg) dose of amphetamine and noted a change in the spatial 
characteristics of the resulting hyperactivity. Mueller et al, (1989a, 1989b) 
examined the changes in locomotor patterns following administration of 
amphetamine over a range of doses between 0.75 and 6.5 mg/kg, but were unable 
to find a dose-related increase in locomotor stereotypy, reporting that - contrary 
to expectations - animals treated with 2mg/kg exhibited the highest and most 
sustained increase in locomotor stereotypy (Mueller et al, 1989b). In this study 
we examined three hypotheses; that thigmotaxic length 4 trips would increase 
with increasing dose of amphetamine; that length 4 trips would decline as the dose 
of amphetamine was increased to a dose at which a 'switch' between locomotor 
behaviour and 'focused' stereotyped behaviours occurred, and finally that the 
increase in 'length 4 trips' would be unrelated to increases in activity levels per 
se. 
Caffeine, a methylxanthine and centrally active phosphodiesterase 
inhibitor, is often used in comparative psychopharmacological studies. It is a 
psychostimulant which produces increases in fonward locomotion without the 
concomitant stereotyped behaviours seen following treatment with amphetamine. 
Caffeine does not seem to affect dopamine activity directly (Modrow et al, 1981; 
Katims et al, 1983), and it is claimed that caffeine stimulates locomotor activity 
independent of neurar mechanisms associated with amphetamine-induced 
hyperactivity (Swerdlow and Koob, 1984). The mechanism of action of caffeine is 
thought to be a result of inhibition of the cyclic nucleotide phosphodiesterases 
(Butcher and Sutherland, 1962), which is responsible for the breakdown of 
cyclic AMP. Thus for systems using cyclic AMP as a second messenger, the effect 
of these transmitters will be potentiated and prolonged. Furthermore, caffeine 
potentiates responses in the autonomic nervous system which are mediated by B1 
and B2 adrenoceptors. It was hypothesised that caffeine would increase open field 
hyperactivity but would not increase the proportion of 'trip lengths' associated 
with thigmotaxic patrolling of the perimeter. 
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Kenyon et al, (1992), used a circular open field and it is unclear whether 
the thigmotaxic nature of length 4 trips which they reported is an artefact of this 
environment. Clearly open field behaviour in drug treated animals can be 
influenced by environmental factors. In Chapter 2 evidence was reviewed which 
suggests that levels of locomotion in rats is affected by illumination and the size of 
the open field. In view of the fact that spatiotempbral characteristics of locomotion 
show a marked change following amphetamine administration there have been no 
reports in the literature of the effect of open field shape on the patterns of 
locomotion seen following psychostimulant drugs. Robbins et al, (1990) claims 
that stereotyped behaviours induced under amphetamine are under a degree of 
environmental control. Oades (1985) reviewed the available evidence which 
claims a functional role for dopamine in facilitating the 'switching' between 
inputs and outputs of information to specific brain regions. He concluded that 
environmental feedback could play an important role in the unfolding of the 
amphetamine response in the open field. Szechtman et al, (1982) reported 
different patterns of stereotypy from two substrains of rats placed in the same 
environment. All the stereotyped behaviours exhibited contained one invariant 
feature: the maintenance of snout contact with a surface. 
The studies conducted by Schiorring (1971; 1979) and by Mueller et al, 
(1989a, 1989b) both used a square shaped open field. A square field contains 
corners which could possibly break snout contact, and as a consequence impede the 
thigmotaxic nature of amphetamine-induced hyperactivity. In contrast, the open 
field used by Kenyon et al, (1992) was circular and it remains unclear whether 
the nature of the unbroken perimeter contributed to the increase in thigmotaxic 
length 4 trips they observed under a dose of 3.5mg/kg amphetamine, or indeed 
whether these were purely an artefact of the circular nature of the environment. 
This present study examined the effects, in rats, of a wide dose 
range of amphetamine on the measure termed 'trip length'. In addition it was 
proposed to examine the effects of caffeine, a psychostimulant thought not to 
Induce stereotyped behaviours, on 'trip lengths'. To provide an insight into the 
effect that properties of the perimeter exert on the stimulant response, animals 
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were tested in square or circular open fields with an equal perimeter length. The 
circular open field was identical to the one used by Kenyon et al, (1992). The 
square open field had an equivalent length perimeter, but contained corners which 
could act to break snout contact with the surface, and possibly impede the animals 
thigmotaxic progression around the apparatus. In addition to providing 
information on the reliability and validity of 'trip length' as a quantification of the 
spatiotemporal characteristics of amphetamine induced locomotion, it was also 
expected that this study would provide information on both the optimum dose of 
amphetamine and the nature of the open field in which to study the spatial 
characteristics of amphetamine-induced hyperactivity. 
3.3 Materials and Methods 
Design. A 2 (field shape) x 9 (drug dose) x 21 repeated measures 
(session interval) experiment was conducted to examine the effects of field shape 
and differing psychostimulants on hyperactivity and trip types. Recordings were 
made (between subjects) in a square or circular open field during 105 minute 
test period, divided into 5 minute intervals. Each field was divided into a matrix of 
4 equal quadrants and the movement between these quadrants was recorded using 
an image analysis system. Distance moved (cm), and the number and proportion of 
each trip type (1-4) was recorded for each 5 minute interval. 
Animals. Seventy two male Wistar rats (3-4 months of age, 300 +- 74g) 
were housed in groups of six in a temperature regulated room (22+-3 ) 
adjacent to the laboratory for a minimum of 48 hours prior to being tested. They 
were maintained on a 12 hour light/dark cycle, lights on at 08:00, with food and 
water continuously available. 
Drugs. Amphetamine was dissolved in phosphate buffered saline at doses 
of 1, 2, 3, 4 or 5 mg/kg and injected IP in a volume of 1 ml/kg. Caffeine was 
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dissolved in pliospiiate buffered saline at a dose of 10 or 30 mg/ml. Caffeine was 
injected IP in a volume of 1 ml/kg (10, 30 mg/kg) and 2 ml/kg (60 mg/kg). 
Apparatus. The square open field (60 x 60 cm) and the circular open field 
(diameter 75 cm) had a perimeter of equal distance. Each apparatus was lit using 
dim red light. A video camera mounted above the open fields relayed an image to a 
monitor, image analyser and microcomputer, which sampled the animals position 
and stored it as XY co-ordinate pairs at a rate of 3 per second. The pattern of 
movement was analysed using TRACKER and STEREO programmes (Kenyon, 1990, 
Kenyon, 1991). A video recording of each experimental session was made. 
Procedure. 72 rats were randomly assigned to saline (SAL), amphetamine 1, 2, 
3, 4, or 5 mg/kg (AMPH), caffeine 10, 30, or 60 mg/kg (CAFF): square (SQ) or 
circular (C) open field groups (n = 8). 
Animals were habituated in the open fields for 30 minutes immediately 
prior to injection. Amphetamine or caffeine was injected IP and the animal 
immediately retumed to the open fields. Testing took place between 09:00 -
19:00 hours on each test day; both square and circular open fields were run 
concurrently with the test order randomised for drug dose and time of day. Each 
animal was used once only. Between each test the apparatus was thoroughly 
cleaned and dried to remove scent trails. 
Data Collection and Analysis. The computer-assisted image analysis system 
recorded distance moved; and analysed the sequence of movements (trips) between 
quadrants in the open fields during a 105 minute test session divided into 5 
minute intervals. Trip length was defined as the number of regions entered (lines 
crossed) during a trip. A trip was terminated when the rat changed direction, or 
completed a tour of the perimeter of the apparatus. 
Amphetamine and caffeine data were analysed separately, using.a mixed 
design Analysis of Variance (ANOVA) with treatment (field shape, drug dose) the 
between subjects factors and 5 minute session intervals the repeated within 
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subjects factor. Specific comparisons were made using tfie Newman-Keuls 
multiple range test (Winer, 1971). All ANOVA's were carried out using the 
STATVIEW package for Apple Macintosh and the follow up analyses were conducted 
manually. 
3.4 Results 
Total distance moved. 
The ANOVA indicated no significant main effect of field shape on the total 
distance moved in cm across the test session for any of the doses tested (F (1,84) 
= 0.001 p< 0.9729. Figure 3.1 shows the total distance moved across the session 
for all the drug doses administered. 
Amphetamine. Amphetamine (1-4 mg/kg) significantly Increased the total 
' distance moved across the session above that of saline treated animals in a dose 
related manner (F (5,84) = 39.37 p< 0.0001.). Animals treated with 4 mg/kg 
amphetamine achieved the greatest increase in distance moved over the 105 
minute test session. Animals treated with the highest dose of amphetamine (5 
mg/kg) showed a significant increase in the total distance moved above that of 
saline treated animals, but this treatment group covered a significantly shorter 
total distance across the session than animals treated with lower doses of 2, 3 or 4 
mg/kg. of the drug. p< 0.05 
Caffeine, 10 & 30 mg/kg. Caffeine significantly increased the total distance 
moved across the session (F (3,56) = 10.32 p< 0.0001). Animals treated with 
10 and 30 mg/kg caffeine travelled approximately equivalent distances to those 
exhibited by animals treated with either 1 or 5 mg/kg amphetamine (ps < 0.05). 
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Caffeine, 60 mg/kg. Animals treated with 60 mg/kg caffeine did not. increase the 
total distance moved across the session above that exhibited by saline treated 
animals. It is possible that this lack of hyperactivity was a result of this dose 
beinig at the threshold of the maximum dose which these animals could tolerate. 
Many of the rats remained immobile during the entire test session, although 
complete recovery from the effects of this drug was evident 2 - 3 hours after 
injection. These data will riot be discussed further. 
Distance moved across the session 
As expected there was a significant effect of time on the level of 
hyperactivity shown by animals treated with amphetamine (F (5,20)= 25.16, p< 
0.0001). Figure 3.2 shows the activity over the test session for all amphetamine 
and caffeine treated groups. All groups treated with amphetamine were most active 
in the first hour of the test session, with only those animals treated with 1 mg/kg 
returning to the level of activity exhibited by saline treated animals, 50 minutes 
after injection. 
In addition the ANOVA indicated a significant Drug Dose x Session Interval 
interaction. ( F(5,100) = 4.44 p<0.0001). As the dose of amphetamine increased 
the latency to maximum level of activity was shortened, with animals treated with 
5 mg/kg having the shortest'latency time of 20 minutes post-injection to reach 
maximum activity levels. 
Animals treated with caffeine (10 or 30 mg/kg) also showed a 
significant effect of time on the level of hyperactivity, with animals being most 
active in the first 45 minutes of the test session (F (2,20) = 10.78 p< 0.0001). 
Caffeine, unlike amphetamine, did not show a Dose x Session Interval interaction 
(F(2,40) = 1.35 p > 0.05). 
Effect of Field Shape on Distance Moved 
The ANOVA showed that field shape did not significantly affect the total 
distance moved across the session for any of the doses tested. Field shape had no 
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significant effect on any of tlie measures recorded for any of tlie caffeine- treatment 
groups. Interestingly, the ANOVA revealed that animals treated with amphetamine 
exhibited a significant Field Shape x Drug Dose x Session Interval interaction for 
distance moved (F(100,1680) =1.35 p< 0.05). Examination of this interaction 
revealed that animals treated with 4 or 5 mg/kg and tested in the square field 
showed a reduction in the peak level of activity, whilst the duration of 
hyperactivity continued further into the test session than the same treatment 
groups tested in the circular field (see figure 3.2). 
Figure 3.3 shows the cumulative percentage of the total distance moved for 
each of the 5 minute session intervals. It is clearly evident that the development 
of the hyperactive response In animals treated with 1, 2 and 3 mg/kg 
amphetamine follows an identical time course when tested in either a square or 
circular open field. In marked contrast, the development of amphetamine-induced 
hyperactivity following treatment with either 4 or 5 mg/kg amphetamine 
exhibited a markedly different time course depending on whether the animals 
were tested in an open field with a square or circular perimeter. Animals treated 
with 4 mg/kg amphetamine had covered a significantly greater distance in the 
circular field compared to this group tested in the square field after 60 minutes of 
the test session had elapsed. Those animals treated with 5 mg/kg amphetamine 
covered significantly greater distances 45 minutes into the test session in a 
circular open field. This significant increase in hyperactivity was maintained for 
the remainder of the test session in both groups. 
Proportion of lengtfi 4 trips. 
Treatment with amphetamine changed the pattern of movement made by 
animals in the open field. Amphetamine treated animals took a locomotor path 
which became increasingly repetitive, remaining close to the perimeter wall 
(thigmotaxis). The qualitative change in the spatial distribution of movement 
exhibited by amphetamine treated animals was reflected in a change in the 
proportions of trip lengths over the session. 
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Figure 3.4 sliows an example of relative proportions of length 1 and length 
4 trips made by a typical group of Vehicle-Saline treated animals, and a typical 
group of Vehicle-Amphetamine (3.5mg/kg) treated animals. 
-Figure 3.4A shows that the majority of trips made by Vehicle-Saline 
treated animals were length 1, with a significantly smaller proportion of length 4 
trips (p < .01). 
Figure 3.4B shows that treatment withan intermediate dose of 
amphetamine increased the proportion of length 4 trips. In addition, amphetamine 
resulted in a significant change in the proportions of trip lengths as a function of 
time interval across the session. At time intervals 15 to 90 minutes the 
proportion of length 4 trips was increased and the proportion of length 1 trips 
was decreased under amphetamine (p < .01). The increase in length 4 trips after 
treatment with amphetamine reflected a tendency for animals to take a path 
around the perimeter of the open field which became increasingly repetitive, 
particularly during the period of peak drug response. 
Number of length 4 trips 
Figure 3.5 shows the total number of length 4 trips made by each of the 
treatment groups. Saline treated animals made relatively few thigmotaxic 
perimeter trips, usually less than 10. In marked contrast, the total number of 
length 4 trips increased following treatment with amphetamine. Groups treated 
with 3 or 4 mg/kg amphetamine made between 120 - 190 perimeter tours of the 
open field during the 105 minute test session. 
Proportion of length 4 trips 
Figure 3.6 shows the effect of amphetamine on the proportion of complete 
trips around the perimeter (length 4 trips) in a square or circular open field 
over time. An ANOVA conducted on this measure revealed that there was no 
significant main effect of field shape on the total proportion of length 4 trips over 
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the entire105 minute test session for any of the treatment groups (F (1,84) = 
1.204 p< 0.2756. The ANOVA confirmed a significant main effect of amphetamine 
dose (F (5, 84) = 13.93, p < 0.0001) on this behaviour. Comparisons using 
Newman-Keuls multiple range test revealed that animals treated with 2, 3, 4 or 
5mg/kg amphetamine showed a significant increase in the proportion of length 4 
trips, and that those animals treated with 3 or 4mg/kg amphetamine showed 
significantly more length 4 trips than any other treatment group (p< 0.05). 
Treatment with caffeine (10 & 30mg/kg) did not result in a significant increase 
in the proportion of length 4 trips above those of saline treated animals (F(2,42) 
= 2.519, p > 0.05). 
Effect of field shape on the proportion of length 4 trips 
The ANOVA conducted on the proportion of length 4 trips data also revealed 
a significant Field Shape x Drug Dose x Session Interval interaction 
(F(100,1680) = 1.41, p< 0.005). Figure 3.6 shows that animals treated with 4 
or 5 mg/kg amphetamine exhibited a time course for the emergence of length 4 
trips which was varied according to field shape. Animals treated with 4 mg/kg 
amphetamine and tested in the square field continued to make thigmotaxic length 4 
trips longer into the test session than in the circular field. This group made 
proportionally more length 4 trips at session interval '65 minutes' (Mean = 
0.39, S E M = 0.14) than in the circular open field (MEAN = 0.18, S E M = 0.07) 
(p < 0.025). This significant increase in the proportion of thigmotaxic trips was 
maintained until 90 minutes into the test session (Circular Field Mean = 0.07, 
S E M = 0.02; Square Field Mean = 0.21, S E M = 0.35 p< 0.025). During the final 
10 minutes of the session the proportion of length 4 trips remained equivalent in 
both the square and circular shaped open fields. 
Figure 3.7 shows the cumulative percentage of the number of length 4 
trips made for each of the 5 minute session intervals. These illustrate the 
development of length 4 trips, ahd show quite clearly the stepwise progression of 
saline treated animals touring the perimeter of the square open field. In marked 
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contrast, treatment with amphetamine (1 to 3mg/l<g) removed this stepwise 
movement and resulted in an identical development of length 4 trips in both types 
of open-field. Treatment with the higher doses of 4 or 5 mg/kg amphetamine 
resulted in a marked facilitatory effect on this measure for animals tested in a 
circular field. Rats treated with the maximum dose of 5mg/kg, tested in a circular 
open field made 100% of the length 4 trips by 45 minutes compared with similar 
treated animals tested in a square field, who made length 4 trips over the entire 
test session. 
3.4 Discussion 
As expected, amphetamine and caffeine increased hyperactivity in the open 
field, resulting in an increase in the distance moved over the 105 minute test 
session. In contrast, amphetamine but not caffeine, resulted in an increase in the 
proportion of thigmotaxic length 4 trips. This increase was most marked for 
groups treated with 3 or 4 mg/kg amphetamine, doses which are also associated 
with the greatest increase in distance moved across the test session. The initial 
locomotor phase is known to decrease in duration at doses greater than 5mg/kg 
(see Rebec and Bashore, 1984), and with increasing dose the animal will spend 
more time engaging in focused stereotyped behaviours. This effect was replicated 
in this experiment; animals treated with 5mg/kg amphetamine covered less 
distance, and made fewer length 4 trips, than animals administered 2-4 mg/kg of 
the drug. The increase in the proportion of length 4 trips exhibited by 
amphetamine - but not caffeine-treated groups - would tend to support the 
suggestion that thigmotaxic patrolling of the perimeter of the open field measured 
as length 4 trips is an aspect of amphetamine-induced hyperactivity rather than 
the stimulant properties of the drug per se. These results remain far from 
unequivocal. The magnitude of the hyperactive response induced by either 10 or 
30 mg/kg caffeine was only equivalent to the increase in activity exhibited by 
animals treated with 1 mg/kg amphetamine. It should be noted that treatment with 
this dose of amphetamine did not result in an increase in the proportion of length 
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4 trips. Caffeine was administered at a dose of 60 nig/l<g in an attempt, to obtain 
increased levels of hyperactivity, but these animals remained hypoactive for 
reasons which are not clear, although one likely explanation is that this high dose 
exerted a toxic, rather than stimulatory, effect on these animals. 
Perhaps the most interesting aspect of these results is the effect of field 
shape on the time course of the amphetamine response. The nature of the 
perimeter had no effect on the time course of hyperactivity exhibited by animals 
treated with caffeine or low doses of amphetamine. Animals treated with the 
highest doses of amphetamine (either 4 or 5 mg/kg) exhibited markedly different 
patterns of response over time when tested in a square or circular open field. 
Animals tested in a circular field covered greater distances at the time of peak 
drug response and jarogressed more rapidly from the locomotor phase of the 
amphetamine response to other static behaviours (see Chapter 5) than animals 
treated with equivalent doses of amphetamine tested in a square open field. Those 
animals tested in a square field exhibited lower peak levels of activity and spent a 
longer time engaged in forward locomotion and thigmotaxic patrolling. At the end 
of the 105 minute test session there was no significant difference in the total 
distance either group of animals had covered: the time course rather than the total 
amount of forward locomotion was influenced by field shape. Surprisingly, the 
corners present in the square perimeter did not impede forward locomotion and 
force the animal to engage in static focused behaviours but actually increased the 
time spent in forward locomotion and thigmotaxic progression around the 
perimeter. The hypothesis put forward by Lyon and Robbins (1975) states that 
administration of amphetamine leads to reductions in pausing and enhanced 
behavioural competition among the different response sequences. These results 
lend support to this hypothesis. The effect of the perimeter on the time course of 
forward locomotion and length 4 trips is relevant only to those doses of " 
amphetamine close to the dose at which the dominant response shifts from 
locomotory behaviours to focused stereotyped behaviours, indicating that at these 
doses the animal is experiencing competition for expression between the 
locomotor effects of the drug and focused stereotyped behaviours. It would appear 
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that far from being an artefact of the circular open field, thigmotaxic length 4 
trips are a link between locomotory and static focused behaviours, with the 
locomotory path taken by the. animal becoming increasingly stereotyped leading 
eventually to focused stereotyped behaviours. Presumably at this time the animal 
experiences increasing competition for the expression of behavioural elements of 
the amphetamine response which are open to sensory input and individual 
expression. 
Szechtman et al (1982) have claimed an important role for the 
maintenance of snout contact in the amphetamine response, particularly linked to 
forward locomotion. The nature of the perimeter could serve to either maintain 
snout contact (circular open field) or disrupt snout contact (square open field) 
which may be an important factor in the unfolding of the behavioural sequence of 
events. The expression of amphetamine-induced forward locomotion could be 
dependent upon snout contact. The findings in this experiment suggest that neither 
open field encouraged more or less fonward locomotion, the influence was merely 
on the time course of the behavioural sequence. 
The finding that thigmotaxic patrolling of the perimeter measured as an 
increase in the proportion of length 4 trips increases with increasing dose of 
amphetamine between 2-4 mg/kg, and that a maximum increase in the proportion 
of length 4 trips was obtained in animals treated with 4 mg/kg amphetamine 
indicates that future studies should utilise a dose within this range. Ideally, 
activity levels should be elevated to such an extent that both inhibitory and 
facilitatory effects of pre-treatment with antipsychotic drugs could be detected. 
These experimental findings indicate that measures of thigmotaxic patrolling 
obtained from animals administered amphetamine at a dose close to that at which 
the dominant response shifts from locomotory behaviours to focused stereotyped 
behaviours are less robust, and that the time course of this behavioural response 
can be readily altered by environmental input. In the light of these findings it 
would be advisable to use a dose of amphetamine which gives near maximum 
increases in the proportion of length 4 trips, but the time course remains 
invariant regardless of open field shape. Kenyon et al, (1992) used 3.5mg/kg 
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amphetamine and pre-treatment with 20mg/kg sulpiride and were able to show a 
decrease in hyperactivity, without entirely eliminating forward locomotion or the 
associated increase in the proportion of length 4 trips. The findings of this 
present experiment, and the findings of Kenyon et al, (1992) would support the 
use of 3.5mg/kg amphetamine in studies designed to examine the effects of pre-
treatment with antipsychotic drugs on amphetamine-induced hyperactivity and 
the associated increase in the proportion of length 4 trips. 
Open field shape had no effect on the total number of length 4 trips, 
although groups treated with 3 or 4 mg/kg amphetamine and tested in the square 
open field showed increased variability in the number of trips around the 
perimeter of the open field, this may have masked a trend for animals to make 
more length 4 trips in the square field at these higher doses. What remains clear 
from these findings is that testing in a circular field produces a sharper dose 
response, with animals reaching higher numbers of length 4 trips at the time of 
peak drug response. It could be argued that this test environment eliminates the 
exploratory component of the locomotor response. Preliminary studies into 
stereotyped forms of locomotor behaviour induced under amphetamine should use 
a circular open field, allowing more explicit measures of exploratory behaviour 
(eg holepokes) to be introduced once measures of the stereotyped component of 
hyperactivity have been well documented. 
Summary 
This experiment tested the hypothesis that thigmotaxic perimeter trips 
(length 4 trips) are a discrete stereotyped component of amphetamine-induced 
hyperactivity. Rats were treated with a range of doses of amphetamine, or 
caffeine, and then tested in either a square or a circular open field. An automated 
tracking system was used to record distance moved and sequences of movements 
between quadrants in the open fields. The results showed that amphetamine (all 
doses) and caffeine (10 or 30 mg/kg) significantly increased the total distance 
moved across the 105 minute test session. Amphetamine (2 to 5 mg/kg), but not 
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caffeine, increased tlie proportion of length 4 trips above those of saline treated 
animals. Field shape did not influence either the total distance moved, or the 
proportion of length 4 trips over the session at any of the doses tested. 
Interestingly, animals treated with 4 or 5 mg/kg amphetamine exhibited a 
significant Field Shape x Drug Dose x Session Interval interaction for both 
distance moved and the proportion of length 4 trips. Analysis of this interaction 
revealed that the duration of hyperactivity and thigmotaxic patrolling was 
prolonged in rats tested in the square field. This experiment also indicated that 
using a dose of amphetamine between 3 and 4 mg/kg and then testing animals in a 
circular open field provides the optimum conditions for studying amphetamine-
induced hyperactivity and trip lengths. 
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Figure 3.1 
Mean (+-SEM) distance moved (cm) during tiie 105-min observation 
period by rats (n = 8 per group) injected wjtii saline, amphetamine (1-
5 mg/kg) or caffeine (10-60mg/kg) and tested in a square or circular 
open field. 
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Figure 3.2 
Mean (+-SEM) distance moved (cm) per 5 min during tlie 105-min 
observation period by rats (n = 8 per group) treated witli saline, 
amphetamine (1-5 mg/kg) or caffeine (10-60 mg/kg), and tested in a 
square (closed squares) or circular (open circles) open field. 
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Figure 3.3 
Cumulative percentage of the total distance moved by rats (n = 8 per 
group) at each of the 5 min session intervals. Rats were treated with 
saline, amphetamine (1-5 mg/kg) or caffeine (10-60 mg/kg) and 
tested in a square (closed squares) or circular (open circles) open 
f i e ld . 
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Figure 3.4 A-B. 
Mean (+-SEM) proportion of lengtli 1 and lengtii 4 trips per 15 min 
over 105 min test session (n=8 per group). Length 1 trips (closed 
circles); Length 4 trips (open circles). (A) Vehicle-Saline; (B) 
Vehicle-Amphetamine. 
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Figure 3.5 
Mean (+-SEM) number of length 4 trips made over the 105-min 
observation period by rats (n = 8 per group) treated with saline, 
amphetamine (1-5 mg/kg) or caffeine (10-60 mg/kg), and tested in a 
square (dark bars) or circular (light bars) open field. 
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Figure 3.6 
Mean (+-SEM) proportion of length 4 trips per 5 min during the 105-
min observation period by rats (n = 8 per group) treated with saline 
or amphetamine (1^5 mg/kg), and tested in a square (closed squares) 
or circular (open circles) open field. 
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Figure 3.7 
Cumulative percentage of the total number of length 4 trip^ 
made by rats (n = 8 per group) at each of the 5 min session 
Intervals, treated with saline or amphetamine (1-5 mg/kg) and tested 
in a square (closed squares) or circular (open circles) open field. 
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Chapter Four 
Effects of Clozapine, Sulpiride and Haloperidoi on 
Amphetamine-Induced Perseverative Locomotor Patterns. 
4.1 Rationale for drug selection 
Antipsychotic drugs used to treat schizophrenia are classified as either 
'classical' or 'atypical' depending on their clinical profile. Both classes of drug 
ameliorate the thought disorders associated with the disease, and some atypical drugs 
(eg clozapine) appear to have a broader therapeutic range and are claimed to improve 
the negative symptoms (Meltzer, 1986). It has also been claimed that atypical 
antipsychotics are less likely to elicit extrapyramidal side effects (Burki, 1979). In 
animal tests of motor dysfunction atypicals, unlike classical antipsychotics, fail to 
produce catalepsy or elicit only a mild form of it. Classical and atypical antipsychotic 
drugs have also been shown to differ in their ability to block amphetamine-induced 
stereotyped behaviours in rats (Ljungberg and Ungerstedt, 1985; Tschanz and Rebec, 
1988), but in contrast, locomotor activity produced under low doses of amphetamine 
is blocked by both classical and atypical antipsychotics (Ljungberg and Ungerstedt, 
1985). This has been seen as evidence that atypical drugs fail to block striatal 
dopamine receptors which play a major role in the induction of stereotyped 
behaviours. 
White and Wang (1983) found that prolonged treatment with classic 
antipsychotic drugs decreased dopamine activity in the substantia nigra and the 
mesolimbic dopamine system, whereas atypical drugs caused a time dependent 
inactivation of the mesolimbic dopamine system only, suggesting that the inability of 
atypical antipsychotics to decrease striatal dopamine activity may be related to their 
lowered potential to induce tardive dyskinesia, whilst the inactivation of the 
mesolimbic dopamine system may be associated with the delay in onset of the 
therapeutic effects. These findings have led to the suggestion that blockade of 
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stereotyped behaviours mediated via striata! dopamine reflect a compound's ability to 
induce possible motor side effects, whereas blockade of amphetamine-induced 
locomotor activity mediated via mesolimbic dopamine is an indication of therapeutic 
effect (Tschanz and Rebec, 1989). 
What is becoming increasingly clear is that the hyperactivity and stereotyped 
behaviour seen following amphetamine administration are not discrete responses. Low 
doses of amphetamine increase locomotion but also increase repetitive sniffing, 
rearing and head swaying, all behaviours which occur under higher doses of 
amphetamine during the focused stereotypy stage when locomotor activity declines 
(Schiorring, 1971; Rebec and Bashore, 1984). Furthermore, there is evidence that 
perseverative motor patterns seen following administration of intermediate doses of 
amphetamine may constitute a stereotyped form of locomotion (Schiorring, 1979; 
Mueller et al, 1989a, 1989b; see Chapter 3). What has become increasingly clear is 
that locomotion does not occur independently of all stereotyped behaviours and that 
stereotypy is not a unitary response (Randrup and Munkvad, 1974; Rebec and 
Bashore, 1984). Indeed interesting results by Robertson and MacDonald (1984, 
1985) have shown that three atypicalantipsychotic drugs: clozapine, thioridazine, 
and sulpiride all potentiated some, but not all, amphetamine-induced stereotyped 
behaviours. 
Kenyon et al, (1992) found that sulpiride, although reducing amphetamine-
induced hyperactivity, had no effect on the proportion of thigmotaxic trips around the 
perimeter of the open field. In view of the fact that atypical antipsychotic drugs fail to 
antagonise all aspects of amphetamine-induced stereotyped behaviours this finding 
lends support to the claim that aspects of amphetamine-induced open field locomotion 
may be stereotyped. In order to evaluate this claim it is necessary to examine the 
effects of a w|de range of doses of both classical and atypical antipsychotic drugs on the 
measure termed 'trip length' to determine whether this behaviour is differentially 
affected by different classes of antipsychotic drug. 
Atypical and classical antipsychotic drugs are not a homogeneous group of 
compounds, and the major method of classification for such a disparate group of drugs, 
irrespective of their ability to induce extrapyramidal symptoms in treatment, is in 
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terms of their chemical structure. The first category of antipsychotic drugs to be 
developed were the phenothiazines, (see Bradley and Hirsch 1986), which includes' 
chlorpromazine. In addition to antipsychotic action the phenothiazines exhibit 
cardiovascular effects, and anti-emetic action. In experimental animals the 
phenothiazines reduce motor activity, induce catalepsy and block conditioned avoidance 
responses. All the phenothiazines, with the exception of the piperidine group (eg 
thioridazine), induce extrapyramidal symptoms, which closely resemble Parkinson's 
disease. Consequently the phenothiazines constitute a major group of the classic 
antipsychotic drugs. 
Another major category of classic antipsychotic drugs are the butyrophenones 
which - unlike the phenothiazines - do not possess tricyclic structure. The first of 
these drugs to be used clinically was haloperidol. Butyrophenones have strong 
antipsychotic action but lack some of the properties of the phenothiazines, having 
little or no antihistaminic, anticholinergic or antiadrenergic activity and as a 
consequence lack sedative properties associated with histamine antagonism, and have a 
reduced tendency to cause autonomic disturbances when compared with the 
phenothiazines. All the butyrophenones have a marked tendency to produce 
extrapyramidal side effects. 
A relatively new class of antipsychotic drugs, classified as atypical, are the 
substituted benzamides, of which the drug sulpiride has been used as an effective 
antipsychotic agent (Borenstein et al, 1969). Sulpiride binds to a subgroup of D2 
receptors which are sodium dependent (Jenner and Marsden, 1982), and are located 
pre-synaptlcally (Verhoeven et al, 1979). Sulpiride does not induce catalepsy even at 
high doses, and at relatively low doses it inhibits apomorphine induced locomotion. 
With long-term treatment sulpiride does not induce an increase in D2 receptors, but 
does produce a significant increase in DI receptors in contrast to antipsychotics such 
as haloperidol which elevate D2 but not DI receptors (Jenner et al, 1980). Sulpiride 
has been shown to induce extrapyramidal side effects, but the incidence of these effects 
are reported to be less than for other antipsychotic drugs (see Tamminga and Gerlach, 
1987). Because of the selective action of sulpiride at D2 receptors there are very few 
autonomic and cardiovascular side effects, hormonal side effects such as galactorrhea 
Classic & Atypical antipsychotics 63 
and amenhorrhea resulting from an increase in prolactin levels are relatively 
common (Gerlach 1991). Since sulpiride shows only part of the activity in animal 
models common to the antipsychotic drugs they are classed as atypical, although 
Meltzer et al, (1989c) has suggested that the substituted benzamides along with 
thioridazine, should not be classified with clozapine as atypical. 
The dibenzazepine derivatives are compounds of immense theoretical interest, 
the principle antipsychotic drug in this group is clozapine. Interest has focused on 
clozapine because although it has weak D2 receptor blockade, it is an extremely 
effective antipsychotic agent (Meltzer et al, 1989a), and has been shown to be more 
effective than the classical antipsychotics in the treatment of schizophrenia (Kane et 
al, 1988). It produces little or no tardive dyskinesia, and few extrapyramidal side 
effects. 
Behavioural studies suggest that clozapine is mainly active at the mesolimbic 
sites, and that the striatal system is relatively unresponsive to clozapine. Clozapine 
produces little or no catalepsy in rats (Bartholini et al, 1972; Burki e t a l , 1975a; De 
Maio, 1972; Honma and Fukushima 1978), which is a classic test of neostriatal 
dopamine receptor blockade (Carlsson, 1978). Amphetamine-induced locomotion 
resulting from enhanced dopaminergic transmission in the nucleus accumbens (Kelly 
and Iversen, 1976; Pijnenberg et al, 1976) is Inhibited by acute clozapine whereas 
amphetamine-induced stereotyped gnawing, sniffing and grooming is unaffected by this 
drug (Iversen and Koob, 1977). Ljungberg and Ungerstedt (1978) have also shown 
that clozapine blocks apomorphine-induced locomotion but not stereotypy. In addition, 
hyperactivity induced by direct injection of dopamine into the nucleus accumbens is 
blocked by lower doses of clozapine than are required to block behaviours elicited by 
striatal dopamine injections (Costall and Naylor, 1976), Robertson and MacDonald 
(1984) report that clozapine potentiated some amphetamine-induced stereotyped 
behaviours. 
Clozapine has been reported to increase the firing rate of mesolimbic but not 
striatal dopamine neurones, whereas acute haloperidol increiased the activity of both 
mesolimbic and striatal neurones (Hand et al, 1987), an effect entirely consistent 
with the concept that clozapine exhibits mesolimbic selectivity. Contradictory 
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evidence was provided by several researchers who found that both clozapine and 
haloperidol increased the firing rate of both striatal and mesolimbic neurones (Sauto 
et al, 1979; Rebec et al, 1980; Chipdo and Bunney, 1983, 1985). This has led 
Meltzer (1991) to conclude that there is some evidence to suggest that clozapine 
exhibits mesolimbic selectivity and that this may account for the drugs lack of 
extrapyramidal symptoms and tardive dyskinesia. Limbic selectivity would be 
unlikely to account for the drugs increased efficacy in treatment. In addition, Meltzer 
(1991) claims that depolarisation inactivation following chronic treatment with 
antipsychotic drugs (Chiodo and Bunney, 1983, 1985; White and Wang, 1983) are 
unlikely to provide an explanation of the mechanism of action because release of 
dopamine from nerve terminals may be more independent of cell firing than was 
originally thought (Abercrombie and Zigmond 1990). 
The selectivity of clozapine for the mesolimbic dopamine system may well be 
the result of interactions with other neurotransmitter systems which would 
compensate for dopamine blockade in the striatum. Clozapine's antagonistic effects on 
cholinergic or adrenergic receptors may account for the drug's mesolimbic 
selectivity. Clozapine has moderately potent antagonistic effects on several types of 
adrenergic receptor (Gross and Schumann, 1982), and there is some evidence that 
enhanced noradrenergic activity contribute to the intensification of negative and 
positive symptoms of schizophrenia (van Kammen et al, 1990), therefore blockade of 
adrenergic receptors may have some clinical relevance (Meltzer, 1991). Clozapine is 
a potent antimuscarinic agent, and this high potency may account for the low 
extrapyramidal symptoms seen in clozapine treated patients, although administering 
large doses of the antimuscarinic drug, cogentin, with halpperidol or chlorpromazine 
did not achieve the same effects as clozapine with respect to extrapyramidal side 
effects, positive symptoms or negative symptoms (Kane et al, 1988). 
A more likely explanation of clozapine's unique clinical profile is its effect on 
serotonin systems. Clozapine has been shown to be an effective 5HT antagonist in vivo 
(see Meltzer, 1991), although the data to support an effect on 5HT metabolism in 
vitro in rat brain are inconclusive (Ichikawa and Meltzer, 1991). Meltzer et al, 
(1989c) have shown that atypical antipsychotics produce two orders of magnitude 
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more 5HT2 receptor blockade than the classical drugs produce. The importance of 
5HT2 receptors in schizophrenia is supported by evidence that 5H t2 receptor density 
is decreased in frontal cortex in patients with schizophrenia (Mita et al, 1986; 
Meltzer, 1991). Meltzer (1991) speculates that serotonergic activity in 
schizophrenia leads to a down regulation of 5HT2 receptors, and that clozapine and 
other atypical drugs may lead to further decreases in 5HT transmission, as a 
consequence of their potent antagonism at 5HT2 receptors. 
There is also evidence that 5HT3 receptor stimulation may increase dopamine 
release (Blandina et al, 1988). There is therefore some expectation that 5HT3 
antagonists may exhibit antipsychotic action as a result of decreasing dopamine 
release, somewhat analogous to the development of autoreceptor agonists as a 
mechanism of decreasing dopamine release. Clozapine exhibits moderate 5HT3 
antagonism (Ashby et al, 1989; Watling et al, 1990), although how this relates to the 
therapeutic action of clozapine is unknown. 
In summary clozapine, in contrast to the classic antipsychotics, exhibits low 
in vitro affinity for the striatal D2 receptors and relatively greater affinity for 
striatal DI receptors, cortical and subcortical 5HT2 and 5HT3 receptors, and central 
adrenergic, histamine and muscarinic receptors (see review by Fitton and Heel, 
1990). It is unlikely that D2 receptor antagonism can fully account for the drugs 
superior antipsychotic action, and it has been suggested that the drugs efficacy may be 
related to D1, or a combination of DI and D2, antagonism (Alter et al, 1988; Andersen 
and Braestrup, 1986; Coward et al, 1989; Criswell et al, 1989), with 5HT2 
antagonism playing a supplementary role (Meltzer, 19.89), whilst the low incidence 
of extrapyramidal symptoms seen following treatment with clozapine result from its 
selective action on mesolimbic dopaminergic mechanisms (Borison and Diamond, 
1 9 8 3 ) . 
Recently the D3 receptor (Sokoloff et al, 1990) has been identified. Limbic 
regions are rich in D3 mRNA, whilst high concentrations of D3 receptors on the cell 
bodies of both striatal and mesolimbic dopamine neurones suggest that the D3 receptor 
may be an autoreceptor. In addition dopamine has been shown to have a twenty fold 
greater affinity for the D3 than for the D2 receptor. Although all antipsychotic drugs 
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are more potent at the D2 than D3 receptor, drugs classified as atypical such as 
clozapine and (-) sulpiride are only two to three times more potent at the D2 
receptor. Sokoloff et al, (1990) suggest that D3 antagonism may be an important 
aspect of antipsychotic activity. 
In studies into the putative mechanisms of dopaminergic and non-dopaminergic 
drugs which are proposed as antipsychotic agents a strong note of caution should be 
made, which is best illustrated by the drug savoxepine. The possibility that the 
hippocampus may be abnormal in schizophrenia has been intensively examined. 
Studies into patients post-mortem (Stevens, 1973), and using magnetic resonance 
imaging techniques, have found hippocampal abnormalities and these could be relevant 
to the memory dysfunction associated with schizophrenia. This led Bischoff (1986) to 
suggest that selective blockade of dopamine receptors in the hippocampus, without 
striatal dopamine receptor blockade, might produce an antipsychotic drug with an 
atypical profile. Savoxepine is a novel tricyclic compound with strong D2 blocking 
effect with a tenfold higher affinity for hippocampal than striatal D2 receptors 
(Bischoff et al, 1986). Furthermore, savoxepine has a profile similar to clozapine in 
that it blocks DI , 5HT2, adrenergic and histaminergic HI receptors (Gerlach, 1991). 
In behavioural tests savoxepine has been shown to antagonise dopamine agonist-
induced locomotion and stereotyped behaviours at relatively low doses, but much 
higher doses are required to induce catalepsy (see Gerlach, 1991). This action in 
animal models led to trials of savoxepine as an antipsychotic agent which, it was 
claimed, would not induce extrapyramidal symptoms at therapeutic doses. 
In three open studies it has been shown that savoxepine has therapeutic effects 
at doses between 0.25 and 2 mg/day (Butler and Bech, 1987; Moller et al, 1989; 
Wetzel et al, 1991). In the last two studies, savoxepine induced Parkinson's 
symptoms, akithisia and acute dystonia. Although these studies were not conducted as 
blind trials it would appear that affinity for hippocampal D2 receptors, and the 
differential doses required to induce catalepsy and block dopamine agonist-induced 
behaviours did not predict a drug with a reduced risk of extrapyramidal side effects at 
therapeutic doses. 
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4.3 Introduction 
Antagonism of ampfietamine-induced beliaviours in animals has been used to 
study the underlying mechanisms of antipsychotic drug treatment, and to detect novel 
antipsychotic agents. Considerable attention has focused on amphetamine-induced 
stereotyped behaviours such as sniffing, licking and gnawing because these behaviours 
are reliably antagonised by classic antipsychotics such as haloperidol and 
chlorpromazine (Szechtman et al, 1988). It is now clear that a group of clinically 
effective drugs - so called atypical antipsychotics - do not antagonise all the 
components of the amphetamine-induced syndrome. 
Tschanz and Rebec (1989) reported that atypical antipsychotics vary in their 
ability to antagonise specific amphetamine-induced behaviours. For example, 
clozapine blocks sniffing but not the rearing or head bobbing produced by the drug. 
Paradoxically several researchers have reported that clozapine and other atypical 
antipsychotics actually enhance the stereotyped head movements and sniffing induced 
by 2 - 5 mg/kg amphetamine (Robertson and MacDonald, 1985; Sharp et al, 1986). 
Under amphetamine, locomotion often takes the form of thigmotaxic 
patrolling of the open field boundary and this behaviour is exhibited repetitively 
under higher doses of the drug (Schiorring 1979; Mueller et al, 1989a, see chapter 
3). Previous studies have reported that approximately 30 - 40% of trips were 
around the perimeter of the apparatus, entering all four quadrants in turn (length 4 
trip) during the period of peak drug response (25 - 45 minutes) after 3 - 3.5 mg/kg 
amphetamine (Mueller et al, 1989a; 1989b; Kenyon et al, 1992). 
Recent work in our laboratory has shown that the atypical antipsychotic 
sulpiride (20mg/kg) reduced locomotor distance, but had no effect on the proportion 
of length 4 trips under amphetamine (3.5 mg/kg). We concluded that sulpiride 
reduced hyperactivity, but did not disrupt the perseverative nature of locomotion 
under amphetamine (Kenyon et al, 1992), suggesting that aspects of amphetamine-
induced locomotion may indeed be stereotyped. 
Recent findings have demonstrated that, in marked contrast to the action of the 
classic antipsychotic haloperidol, atypical neuroleptics do not elicit comparable 
effects on locomotor behaviours mediated via dopaminergic mechanisms. Specifically 
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sulpiride, thiioridazine and clozapine antagonised the enhanced locomotion in 
apomorphine-treated rats which had been rendered selectively 6-OHDA 
'supersensitive' in the nucleus accumbens (Schremmer et al, 1990). In a recent 
study by White et al, (1991), sulpiride, in contrast to the effects of haloperidol and 
clozapine, failed to impair lever release avoidance response rates even at doses that 
significantly reduced amphetamine-induced locomotion. 
These findings, indicating that typical and atypical antipsychotics 
differentially affect various dopaminergic mediated behaviours, led us to investigate 
the hypothesis that classical and atypical antipsychotic drugs would exhibit different 
actions on amphetamine-induced length 4 trips; that only a classic antipsychotic 
would antagonise both hyperactivity and length 4 trips. We also considered the 
possibility that atypical antipsychotic drugs might even potentiate length 4 trips. 
The present study examined the effects of haloperidol, clozapine and sulpiride 
on amphetamine-induced hyperactivity and perseverative locomotor patterns in an 
open field. Haloperidol is a clinically effective antipsychotic but is known to induce 
extrapyramidal side-effects (EPS; Green and Costain, 1981). Clozapine and sulpiride 
are known to elicit fewer EPS (Tamminga and Gerlach, 1987), and they do not exhibit 
typical antipsychotic properties in animal models (Ljungberg and Ungerstedt, 1985; 
Robertson and MacDonald, 1984; 1985; Tschanz and Rebec, 1989; Schremmer et al, 
1990; White et al, 1991). 
A single intermediate dose of amphetamine (3.5 mg/kg) was used in this study 
because it provides a suitable baseline for detecting either facilitatory or inhibitory 
effects of a wide dose range of antipsychotic drugs on locomotor patterns, without 
eliminating fonward locomotion completely. 
All three antipsychotic drugs antagonised amphetamine-induced 
hyperactivity; however only haloperidpl significantly reduced the perseverative 
nature of hyperactivity under amphetamine. 
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4.4 Mater ia ls and methods 
Animals. Male Wistar rats weighing 300 - 400 g (bred at the University animal 
house facilities) were used. Rats were housed in groups of six on a 12h light/dark 
cycle and allowed free access to food and water. The groups to be tested were allowed at 
least 3 days acclimation in a temperature regulated room (18 - 22° C) adjacent to the 
laboratory. Each animal was tested only once in the open field. 
Drugs. The following drugs were used and all doses are expressed as the salt: d-
amphetamine sulphate (Sigma) 3.5 mg/kg dissolved in phosphate buffered saline; 
(+-) sulpiride (Sigma) 10, 20 and 50 mg/kg dissolved in 1% lactic acid; clozapine 
(donated by Sandoz Products Ltd) 5, 10 and 20 mg/kg dissolved in 0.2N HCI, final 
volume achieved with sterile distilled water, and the pH adjusted to 4.5; haloperidol 
(Sigma) 0.01, 0.025, 0.05 and 0.075 mg/kg dissolved in 1% lactic acid. 
Amphetamine and saline were injected intra-peritoneally (IP) Immediately 
before testing in the open field. All other drugs were injected subcutaneously (SC) 30 
minutes prior to the injection of either amphetamine or saline. 
Experimental procedure. Animals were randomly assigned to a treatment group (n = 8 
per group). A Vehicle-Control and Vehicle-Amphetamine group was included with 
each of the three antipsychotic drugs tested. Rats received a S C injection of 
antipsychotic drug or vehicle before being placed in the open field. They were removed 
after 30 minutes, given amphetamine or saline IP and replaced immediately in the 
open field, where they remained for 105 minutes. 
Apparatus. Four circular open fields (75 cm diameter, height 30 cm) constructed 
from black Perspex were used. A video camera was mounted above each field. In a 
separate room the camera picture was analysed by an HVS image systems VP112 unit 
which converted the video signal into a stream of XY co-ordinate pairs representing 
the position of the animal. The subject's pattern of movement was analysed using 
software, described in detail elsewhere (Kenyon, 1990; 1991), which was modified 
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to accept input from tlie VP112 unit. All data are stored permanently in disk files for 
subsequent data analysis. 
Data collection. During the 105 minute test session the output from the camera and the 
HVS image analyser was nionitored on a TV screen. The path taken by the subject was 
displayed on the computer screen by the T R A C K E R software (Kenyon, 1990). The 
screen showed a representation of the floor of. the open field subdivided by lines into 
four equal-sized areas. The software tracked the animal's movements between these 
quadrants. Horizontal movement was recorded as distance (in cm) moved by the animal 
in each 5 minute time interval, with the total distance moved resulting from the sum 
of the 21 five minute intervals recorded over the test session. 
The subjectis sequence of movements between adjacent quadrants of the 
apparatus was subdivided into a series of trip lengths using S T E R E O software (Kenyon, 
1991). A single trip consists of a sequence of movements between adjacent quadrants 
of the open field. A trip is terminated when the rat changes direction, or completes a 
tour of the perimeter of the apparatus. Trip length can take values of 1, 2, 3 or 4 in 
an open field divided into four regions. In reality, very few trips exhibited by either 
saline- or amphetamine-treated animals are of length 2 or 3 (less than 10%), 
therefore in subsequent arialysis length 2 and 3 trips were discarded. The proportion 
of length 1 and length 4 trips were calculated as a proportion of all trip types, and 
used in the statistical analysis. 
Data analysis. Logarithmic transformations were performed on the distance moved 
data, and arcsin transformations were performed on the proportional data, as 
recommended by Howell (1992). 
Data were analysed separately for each antipsychotic.drug, using analysis of 
variance (ANOVA) with treatment (drug dose) the between subjects factor, and 5 
minute intervals the repeated within subjects factor. Differences were evaluated using 
the Newman-Keuls multiple range test (Howell 1992). Vehicle-Amphetamine groups 
were compared with Vehicle-Saline groups and all antipsychotic pre-treatment 
groups were compared with Vehicle-Amphetamine groups. 
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4.5 Results. 
Amphetamine. 
Distance Moved. In each phase of the study, treatment with amphetamine (3.5 
mg/kg) increased locomotor activity. During the 105 minute test session rats treated 
with amphetamine moved a significantly greater distance (Mean Vehicle-Saline = 
11750 cm, S E M +- 5576 cm [n=24]; Mean Vehicle-Amphetamine = 63560 cm, 
SEM+- 2071 cm [n=24]; p < .01; Newman-Keuls post hoc test). 
Pre-treatment with antipsychotic drug. 
Distance moved. Figure 4.1 A shows that haloperidol had a significant effect on 
amphetamine-induced hyperactivity (F (4,35) = 12.21, P< .0001). Pre-treatment 
with .025, .05, .075 mg/kg haloperidol resulted in a significant decrease in the total 
distance moved by amphetamine treated animals (p <.05). Pre-treatment with the 
lowest dose of haloperidol (.01 mg/kg) did not significantly reduce amphetamine-
induced hyperactivity. 
Figure 4.1 B shows that sulpiride also had a significant effect on amphetamine-
induced hyperactivity (F(3,28) = 3.329 p< .03). Pre-treatment with 20 and 50 
mg/kg sulpiride significantly reduced the distance moved by amphetamine treated rats 
over the test session (p< .05). 
Clozapine (Fig. 4.1 C) had a significant effect on the hyperactivity produced by 
amphetamine (F(3,28) = 8.76 p< .0004). Pre-treatment with 10 and 20 mg/kg 
clozapine reduced the distance amphetamine treated animals moved over the test 
session (p< .01). Rats'pre-treated with the lowest dose of clozapine (5 mg/kg), did 
not differ significantly from Vehicle-Amphetamine treated rats on this measure over 
the 105 minute test session; during the first 30 minutes of the test session this 
group showed increased levels of hyperactivity, thereafter, activity levels in this 
treatment group remained comparable to those exhibited by Vehicle-Amphetamine 
treated animals (ps < .05 for first 30 minutes). 
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Proportion of lengtli 4 trips. Figure 4.2A sliows that haloperidol had a significant 
effect on the increased proportion of length 4 trips associated with amphetamine 
treatment (F (4,35) = 7.68 p< .0001). Pre-treatment with .025, .05, .075 mg/kg 
haloperidol significantly reduced the proportion of length 4 trips under amphetamine 
(ps <.01). The lowest dose of haloperidol (.01 mg/kg) did not significantly reduce the 
proportion of length 4 trips induced by amphetamine. 
Figure 4.1B and 4.1C show that sulpiride (F(3,28) =1.092 p<.369). 
and clozapine (F(3,28) = 2.136 p< .118) did not result in a significant decrease in 
the proportion of length 4 trips exhibited after treatment with amphetamine. 
4.6 Discussion. 
In agreement with previous findings, an intermediate dose of amphetamine 
increased open-field locomotion and the proportion of length 4 trips around the 
periphery of an open field (Mueller et al, 1989; Kenyon et al, 1992, chapter 3). 
Pre-treatment with haloperidol, clozapine and sulpiride, antagonised amphetamine-
induced locomotion. These findings are in agreement with reports that a consistent 
feature of both typical and atypical antipsychotic drugs is their ability to antagonise 
amphetamine-induced hyperactivity. (Ljungberg and Ungerstedt, 1985; Rebec and 
Bashore, 1984). 
In addition to reducing forward locomotion, haloperidol (.025, .05, 
.075mg/kg) also reduced the proportion of length 4 trips associated with 
amphetamine-induced hyperactivity. Although both clozapine and sulpiride 
antagonised hyper-locomotion, neither of these atypical drugs significantly reduced 
the proportion of length 4 trips under amphetamine. This suggests that following pre-
treatment with an atypical antipsychotic - whilst hyperactivity is reduced - the 
perseverative nature of the remaining locomotion remains unchanged. It should be 
noted that the finding that sulpiride did not antagonise length 4 trips is by no means 
unequivocal. Animals pre-treated with sulpiride did show a reduction in the 
proportion of length 4 trips, but the large variability in this measure for these 
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groups may account for the lack of statistical significance, specifically for animals 
pre-treated with 10 mg/kg sulpiride. 
Pre-treatment with .025mg/kg haloperidol, 20mg/kg sulpiride or lOmg/kg 
clozapine reduced the distance moved by amphetamine treated animals by an equivalent 
amount over the entire test session (total distance moved approx. 3000cm.). Only 
this dose of haloperidol (.025mg/kg) resulted in a significant reduction in the 
proportion of length 4 trips, suggesting that although all three antipsychotic drugs are 
equipotent in reducing hyperactivity at these doses, only the classic antipsychotic, 
haloperidol, blocks the repetitive boundary patrolling associated with hyperactivity. 
The results reported in this study replicate the previous observation that 
20mg/kg sulpiride did not disrupt amphetamine-induced perseverative locomotor 
paths in hyperactive rats and broadens the findings to include the atypical 
antipsychotic clozapine. These findings support the gathering evidence that clozapine 
and sulpiride do not exhibit actions similar to haloperidol on all forms of 
amphetamine-induced locomotor behaviours (Schremmer et al, 1990; Kenyon et al, 
1992), and that locomotion cannot be defined as a unitary behavioural response to 
amphetamine. 
These studies have found consistent repetitive patterns of movement exhibited 
by animals treated with 3.5 mg/kg amphetamine, which are manifest as repetitive 
thigmotaxic boundary patrolling, resulting in a quantifiable increase in the 
proportion of length 4 trips. There was no evidence for a systematic increase in any 
other type of trip length under this dose of amphetamine. The results reported here 
add weight to the suggestion that hyperactivity induced by intermediate doses of 
amphetamine has stereotypic features by way of its invariance and repetition of route 
around the open field (Ljungberg and Ungerstedt, 1978; Schiorring, 1979; Kenyon et 
al, 1992). The Lyon-Robbins hypothesis (1975) suggests that stereotypy is the end 
point of a continuous process of psychomotor stimulation and behavioural competition. 
This would predict competition and blending between locomotor effects of 
amphetamine, mediated by the ventral striatum in particular the nucleus accumbens 
and stereotyped behaviours mediated, at least in part, by the caudate putamen 
(Pijnenburg et al, 1973; Kelly et al, 1975, Creese and Iversen, 1975). The 
Classic & Atypical antipsychotics 75 
dissociation of lengtfi 4 trips from locomotor effects per se by the atypical 
antipsychotics clozapine and possibly sulpiride which is reported here suggest that 
perseverative patterns of hyperactivity constitute a 'blending' of behavioural 
responses in an attempt to resolve competition between amphetamine-induced 
locomotion and more overt stereotyped behaviours. 
This study has examined only a small number of classic and atypical 
antipsychotic drugs, and the results are not entirely unequivocal, particularly with 
respect to sulpiride. Clearly further investigation of length 4 trips as a proposed 
measure of repetitive perseverative patterns of hyper-locomotion are required. It is 
not clear whether the inability of clozapine and sulpiride to block perseverative 
patterns in amphetamine-induced hyper-locomotion would generalise to other 
atypical antipsychotics, or the 5 - H T 3 antagonists which have been suggested as 
putative antipsychotic agents because of their selectivity in blocking the mesolimbic 
dopamine system (Costall et al, 1987). 
It is now evident that much additional information can be gained by examining 
drug-induced effects on the spatial patterns inherent in open field activity (Geyer et 
al, 1987; Mueller et al, 1989; Paulus et al, 1988; Paulus and Geyer, 1991; Kenyon 
et al, 1992). The analysis of locomotion using computer imaging techniques has 
revealed consistent repetitive patterns of movement exhibited by amphetamine treated 
rats in an open field, and the use of trip length as a method of quantifying the 
perseverative patterns in amphetamine-induced locomotion has provided a useful and 
sensitive tool which may discriminate classic and atypical antipsychotics, in much the 
same way that antagonism of hyperactivity and antagonism of stereotyped behaviours 
discriminates these drugs. 
The rate and duration of length 4 trips may provide additional information 
concerning the spatial distribution of perseverative patterns in amphetamine-induced 
hyper-locomotion and may also discriminate antipsychotic drugs (personal 
observations). 
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Summary 
An automated tracking system was used to analyse stereotyped locomotion in 
amphetamine-treated rats. Amphetamine (3.5mg/kg) increased the horizontal 
distance moved and the number and proportion of thigmotaxic trips around the 
perimeter of the apparatus (length 4 trips). The ability of the classic antipsychotic, 
haloperidol, and the atypical antipsychotics, clozapine and sulpiride, to block 
amphetamine-induced length 4 trips was investigated. The results showed that the 
classic antipsychotic haloperidol antagonised both hyperactivity and the increased 
proportion of length 4 trips. In marked contrast, the atypical antipsychotics clozapine 
and sulpiride antagonised hyperactivity but did not reduce the proportion of length 4 
trips. The inability of atypical antipsychotics to reduce the repetitive boundary 
patrolling associated with amphetamine-induced hyperactivity is consistent with the 
action of these drugs on other forms of amphetamine-induced stereotyped behaviour, 
and indicates that locomotor routes under amphetamine are stereotyped. The 
measurement of trip lengths provides a sensitive tool for examining drug action on the 
spatial distribution of open field locomotion. 
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Figure 4.1 A-C. 
Mean (+-SEM) distance moved (cm) during tine 105 min test session 
(n=8 per group). (A). 3.5mg/kg amphetamine pre-treated with vehicle, 
0.01, 0.025, 0.05 or 0.075 mg/kg haloperidol. (B). 3.5mg/kg 
amphetamine pre-treated with vehicle, 10, 20 or 50 mg/kg sulpiride. 
(C). 3.5mg/kg amphetamine pre-treated with vehicle, 5, 10 or 20 
mg/kg clozapine (*p< 0.05, **p< .01. Antipsychotic pre-treatment 
versus Vehicle-Amphetamine). 
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Figure 4.2 A -C . 
Mean (+-SEM) proportion of lengtli 4 trips during 105 min test session 
(n=8 per group). (A). 3.5mg/l<g amplietamine pre-treated with vehicle, 
0.01, 0.025, 0.05, or 0.075 mg/kg haloperidol. (B). 3.5mg/kg 
amphetamine pre-treated with vehicle, 5, 10 or 50 mg/kg sulpiride. 
(C). 3.5mg/kg amphetamine pre-treated with vehicle, 5, 10 or 
20mg/kg clozapine. (**p< 0.01. Antipsychotic pre-treatment versus 
Vehicle-Amphetamine). 
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Chapter Five 
Behavioural analysis 
5.1 Introduction 
Rebec and Bashore (1984) state that 'the mechanisms of action of 
amphetamine and the antipsychotic drugs will not be fully understood nor will new 
light be shed on the neuropathology of paranoid schizophrenia until the behavioural 
syndrome produced by amphetamine and the specific components antagonised by the 
antipsychotic drugs are precisely delineated' (p154). This view is entirely 
consistent with the ideas put forward in the preceding chapters concerning the 
adequate description and quantification of amphetamine-induced locomotor behaviour. 
Locomotion is only one aspect of the amphetamine response, dose dependent changes in 
other behaviours also occur (see Chapter 1 section 1.4). Many reviewers of the 
methodological considerations to be taken into account in the assessment of motor 
activity recommend the assessment of multiple aspects of unconditioned behaviour 
following drug manipulations (Lat, 1965; Reiter and MacPhail , 1979; Robbins, 
1977; Geyer, 1990). Geyer, (1990) claims that in addition to automated recording 
of locomotor activity, the use of direct observation should also be utilised. Some 
behaviours following treatment with amphetamine will be mutually exclusive, and 
will compete for expression, therefore an effective characterisation of the drug effect 
.will require the measurement of all behaviours which occur under the drug. It may 
well be that correct Interpretation of the data obtained from automated measures of 
locomotor activity is dependent upon the use of observational techniques. The use of 
multivariate assessment provides an opportunity to assess the validity of the 
hypothetical constructs, to make comparisons with results reported in the literature, 
to examine the relative specificity of the effect, to identify aspects of response 
competition and to detect artefacts (Geyer, 1990). 
Behavioural analysis 
In an earlier experiment (see Cliapter 3) conducted to examine tiie dose 
response cliaracteristics of amplietamine on tlie spatial distribution of open-field 
locomotion and the influence that field shape made to the behavioural response, 
findings suggested that animals treated with 4 or 5 mg/kg amphetamine and 
subsequently tested in a circular open field progressed more rapidly from the 
locomotor phase to the stereotypy phase. Without concurrent behavioural 
observations it is impossible to determine whether this is a correct interpretation of 
these data, or indeed what behaviours animals tested in a circular open/field were 
performing during those session intervals when their counterparts in the square 
field continued to engage in locomotor behaviours. In further experiments (Chapter 
4), examining the effects of antipsychotic drugs on the stereotyped nature of 
hyperactivity, none of the drugs tested potentiated stereotyped locomotion. Without 
measuring the action of these drugs on all aspects of the amphetamine syndrome it is 
impossible to draw conclusions concerning the relative contribution of stereotyped 
behaviours. The aim of this current investigation was to provide an adequate 
description of those behaviours which occurred in conjunction with hyperactivity. 
What follows is a detailed discussion of the methodological considerations which were 
met to achieve this. 
Stereotypy has been defined as the performance of an invariant sequence of 
movements in a repetitive manner (eg Fray et al, 1980; Rebec and Bashore, 1984). 
Rating scales have frequently been used to assess the intensity of stereotyped 
behaviours (eg Costall et al, 1972; Creese and Iversen, 1973; Sahakian et al, 
1975). Although these rating scales have proved useful in the study of drugs and 
behaviour, there are problems associated with rating scales. The degree to which a 
behaviour is stereotyped is somewhat subjective and human observers do not always 
record behavioural types accurately or consistently (see Fray et al, 1980; Jacobs, 
1988), this can create difficulties for both inter- and intra-laboratory reliability 
even when studies are rated blind. Both behavioural rating scales and automated 
recordings of locomotor activity (typically using photobeams) fail to distinguish the 
individual components of the amphetamine response (see Fray et al, 1980), and 
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many rating scales confuse stereotypy with specific behaviours, summing separate 
behavioural components together to obtain a global stereotypy score, resulting in a 
loss of information with respect to the individual behavioural elements of the 
response. For example Costall and Naylor (1977) showed that selective damage to 
dopamine neurones in the neostriatum abolished licking and biting but not sniffing. 
Lesion studies have demonstrated that dopamine projections to various brain regions 
including the olfactory tubercle, nucleus accumbens and the amygdala are responsible 
for various behavioural responses seen under amphetamine (Costall et al, 1977; 
Costall and Naylor, 1977; 1975). Rating scales which combine behavioural 
categories are unable to make this type of distinction. In addition, not all aspects of 
the amphetamine response have been shown to be enhanced by multiple injections of 
amphetamine, suggesting that not all amphetamine-induced behaviours provide an 
adequate model of clinical psychosis (Rebec and Bashore, 1984). Rebec and Bashore 
(1984) also argue that photobeam analysis of locomotor behaviour can lead to 
inaccurate interpretations. Fink and Smith (1979; 1980) observed behaviour 
directly and reported that neostriatal lesions reduced amphetamine-induced 
hyperactivity, but the effect was not apparent when photocell beam breaks were 
automated, as the lesions reduced the length of locomotion rather than its frequency. 
Some researchers have noted that photocell counts lead to exaggerated measures of 
locomotor activity (eg Krsiak et al, 1970 and Fray et al, 1980). 
Fray et al, (1980) developed a method for scoring the presence or absence of 
behavioural response categories without rating the stereotyped nature of the 
behaviour in an attempt to overcome some of these problems. Using this method these 
authors were able to provide a detailed comparison between the unconditioned 
behavioural effects of d-amphetamine and apomorphine in the rat. They were able to 
describe the different threshold doses required to elicit each behaviour and also the 
temporal aspects of the behavioural response. 
In an adaptation of the method described by Fray et al, (1980) video tapes of 
all experimental subjects were analysed in order to provide a detailed behavioural 
description to address specific questions relating to the findings reported in Chapter 
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3 and Chapter 4. First, is there a difference in snout contact resulting from 
differences in-open field shape, or amphetamine dose? Second, does locomotor activity 
occur persistently or do the animals pause between bouts of locomotion, and how does 
this relate to drug treatment and environmental factors? Finally, what behaviours 
occur concurrently with locomotion and how are these affected by environmental 
factors or antipsychotic drug pre-treatment? 
The information statistic employed by Fray et al, (1980) used planned 
contrasts and did not allow for direct pairwise comparisons. In addition, this 
statistical test is biased towards behaviours which occur infrequently. Recently a 
non-parametric analysis of changes in community structure was introduced into 
marine ecology (see Clarke, 1993; Field et al, 1982). This approach uses 
multivariate methods to incorporate formal hypothesis-testing without sacrificing 
the 'distribution-free' nature of analyses based on rank similarities. Such an 
approach has direct parallels with the study of drug-induced behavioural change and 
can be directly applied to records of behaviour similar to those described by Fray et 
a l , (1980). 
The data are organised into an 'abundance array' whose columns represent 
individual animals and whose rows are the full set of behaviours observed for each 
animal. The behavioural relationship between any two animals is distilled into a 
coefficient measuring similarity or dissimilarity in behavioural composition. The 
resulting triangular matrix of similarities between each pair of animals is used to 
classify them into groups using either a dendrogram (Clifford and Stephenson, 1975) 
or by ordination to 'map' the interrelationships between animals by non-metric 
multi-dimensional scaling (MDS eg Kruskal and Wish 1978). Briefly the main 
features of MDS can be best illustrated uising the example given by Clarke (1993), 
using the analogy of reconstructing a map of the world . Starting from the triangular 
matrix of distances between every pair of major cities in the world a map of the 
world can be reconstructed by placing the cities in their correct location; the result 
is an almost perfect map of the world. The algorithm works by initially placing the 
cities in three dimensional space at arbitrary locations, and then refining their 
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relative positions in an iterative cycle. Thus the rank order of the inter-city 
distances gets closer to the rank order of the original triangular matrix. The extent to 
which the ordination and triangular matrix disagree is reflected in the 'stress' 
coefficient, where this value tends to zero the rank orders reach perfect agreement, 
although this will rarely actually be achieved. Clarke (1993) suggests that practical 
experience with ecological data indicates the following rule of thumb for Kruskal's 
stress formula 1 (Kruskal and Wish 1978). 
Stress < 0.05 gives an excellent representation with no prospect of 
misinterpretation. 
Stress < 0.1 corresponds to good ordination with no real risk of drawing false 
inferences, though in a tightly clustered situation the fine structure of individual 
groups might bear separate examination. 
Stress < 0.2 values at the upper end of this range may have a tendency to mislead but 
nevertheless this can still lead to a utilisable picture. 
Stress > 0.2 is likely to lead to plots which are misleading. By the time stress reaches 
0.35-0.4 the samples are effectively randomly placed, bearing little relation to the 
original similarity matrix (see Clarke, 1993, for a more detailed description of 
stress and its interpretation). 
It is possible to determine which behaviours are responsible for grouping 
animals together, using Bray-Curtis dissimilarities (3jk) between any two samples 
j and k defined as 
equation 2 is the contribution of the ith behaviour and yij is the transformed 
abundance of the ith behaviour in the jth animal. Averaging 9jk over all sample pairs 
Ck) with j in the first group and k in the second group gives the overall average 
dissimilarity (3) between the two groups. The same averaging over each 3jk(i) gives 
the average contribution to 31 from the ith behaviour to the overall dissimilarity 
(equation 1) 
where 
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(3). As there are many pajrs of samples (jk) making up the average 31 a useful 
measure of how consistently a behaviour contributes to 3i is the standard deviation 
SD(3i) of the 3jk(i) values. If 31 is large and SD(3i) small (the ratio of 3i/SD(3i) is 
also large), then the ith behaviour contributes consistently to the dissimilarity 
between the two groups. In much the same way one can examine the contribution each 
behaviour makes to the average similarity within a group (S). The average 
contribution of the ith behaviour (Si) is defined by taking the average, over all pairs 
of rats (jk) within a group, of the ith behaviour Sjk(i) in the alternative definition 
of the Bray-Curtis similarity: 
the more a behaviour occurs within a group the more it will tend to contribute to the 
intra-group similarities. Therefore one would expect the ratio of Si/SD(si) to be 
high. These similarity-dissimilarity breakdowns are termed the 'similarity' 
percentages' or SIMPER procedure. So far the explanation has relied upon a 
posteriori grouping of the animals in examining which behaviours are principally 
responsible for an observed clustering. In experimental work the groups are 
determined a priori and the need is for a more theoretical statistical framework 
within which to test hypotheses concerning differences in behaviour and responses 
between groups. Such a test is based on the ranked similarities between animals 
within the triangular similarity matrix. If rw is defined as the rank similarities 
between replicates within treatments and rB is the average of rank similarities 
arising from all pairs between treatments then the following test statistic may be 
used. 
SJk=I,P^lSJk(i) (equations) 
where 
sjk{i)=200Tjdn{yij,yik)/lP^i{yij+yik) (equation 4) 
/ _ (equation 5 ) 
V 
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where M= n(n-1)/2 and n is the total number of animals under consideration. 
The denominator constant has been chosen so that R can never lie outside the 
range (-1,1); R=1 only if all replicates within groups are more similar to each 
other than any replicates from different groups; R=0 if the null hypothesis is true so 
that similarities within and between treatments are the same on average. R will 
generally fall between 0 and 1 indicating some degree of discrimination between 
treatments. An R value substantially less than zero is an unlikely event.since it would 
correspond to similarities across different treatments being smaller than those 
within treatments, an occurrence most likely to indicate incorrect labelling of 
animals. Under the null hypothesis HO: ' no differences between treatments', there 
will be little effect on average to the value R by arbitrarily assigning animals to 
different treatments, as animals are merely replicates of a single treatment group if 
HO is true. This is essentially the rationale for permutation test of HO, using the 
randomisation principle (Hope 1968). Essentially the labels to each animal are 
randomly shuffled and the R statistic re-calculated for each random reshuffle. There 
are 
(kn)! [(n!)k k ! ] (equation 6) 
ways of permutating the labels for n animals in each of k treatments. The full set of 
permutations is often extremely large, even with few animals in each treatment 
group so the full set of random permutations is randomly sampled tp give the null 
distribution of R, giving the range of likely values of R if Ho is correct. These can be 
compared with the true value of R derived from the correct labelling of animals 
within treatment groups. 
Again for a full detailed explanation of the rationale and iterative procedure see 
Clarke (1993). This test (ANOSIM) was carried out using a specially written 
FORTRAN program. 
Behavioural data from all experiments were analysed using this novel non-
parametric analysis to test for differences between treatments and to determine the 
relative contribution of various behavioural categories to between group differences. 
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5.2 Materials and Methods 
Subjects. The subjects were male Wistar rats whose experimental data has 
already contributed to the findings reported in Chapter 3 and Chapter 4. Video 
recordings were made of each test session and stored until required for behavioural 
analysis. 
Apparatus. The open field and computer imaging system have been described in 
detail in Chapter 2. A video-player was calibrated to determine 5 minute session 
intervals. Video tapes were viewed on a black and white monitor (Hitachi 900E/K) 
with the rater in full control of the stop/start mechanism. At each 5 minute interval 
of the 105 minute test session each rat was observed on the monitor for 10s by the 
rater (author). Timing was achieved using a hand held stopwatch. 
Procedure. Video tapes were randomised and all treatments were analysed blind, 
with the exception of field shape. The occurrence of any behaviour in Table 5.1 was 
recorded; any combination of these categories could be exhibited by a rat in the 10s 
observation period with the exception of continuous locomotion (LOGO), which could 
not occur in conjunction with locomotion with pause (LOCO+P) or with STILL. A 
random subset of video tapes were resampled and the percentage agreement 
determined between the first and second sample for each behavioural category. 
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Table 5.1a Definition of beliavioural categories based on 10s observation periods. 
C a t e g o r y D e f i n i t i o n 
S T I L L (still) 
L O C O (continuous locomotion) 
L O C O + P (locomotion with 
pause) 
R E A R O (rearing in the open) 
R E A R W (rearing against a 
wa l l ) 
S N I F F (sniffing) 
H E A D - D (head down) 
H E A D - S (head swaying) 
G R O O M (grooming) 
M I S C (miscellaneous) 
Asleep or not moving with the occasional sniff. 
All four legs moving without a pause for the 
entire 10s period. 
All four legs moving but the animal may pause 
for longer than 3s. 
Both front feet off the floor. 
Both front feet raised against the wall, only one 
of which may be touching the wall surface. 
Sniffing for longer than 3s. 
Snout in contact with floor for longer than 3 s. 
Head swaying fom side to side for longer than 
3s. 
Grooming for more than 3s. 
Any category of behaviour not already defined 
that occurs for more than 3s. Noted in detail. 
Tab le 5.1 b Mean percentage agreement between the first and second sample for 
each behavioural category. 
BEHAVIOUR PERCENTAGE AGREEMENT 
S T I L L 98 .4 
L O C O 96 .5 
L O C O + P 97 .2 
R E A R - 0 86 .5 
R E A R - W 87 .8 
S N I F F 94 .6 
H E A D - D 88 .4 
H E A D - S 83 .2 
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Drugs. The drugs and doses have been described in detail in Chapter 3 and 
Chapter 4. A summary of experiments and treatment groups is provided in Table 5.2 
Data analysis. Each experiment (see Table 5.2) was analysed separately. The 
data were arranged into an array whose columns represented animals and whose rows 
represented individual behaviours. The data were then analysed using PRIMER 
(Plymouth Routines in Multivariate Ecological Research; Carr et al, 1993), a 
program written specifically for IBM-compatible P C s running under DOS. 
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Table 5.2 Experiments and treatment groups. 
Exper iment Var iab le Treatment/Dose (mg/kg) 
Exp. 1 Field shape 
d-amphetamine 
SF3 SF4 
3.0 4.0 
SF5 CF3 CF4 CF5 
5.0 3.0 4.0 5.0 
Exp. 2 
d-amphetamine 
clozapine 
V-AMPH 
3.5 
0 
5CLOZ 10CLOZ 20CLOZ 
3.5 3.5 3.5 
5.0 10.0 20.0 
Exp. 3 
d-amphetamine 
sulpiride 
V-AMPH 
3.5 
0 
10SULP 20SUIP 50SULP 
3.5 3.5 3.5 
10.0 20.0 50.0 
Exp.4 
d-amphetamine 
haloperidol 
V-AMPH 
3.5 
0 
.01 HAL .025HAL .05HAL.075HAL 
3.5 3.5 3.5 3.5 
.01 .025 .05 .075 
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5.3 Results. 
Experiment 1. (field sfiape) 
Figures 5.1 and 5.2 show the percentage of animals exhibiting each of the 
behavioural categories for groups treated with 0, 3, 4, or 5 mg/kg amphetamine 
tested in the square and circular field respectively. 
The results of the two-way ANOSIM indicated that there was no significant 
difference between field shape groups [(Global R) = 0.054, p> 0.1]. There was an 
overall effect of dose averaged across field shape groups, [(Global R) = 0.585, p< 
.0001]. A series of pairwise tests between the doses of amphetamine indicate those 
behaviours which contributed most to the significant differences between the groups. 
Pairwise tests. 
3ma/ka amph. v 4mg/kg amph. 
Table 5.3 shows behaviours in order of their contribution to 31 to the average 
dissimilarity 3(=48.44) between groups treated with 3mg/kg and 4mg/kg 
amphetamine with a cut-off (E3(i)%) = 20%; The behaviours which contributed 
most to the difference between these two doses were locomotion ( L O C O + P ) and snout 
contact ( H E A D - D ) . Animals treated with the higher dose of 4 mg/kg showed an 
increase in locomotion at the beginning of the test session between intervals 10-15 
minutes and an increase in head-down posture between session intervals 70-105 
minutes. Interestingly, 50 minutes into the session animals treated with the lower 
dose of 3mg/kg amphetamine were moving much faster, with 63% of animals moving 
without a pause ( L O C O ) , compared with only 38% of animals treated with 4 mg/kg 
amphetamine. Therefore increasing the dose of amphetamine to 4 mg/kg resulted in 
increased locomotion early in the session followed by a decline in locomotion in 
session intervals accompanied by an increase in head down posture. 
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Table 5.3. Percentage (ABUND) of behaviours in group A (4mg/!<g) and group B (Smg/kg). Behaviours are listed in order of their contribution (di) to the 
average dissimilarity d(= 48.44) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) to d reaches 20%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD(di) iai% 
70 rearo 0.00 0.75 .70 .41 1.70 1.45 
80 head-d 0.75 0.00 .69 .41 1.69 2.87 
10 still 0.13 0.75 .64 .44 1.46 4 .20 
95 head-d 0.75 0 .13 .63 .43 1.45 5.50 
10 loco+p 0.75 0.25 .58 .46 1.27 6.70 
5 sniff 0.63 0 .13 .56 .47 1.19 7.85 
85 head-d 0.63 0.13 .54 .46 1.19 8.97 
90 head-d 0.63 0 .13 .54 .45 1.19 10.09 
100 head-d 0.63 0 .13 .54 .45 1.19 11.20 
105 head-d 0.63 0 .13 .54 .45 1.19 12.31 
55 loco+p 0.75 0.38 .52 .47 1.12 13.39 
35 loco+p 0.38 0.75 .52 .47 1.12 14.47 
70 head-d 0.62 0.25 .52 .47 1.12 15.54 
75 head-d 0.63 0.25 .51 .46 1.11 16.60 
25 loco+p 0.63 0.38 .49 .47 1.05 17.62 
50 loco+p 0.63 0.38 .49 .47 1.05 18.64 
50 loco 0.38 0.63 .49 .47 1.05 19.66 
15 still 0.00 0.50 .47 .48 0.99 20 .64 
—==- • • • • • • — 
3mg/kg amph. v 5ma/kg amph. 
Table 5.4 shows behaviours in order of their contribution to 3(1) to the 
average dissimilarity 3 (=57.74) between groups treated with 3mg/kg and 5mg/kg 
amphetamine with a cut-off when the cumulative % contribution (Z3(i)%) to 3 
reaches 20%. Behaviours which contributed most to the difference between these two 
doses were locomotion with pause (LOCO+P)and snout contact (Head-D). Animals 
treated with 5 mg/kg amphetamine were less active between session intervals 50-75 
minutes. In addition, animals treated with 5mg/kg amphetamine showed an increase 
in head-down posture (Head-D) betwen session intervals 45-90 minutes. 
Behavioural analysis 91 
Table 5.4. Percentage (ABUND) of behaviours in group A (5mg/kg) and group B (3mg/kg). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(= 57.74) between the two groups, with a cut-off when the cumulative % contribution (Idi%) to d reaches 20%. 
TIME BEHAVIOUR ABUNDA ABUNDB a(i) SD(di) d(i)/SD(d 
i) 
Zdi% 
70 still 0.88 0.00 .74 .29 2.57 1.29 
90 rearo 0.00 0.86 .73 .31 2.38 2.55 
60 head-d 0.88 0 .14 .66 .37 1.78 3.68 
45 head-d 0 .88 0 .14 .66 .37 1.78 4 .82 
65 head-d 0.88 0 .14 .66 .37 1.78 5.96 
55 still 0.88 0 .14 .66 .37 1.78 7.09 
60 still 0.88 0 .14 .65 .37 1.78 8.22 
55 loco+p 0.00 0.71 .63 .40 1.55 9.30 
50 head-s 0.75 0.00 .63 .37 1.70 10.39 
50 loco+p 0.25 0.86 .59 .42 1.43 11.42 
40 loco+p 0.25 0,86 .59 .41 1.43 12.43 
55 head-d 0.75 0 .14 .58 .41 1.43 13.44 
50 head-d 0.75 0 .14 .58 .41 1.43 14.44 
75 still 0.75 0 .14 .58 .40 1.43 15.44 
80 head-d 0.75 0 .14 .58 .40 1.43 16.44 
75 head-d 0.75 0 .14 .58 .40 1.43 18.43 
75 still 0.75 0 .14 .58 .40 1.43 •19.43 
90 head-d 0.75 0 .14 .58 .40 1.43 20.42 
4mg/kg amph v Sma.ka amph. 
Table 5.5 shows behaviour in order of their contribution to 3(1) to the 
average dissimilarity 3(=43.27) between groups treated with 4mg/kg and 5mg/kg 
with a cut off (E3(l)%) = 30%. Behaviours which contributed most to the difference 
between the two doses were locomotion with pause (LOCO +P) and snout contact 
(HEAD-D). Animals treated with the higher dose of 5 mg/kg amphetamine were less 
active between session intervals 55-105 minutes, and showed an increase in head-
down posture (HEAD-D) between session intervals 45-50 minutes. In addition, by 
session intervals 70 & 75 minutes, 62% of animals treated with 5 mg/kg 
amphetamine were engaged in head-swaying behaviour (HEAD-S) compared with 
only 13% of animals treated with 4mg/kg amphetamine. Thus increasing the dose of 
amphetamine to 5 mg/kg increased head down posture and head swaying whilst 
reducing locomotion. 
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Table 5.5. Percentage (ABUND) of behaviours in group A (5mg/i<g) and group B (4mg/l<g). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(=43.27) between the two groups, with a cut-off when the cumulative % contribution (Idi%) to d reaches 30%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD( 
di) 
Zdi% 
60 still 1.00 0.00 .87 .07 12.83 2.02 
65 still 1.00 0 .13 .78 .30 2.57 3.81 
55 still 0.88 0.00 .77 .30 2.56 5.58 
70 still 1.00 0.25 .67 .39 1.70 7.13 
80 still 1.00 0.25 .67 .39 1.70 8.67 
60 loco+p 0.00 0.75 .65 , .38 1.70 10.18 
50 still 0.75 0.00 .65 .38 1.70 11.67 
45 head-d 0.88 0.25 .61 .42 1.46 13.09 
55 loco+p 0.13 0.75 .60 .41 1.46 14.47 
75 loco+p 0.00 0.63 .55 .44 1.27 15.57 
75 still 1.00 0.38 . 5 5 .44 1.27 17.03 
70 loco+p 0.00 0.63 .55 .43 1.27 18.30 
100 still 0.75 0.25 .55 .43 1.27 19.57 
95 loco+p 0.25 0.75 .55 .43 1.27 20.83 
70 head-s 0.63 0.00 .55 .43 1.27 22.09 
65 loco+p 0.00 0.63 .55 .43 1.27 23.35 
50 head-d 0.88 0.38 .53 .44 1.19 24.57 
10 still 0.63 0.13 .53 .44 1.19 25.79 
105 loco+p 0.13 0.63 .52 .44 1.19 27.00 
105 still 0.88 0.38 .52 .44 1.19 28.20 
75 head-s 0.62 0.13 .51 .43 1.19 29.38 
10 loco+p 0.38 0.75 .50 .44 1.12 30.53 
Figure 5.1. 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n - 8) per 
group) injected with vehicle-saline (red), vehicle + 3mg/kg 
amphetamine (blue), vehicle + 4mg/kg amphetamine (yellow), or 
vehicle + 5mg/kg amphetamine (green) and tested in a square open 
f ie ld . 
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Figure 5.2. 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n =8) per 
group) injected with vehicle-saline (red), vehicle + 3mg/kg 
amphetamine (blue), vehicle + 4mg/kg amphetamine (yellow), or 
vehicle + 5mg/kg amphetamine (green) and tested in a circular open 
f i e ld . 
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Experiment 2. (3.5 mg/kg amptietamine pre-treated with clozapine). 
Figure 5.3 sfiows ttie percentage of animals exhibiting each of the behavioural 
categories for animals treated with 3.5 mg/kg amphetamine, pre-treated with 0, 5, 
10 or 20mg/kg clozapine. The results of the one-way ANOSIM indicated that there 
was no significant difference in the behaviours exhibited by the treatment groups. 
The sample statistic (Global R) = 0.023, (not significant NS). Table 5.6 shows the 
significance levels for the pairwise tests between animals treated with vehicle-
amphetamine and each of the clozapine pre-treatment doses following the one-way 
ANOSIM and the value of B derived from the similarities terms analysis. 
Table 5.6. Significance levels of pairwise tests following one-way ANOSIM, and the 
average dissimilarity (3) between vehicle-amphetamine and clozapine pre-treated 
groups. 
Veh-Amph. 5mg/kg 1 Omg/kg 20mg/kg 
versus clozapine clozapine clozapine 
37.86 (NS) •43.71 (NS) 41.61 (NS) 
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Figure 5.3. 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n =8) per 
group) injected with vehicle-saline (red), vehicle + 3.5mg/kg 
amphetamine (green), 5mg/kg. clozapine + 3.5mg/kg amphetamine 
(blue), 10mg/kg clozapine + 3.5mg/kg amphetamine (yellow) or 
20mg/kg clozapine + 3.5mg/kg amphetamine (magenta) and tested in 
a circular open field. 
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Experiment 3. (3.5 mg/l<g amplietamine pre-treated witfi sulpiride). 
Figure 5.4 sliows thie percentage of animals exiiibiting eacli of tiie befiavioural 
categories for animals treated with 0, 10, 20 or 50 mg/kg sulpiride before 
receiving 3.5mg/kg amphetamine. 
The results of the one-way ANOSIM indicated that there was a significant 
difference in the behaviours exhibited by the treatment groups. The sample statistic 
(Global R) = 0.366, p< .0001. Examination of the differences between treatment 
groups revealed that pre-treatment with 10, 20, or 50 mg/kg sulpiride resulted in 
a significant difference in behavioural categories compared to vehicle-amphetamine 
treated animals see table 5.7. 
Pairwise tests 
Veh-Amph v 10SULP 
Table 5.8 shows the behaviours in order of their contribution to the average 
dissimilarity 3(=39.89) between vehicle-amphetamine and animals pre-treated 
with 10mg/kg sulpiride with a cut-off (23(i)%) = 30%. 
Behaviours which contributed most to the difference between the two groups 
were locomotion with pause (LOCO+P), and head-swaying (HEAD-S). Animals 
pre-treated with 10mg/kg sulpiride were less active 15^20 min following 
administration of amphetamine. There was an increase in the percentage of animals 
not moving (STILL) during session intervals 85-100 min accompanied by an 
increase in head-swaying (HEAD-S) between 65-105 min, there was also a 
decrease in the percentage of animals engaged in rearing against the wall (REARW) 
at session intervals 70 and 80 min. 
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Figure 5.4. 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n = 8) per 
group) injected with vehicle-saline (red), vehicle + 3.5mg/kg 
amphetamine (green), 10mg/kg sulpiride + 3.5mg/kg amphetamine 
(blue), 20mg/kg sulpiride + 3.5mg/kg amphetamine (yellow) or 
50mg/kg sulpiride + 3.5mg/kg amphetamine (magenta) and tested in 
a circular open field. 
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Table 5.7. Significance levels of painwise tests following one-way ANOSIM, and the 
average dissimilarity (3) between vehicle-amphetamine and sulpiride pre-treated 
groups. 
Veh-Amph 10mg/kg 20mg/kg 50mg/kg 
versus Sulpiride Sulpiride Sulpiride 
3 3 9 . 8 9 4 8 . 6 4 4 2 . 8 2 
(p< 0.016) (p<0.0001) (p<0.0001) 
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Table 5.8. Percentage (ABUND) of behaviours in group A (10SULP) and group B (veh-amph). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(=39.89) between the two groups, with a cut-off when the cumulative % contribution (Idi%) to d reaches 32%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di 
) 
d(i)/SD(d 
i) 
Zd]% 
100 loco+p 0.14 0.83 .70 .44 1.60 1.75 
95 loco+p 0.14 0.83 .70 .44 1.60 3.51 
100 still 0.86 0 .17 .70 .44 1.60 5.26 
95 still 0.86 0 .17 .70 .44 1.60 7.02 
90 loco+p 0.29 1.00 .68 .45 1.51 8.72 
90 still 0.71 0.00 .68 .45 1.51 10.43 
105 head-s 0.86 0 .17 .68 .42 1.62 12.31 
95 head-s 0.86 0.17 .68 .42 1.62 13.82 
80 rear-w 0.00 0.67 .61 .44 1.37 15 .34 
90 head-s 0.71 0.17 .59 .44 1.30 16.82 
100 head-s 0.86 0 .33 .58 .47 1.24 18.27 
70 rear-w 0.14 0.67 .57 .46 1.24 19.70 
20 loco+p 0.71 0.33 .54 .48 1.12 21.05 
20 still 0.29 0.67 .54 .48 1.12 22.40 
15 loco+p 0.57 0 .17 .53 .49 1.07 23.72 
15 still 0.43 0.83 . 5 3 .49 1.07 25.04 
85 still 0.57 0 .17 .52 .49 1.06 26 .34 
85 loco+p 0.43 0.83 .52 .49 1.06 27.65 
65 head-s 0.57 0.00 .51 .45 1.13 28.92 
80 head-s 0.57 0.17 .49 .46 1.07 30 .16 
75 head-s 0.57 0.17 .49 .46 1.07 31.39 
85 head-s 0.57 0.17 .49 .46 1.07 32.63 
Veh-Amph v 20SULP. Table 5.9 shows the behaviours in order of their 
contribution to the average dissimilarity 9(=48.64) between vehicle-amphetamine 
and animals pre-treated with 20mg/kg sulpiride with a cut off (E3(i)%) = 35%. 
Behaviours which contributed most to the differences between these two groups were 
locomotion with pause (LOCO+P), head-down (HEAD-D) and head-swaying 
(HEAD-S) in the latter half of the test session. An increased percentage of animals 
showed head-down posture (HEAD-D) and head-swaying (HEAD-S) following 
pre-treatment with 20mg/kg sulpiride during session intervals 60-105 min. In 
addition, pre-treatment with 20mg/kg sulpiride increased the percentage of animals 
who were immobile (STILL) between session intervals 85-105 min. 
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Table 5 .9 . Percentage (ABUND) of behaviours in group A (20SULP) and group B (veh-amph). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(=48.64) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) to d reaches 35%. 
TIME . BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD( 
di) zai% 
65 head-s 1.00 0.00 .84 .07 12.9 1,73 
105 loco+p 0.00 1.00 .84 .07 12,9 3,47 
9 0 loco+p 0.00 1.00 .84 .07 12.9 5,20 
105 still 1.00 0.00 .84 .07 12.9 6,93 
90 still 1.00 0.00 ,84 .07 12.9 8.67 
60 head-s 0.88 0.00 ,73 .29 2.56 10.17 
70 head-d 0.88 0.00 ,73 .29 2.56 11.67 
75 head-d 0.88 0.00 ,73 .29 2.56 13.18 
100 head-d 0.88 0.00 .73 .29 2.56 14.68 
105 head-d 0.88 0.00 ,73 .29 2.56 16.18 
70 head-s 1.00 0 .17 .71 .33 2.17 17.64 
85 loco+p 0.00 0.83 .71 .33 2.17 19.10 
100 loco+p 0.00 0.83 .71 .33 2.17 20.55 
100 still 1.00 0 .17 .71 .33 2.17 22.01 
95 still 1.00 0 .17 .71 .33 2.17 23.47 
95 loco+p 0.00 0.83 .71 .33 2.17 24.92 
85 still 1.00 0 .17 .71 .33 2.17 26.38 
75 head-s 1.00 0 .17 .71 .32 2 .17 27.83 
80 head-s 1.00 0 .17 .71 .32 2.17 29.28 
•85 head-s 1.00 0 ,17 .71 .32 2.17 30.73 
90 head-s 1.00 0 .17 .71 .32 2 .17 32 ,18 
95 head-s 1.00 0 ,17 .71 .32 2 .17 33.63 
105 head-s 1.00 0 .17 .71 .32 2 .17 35.08 
Veh-Amph v 50SULP. Table 5.10 shows the behaviours in order of their 
contribution to the average dissimilarity 3(=42.82) between vehicle-amphetamine 
and animals pre-treated with 50mg/kg sulpiride with a cut-off (S3(i)%) .= 36%. 
Behaviours which contributed to the difference between these two groups were 
locomotion with pause (LOCO+P), (STILL) and head-swaying (HEAD-S) during 
the latter half of the test session. The percentage of animals engaged in head-swaying 
(HEAD-S) behaviour increased following pre-treatment with 50mg/kg sulpiride, 
during session intervals 55-105 min, particularly at interval 65 min, where 
100% of sulpiride pre-treated animals were engaged in head swaying behaviour 
compared with none of the vehicle-amphetamine treated animals. Pre-treatment with 
50mg/kg sulpiride also increased the percentage of animals who were not moving 
(STILL) between session intervals 80-105 min. 
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Table 5.10. Percentage (ABUND) of behaviours in group A (50SULP) and group B (veh-amph). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(=42.82) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) to d reaches 35%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD( 
ai) 
i a i% 
65 head-s 1.00 0.00 
.91 .09 9.27 2.12 
105 loco+p 0.14 1.00 .79 .34 2.34 3.97 
80 loco+p 0.14 1.00 .79 .34 2.34 5.81 
70 head-s 1.00 0.17 .77 .36 2.14 7.60 
55 head-s 0.86 0.00 .76 .33 2.35 9.39 
60 head-s 0.86 0.00 .76 .33 2.35 11.17 
105 still 0.86 0.00 .76 .33 2.35 12.96 
80 still 0.86 0.00 .76 .33 • 2.35 14.74 
95 loco+p 0.14 0.83 .68 .42 - 1.63 16.34 
75 head-s 0.86 0.17 .67 .41 1.62 17.90 
80 head-s 0.86 0.17 .67 .41 1.62 19.46 • 
85 head-s 0.86 0.17 .67 .41 1.62 21.02 
90 head-s 0.86 0.17 .67 .41 1.62 22.58 
95 head-s 0.86 0.17 .67 .41 1.62 24.14 
105 head-s 0.86 0.17 .67 .41 1.62 25.70 
100 still 0.86 0.17 .67 .41 1.63 27.26 
95 still 0.86 0.17 .67 .41 1.63 28.81 
75 loco+p 0.29 1.00 .66 .43 1.53 30.35 
90 loco+p 0.29 1.00 .66 .43 1.53 31.88 
90 still 0.71 0.00 .63 .41 1.54 33.36 
85 loco+p 0.29 0.83 .59 .45 1.30 34.74 
70 rearw 0.00 0.67 .59 .42 1.38 36.12 
Experiment 4. (3.5mg/kg amptietamine pre-treated witti haloperidol). 
Figure 5.5 shows the percentage of animals exhibiting each of the behavioural 
categories for amphetamine treated animals pre-treated with 0.01, 0.025, 6.05 or 
0.075 mg/kg haloperidol. 
The results of the one-way ANOSIM indicated that there was a significant 
difference in the behaviours exhibited by the treatment groups. The sample statistic 
(Global R) = 0.478, p< 0.0001. Examination of the difference between treatment 
groups revealed that pre-treatment with haloperidol (0.025, 0.05, or 0.075 
mg/kg) resulted in a significant difference in behavioural categories compared with 
vehicle-amphetamine treated animals, see Table 5.11 
Pairwise tests 
Veh Amph v .025HAL. Table 5.12 shows the behaviours in order of their 
contribution to the average dissimilarity 3(=31.30) between vehicle-amphetamine 
and animals pre-treated with .025mg/kg haloperidol with a cut-off (S3(i)%) = 10. 
Those behaviours which contributed to the first 10% of the difference between the 
two groups contributed consistently, (the ratio 3i/SD(3i) is large), behaviours 
which contributed thereafter had a lower ratio and are not reported. Behaviours 
which contributed most to the difference between the two groups were rearing against 
the wall (REARW) and STILL. Animals pre-treated with 0.025mg/kg haloperidol 
showed an increase in rearing against the wall (REARW) at session intervals 75-90 
min. This group also showed an increase in the percentage of animals who were 
STILL at session interval 20 min. 
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Figure 5.5. 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n = 8) per 
group) injected with vehicle-saline (red), vehicle + 3.5mg/kg 
amphetamine (green), 0.01 mg/kg haloperidol + 3.5mg/kg 
amphetamine (dark blue), 0.025mg/kg haloperidol + 3.5mg/kg 
amphetamine (yellow), 0.05 mg/kg haloperidol + 3.5mg/kg 
amphetamine (magenta) or 0.075mg/kg haloperidol + 3.5mg/kg 
amphetamine (light blue) and tested in a circular open field. 
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Table 5 .11 . Significance levels of pairwise tests following one-way ANOSIM, and the average dissimilarity (d) between vehicle-amphetamine and 
haloperidol pre-treated groups. 
Veh-Amph 0.01 mg/kg 0.025mg/kg 0.05mg/kg 0.075mg/kg 
versus Haloperidol Haloperidol Halcperldol Haloperidol 
d 34.30 (NS) 31.30 35.56 60.13 
(p<0.008) (p<0.0001) (p<0.001) 
Table 5.12. Percentage (ABUND) of behaviours in group A (.025HAL) and group B (veh-amph). Behaviours are listed in order of their 
contribution (di) to the average dissimilarity d(=31.30) between the two groups, with a cut-off when the cumulative % contribution (Z6i%) to d 
reaches 10%, 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD( 
di) 
zai% 
90 rearw 0.70 0 .14 .60 .46 1,33 1,93 
80 reanw 0.60 0.29 .51 ,48 1.08 3.57 
75 rearw 0.60 0.29 .51 .48 1,08 5,21 
10 sniff 0.70 0.43 .51 ,49 0,99 6.85 
20 still 0.50 0 .14 .48 .49 0,99 8,39 
20 loco+p 0.50 0.86 .48 ,49 0,99 9.93 
Veh-Amph v .OSHAL. Table 5.13 shows the behaviours in order of their contribution 
to the average dissimilarity 3(=35.36) between vehicle-amphetamine and animals 
pre-treated with .05mg/kg haloperidol with a cut-off (E3(i)%) = 12%. The 
behaviour which contributed to the first 12% difference between the two groups was 
locomotion with pause (LOCO+P), (STILL). Animals pre-treated with 0.05mg/kg 
showed an increase in the percentage of animals who were STILL at session intervals 
15-20 and 100-105min. 
Veh-Amph v .OTSHAL. Table 5.14 shows the behaviours in order of their 
contribution to the average dissimilarity a(=60.13) between vehicle-amphetamine 
and animals pre-treated with .075mg/kg haloperidol with a cut-off (S3(i)%) = 
30%. Behaviours which contributed to the first 30% difference between the two 
groups were locomotion with pause (LOCO+P), (STILL) and SNIFF. Animals pre-
treated with 0.075mg/kg haloperidol showed a marked decrease in locomotion 
(LOCO+P) between session intervals 20-25 and between session intervals 45-
105, with 100% of the haloperidol treated animals STILL from session interval 70 
to the end of the session compared with 0% of the vehicle-amphetamine treated 
animals. Animals pre-treated with this dose of haloperidol also showed a decrease in 
sniffing (SNIFF) between session intervals 15-25 min. 
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Table 5 .13. Percentage (ABUND) of behaviours in group A (.05HAL) and group B (veh-amph). Behaviours are listed in order of their contribution 
(di) to the average dissimilarity d(=35.36) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) to d reaches 12%. 
TIME BEHAVIOUR ABUNDA ABUNDB a(i) SD(di) d(i)/SD(d 
i) 
Idi% 
20 loco+p 0.13 0.86 .81 .45 1.78 2.27 
20 still 0.88 0 .14 .81 .45 1.78 4 .54 
105 still 0.63 0 .14 .61 .52 1.18 6.25 
15 still 0.75 0.43 .56 .53 1.06 7.83 
15 loco+p 0.25 0.57 .56 .53 1.06 9.41 
10 sniff 0.63 0.43 .54 .53 1.02 10.93 
100 still 0.63 0.43 .54 .53 1.02 12.45 
Table 5.14. Percentage (ABUND) of behaviours in group A (.075HAL) and group B (veh-amph). Behaviours are listed in order of their 
contribution (di) to the average dissimilarity d(=60.13) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) to d 
reaches 30%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(ai) d(i)/SD( 
di) 
Zdi% 
70 loco+p 0.00 1.00 1.19 .10 11.5 1.97 
75 loco+p 0.00 1.00 1.19 .10 11.5 3.95 
15 sniff 0.00 1.00 1.19 .10 11.5 5.92 
20 sniff 0.00 1.00 1.19 .10 11.5 7.90 
25 sniff 0.00 1.00 1.19 .10 11.5 9.87 
70 still 1.00 0.00 1.19 .10 11.5 11.85 
75 still 1.00 0 .14 1.02 .43 2.36 13.55 
25 still 1.00 0 .14 1.02 .43 2.36 15.25 
25 loco+p 0.00 0.86 1.02 .43 2.36 16.95 
65 sniff 0.17 1.00 1.00 .46 2 .16 18.61 
45 still 0.83 0.00 1.00 .46 2.16 20 .27 
45 loco+p 0.17 1.00 1.00 .46 2 .16 21.93 
65 still 0.83 0.00 0.99 .46 2 .16 23 .58 
65 loco+p 0.17 1.00 6.99 .46 2.16 25.23 
50 still 0.83 0.00 0.99 .46 2.16 26.87 
20 loco+p 0.17 0.86 0.88 .54 1.63 28.33 
20 still 0.83 0 .14 0.88 .54 1.63 29.79 
105 still 0.83 0 .14 0.87 .53 1.64 31.24 
Discussion. 
Administration of amplietamine fias been siiown to induce cfianges in open-
field beliaviour in tfie rat in a dose dependent manner (eg Fray et al, 1980, Rebec and 
Basliore, 1984). In the present study it was found that amphetamine increased snout 
contact (HEAD-D), head swaying (HEAD-S) and sniffing (SNIFF) in a dose 
dependent manner, and also rearing in the open (REARO), rearing against the open 
field wall (REARW) ahd locomotion (LOCO+P). Snout contact, head swaying and 
locomotion contributed most to the significant differences between the doses tested in. 
this study. With increasing dose of amphetamine the percentage of animals with head 
down (HEAD-D) and engaging in head swaying (HEAD-S) behaviour increased. 
Animals treated with 5mg/kg amphetamine showed a decrease in the duration of the 
locomotor phase, at the same time as exhibiting an increase in focused stereotyped 
behaviours. 
Although a significant difference was found between animals treated with 4 or 
5 mg/kg amphetamine when tested in a square or circular open field on automated 
measures of locomotor activity, there was no significant difference in behavioural 
categories between the two open fields at any of the doses tested. There appeared to be 
a trend for animals tested in a circular open field to make snout contact (HEAD-D) 
at a lower threshold dose, 4mg/kg compared to 5mg/kg, than animals tested in the 
square field. 
A significant proportion of rats treated with 3.5 mg/kg amphetamine did not 
engage in either HEAD-D or HEAD-S behaviour. Pre-treatment with sulpiride 
(10, 20 or 50mg/kg) produced an increase in both of these behaviours, suggesting 
that in agreement with the findings of Robertson and MacDonald (1985) sulpiride 
administered at these doses potentiates some aspects of stereotyped behaviour. 
Somewhat surprisingly, pre-treatment with clozapine did not significantly change 
the behavioural 'profile' of animals treated with 3.5mg/kg amphetamine." 
In this study locomotor activity was divided into locomotion which took place 
over the entire 10s observation period without a pause (LOCO), and locomotion 
which contained pauses lasting longer than 3s (LOCO+P). It was anticipated that this 
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might distinguish the period of peal< locomotor activity and that this peak might vary 
following antipsychotic drug treatment. Iii only one comparison, that between 3 and 
4mg/kg amphetamine, did locomotion without a pause over the 10s observation 
period (LOCO) contribute to the difference between'groups. As might be expected, 
measurement of locomotor activity using behavioural categories provided a less 
sensitive measure of locomotion than measures of distance moved and trip length 
using automated computer-assisted image analysis. The behavioural categorisation of 
locomotion failed to find significant differences between vehicle-amphetamine and 
clozapine pre-treated animals, although significant differences were found on 
automated measures of distance moved following pre-treatment with 10 or 20mg/kg 
clozapine. In contrast, behavioural categorisation of differences in locomotion 
(LOCO+P) contributed to the significant difference between vehicle-amphetamine 
and sulpiride pre-treated groups and to the significant difference between vehicle-
amphetamine and haloperidol pre-treated groups, findings which support the 
significant decreases in locomotor activity found on automated measures of distance 
moved. In the case of haloperidol a decline in LOCO+P was the major behavioural 
category which contributed to the difference between haloperidol pre-treated groups 
and vehicle-amphetamine groups. 
The behavioural analysis conducted on experiments 1-4 was made as an 
adjunct to the area of main interest, which was to examine the effects of 
environmental factors and antipsychotic drug pre-treatment on measures of 
stereotyped locomotion. Therefore doses of amphetamine were chosen which would 
elicit locomotion in the 105 minute test session. Chapter 3 described in detail the 
duration of the initial locomotor phase for each of the doses tested and the finding that 
the maximum duration of locomotion was observed following a dose of 4mg/kg 
amphetamine. 
It was anticipated that the difference between behaviours elicited under doses 
of amphetamine that were very similar would be minimal, with the possible 
exception of animals treated with 5mg/kg amphetamine where computer image 
analysis had shown that the duration of the locomotor phase declined, and it was 
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hypothesised that at this dose animals were engaging in focused stereotyped 
behaviours rather than ambulation. The findings of the observational study support 
this claim showing that the percentage of animals engaging in head down and head 
swaying markedly increased following treatment with 5 mg/kg amphetamine. It was 
also noted that differences were found between all the doses of amphetamine on 
several of the behavioural categories as noted above. Fray et al, (1980) found no 
significant difference in locomotor activity between animals treated with 3 and 5 
mg/kg amphetamine, and reported only minimal differences between these groups on 
measures of rearing and head down. As most of the behaviours which contributed to 
the difference between animals treated with 3, 4 and 5mg/kg amphetamine in the 
present study occurred between session intervals 60-105 minutes it is likely that 
the study undertaken by Fray et al, (1980) was too short to detect differences in 
behavioural response under these doses of amphetamine. 
The multivariate analysis provided a detailed 'picture' of the behaviours 
which contributed to the between group differences. The advantage of such an analysis 
is that it does not examine behaviours in isolation but compares the overall 
behavioural profile. Behavioural effects following treatment with amphetamine are 
seen as exhibiting different thresholds for response activation, with each behaviour 
having its own characteristic inverse U-shaped function (Robbins et al, 1990). The 
present analysis examined all the behaviours measured as a complete and distinct 
expression of the effects of a specific dose, subsequently examining the contribution 
of behavioural categories to the differences between treatments rather than 
examining differences in behavioural categories per se. Such an approach can be seen 
as 'slicing through' all the behaviours present at any given dose and comparing 
'slices'. This analysis provides a novel way of examining the differences between drug 
treatments and can be seen as an adjunct, rather than a replacement, to testing for 
differences in specific behavioural categories between treatment groups. This 
approach is directly in accordance with the view that examining behaviour as inter­
related acts gives greater insight into the patterns of behaviour which develop in drug 
treated animals. Clearly, the emphasis in these studies has been on a more integrated 
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approach to behavioural analysis rather than to measuring drug-induced behaviour 
as isolated components of the response. For example the approach taken by Teitelbaum 
et al, (see Teitelbaum et al, 1990), using the Eshkol-Wachman movement notation 
(Eshkol and Wachman, 1958) to analyse movement in rats, has shown that the 
expression of apparently unrelated stereotyped behaviours relies on values of three 
component variables: snout contact; forward progression and turning. The current 
study has found that an increase in snout contact and a decrease in fonward 
progression is a major contributing factor to the significant difference between 
increasing doses of amphetamine, and are seen as support for the findings (see 
Teitelbaum et al, 1990) that an interaction between snout contact and forward 
locomotion contribute to the development of stereotyped behaviour with increasing 
dose of amphetamine. 
Summary 
A number of behaviours induced following administration of amphetamine 
were examined using a distribution-free analysis based on rank similarities of 
behaviours and non-metric multi-dimentional scaling (MDS). With increasing dose 
of amphetamine from 3 to 5 mg/kg, there was a significant decrease in locomotion 
accompanied by an increase in two fonns of stereotyped head movements: head-down 
and head-swaying behaviour. 
Following treatment with 3.5mg/kg amphetamine, rats showed high levels of 
locomotion without displaying head-swaying or head-down stereotyped behavours. 
Pre-treatment with the classic antipsychotic haloperidol reduced locomotor activity 
without inducing stereotyped head movements. The atypical antipsychotic, clozapine, 
had no significant effect on any of the behavioural measures. In contrast pre-
treatment with the atypical antipsychotic, sulpiride, decreased locomotor- activity and 
significantly increased stereotyped head movements. 
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Chapter Six. 
The Effects of Ondansetron on Behaviours Exhibited 
Following Treatment with 3.5mg/kg Amphetamine. 
6.1 Introduction 
Serotonin (5HT) is tliought to play a role in various types of pathological 
conditions including anxiety, depression, aggressiveness, panic, obsessive-
compulsive disorders, suicidal behaviour, neurodegenerative disorders such as 
Alzheimer's disease. Parkinsonism and Huntington's Chorea, as well as migraine, 
emesis and alcoholism. It is not surprising that serotonin has been suggested as 
playing a role in the aetiology of schizophrenia and in dopamine mediated behaviours 
(see review by Zifa and Fillion 1992). However, studies which have evaluated the 
role of 5HT transmitter systems in schizophrenia show varying and often 
contradictory results (For review see Bleich et al, 1988). 
Stimulation of post synaptic 5HT receptors in rodents by various 
pharmacological agents results in a complex behavioural syndrome. The behaviours 
elicited include hind limb abduction, 'wet dog' shakes, side to side head swaying, 
reciprocal forepaw treading, tremor, Straub tail and increased reactivity to stimuli. 
Head swaying and forepaw treading are stereotyped in that they are repetitive and 
apparently meaningless fragments of normal behaviour (see Curzon, 1990). 
Hyperactivity induced following 5HT changes is in part mediated by associated 
activation of dopaminergic systems (Crow and Deakin, 1977; Jenner et al , 1980; 
Marsden, 1980; Deakin and Dashwood, 1981). 
The 5HT receptors can be subdivided into three families: the 5HT1 family 
consisting of the 5HT1a, 5HT1b and 5HT1d receptors, the 5HT2 family consisting of 
5HT1c, 5HT2a and 5HT2b receptors and 5HT3 receptors. The relevant 
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psychopharmacological agents with antipsychotic potential are 5HT1 agonists, 5HT2 
antagonists and 5HT3 antagonists (for review see Zifa and Fillion 1992). 
The behavioural role In rodents of many of the 5HT receptor types have been 
evaluated. 5HT1a agonists induce hyperlocomotion, headswaying, reciprocal forepaw 
treading and flat body posture (Tricklebank, 1987; Yamada et al, 1988; 1989), 
whilst it is thought that pre-synaptic autoreceptors in the median raphe are more 
likely to induce hypolocomotion, especially of horizontal movements (Mittman and 
Geyer, 1989). 5HT1a activity is thought to play a role in sexual behaviour, although 
the mechanism is unknown. This receptor also plays an important role In feeding 
behaviour as 5HT1a agonists have been shown to increase food intake in rats 
(Dourish et al, 1985). These receptors are implicated in psychiatric disorders such 
as anxiety and depression. 5HT1a agonists have been shown to have anxiolytic 
properties which are very different from those of the benzodiazepines, and also 
exhibit antidepressant properties in animal models of depression. 
The 5HT2 receptor was initially identified as the site that could bind [3H] 
spiroperidol and that had specific serotonergic pharmacological properties (Leysen 
et al, 1978). These receptors are involved in motor behaviour in rodents. Head 
twitch can be induced by 5HT2 agonists and blocked by selective antagonists eg 
Ketanserin (Ogren and Fuxe, 1989). 'Wet dog shake" is also inhibited by 5HT2 
antagonists (Fone et al, 1989) The number of 5HT2 receptors has been shown to 
decrease in schizophrenic patients (Mita et al, 1986). Therefore on the basis of this 
and experimental findings, 5HT2 antagonists are being developed as antipsychotic 
agents (Ortmann et al, 1982; Gelders et al, 1986; Wander et al, 1987; Lowe et al, 
1988; Van der Heyden, 1989). The antipsychotic activity of 5HT2 antagonists has 
not yet been clearly demonstrated in the clinical setting, although many 
antipsychotic drugs have considerable potency as 5HT2 antagonists eg thioridazine 
and clozapine. Recently much attention has focused on combining 5HT2 and D2 
antagonistic effects in the development of new antipsychotic agents. There is 
considerable evidence to suggest that clozapine is a more effective antipsychotic 
agent than classical antipsychotic drugs for both schizophrenic patients (Claghorn, 
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1987) and treatment resistant scliizoplirenic patients (Kane et al, 1988; Meltzer et 
al, 1989). Indeed, Meltzer et al. (1989) has suggested that clozapine's ability to 
alter both dopamine and serotonin in an integrated manner reflects an abnormality 
in the interaction of the dopaminergic and serotonergic system in the aetiology of 
schizophrenia, rather than in either of the systems alone. 
The ability of clozapine to act as a 5HT antagonist (Lai et al, 1980; Fink et 
al, 1984; Freidman et al, 1985) has been suggested as an explanation of its low 
induction of extrapyramidal symptoms. In support of this claim lesions to the 
serotonergic systems or inhibition of 5HT synthesis with P C P A has been shown to 
decrease neuroleptic-induced catalepsy in rodents (Kostowski et al, 1972). Meltzer 
(1989) postulates that dorsal and median raphe serotonergic activity on frontal 
cortical, mesolimbic and mesostriatal dopaminergic systems could lead to decreased 
dopaminergic activity in frontal cortex, and increased dopaminergic activity in the 
mesolimbic and mesostriatal system, and that the primary abnormality in 
schizophrenia is in dopaminergic-serotonergic interactions with the possibility that 
if the ratio of serotonergic to dopaminergic activity is high, negative symptoms 
predominate, while in the opposite case positive symptoms would predominate. In 
addition clozapine has been shown to have affinity for the 5HT3 receptor (Ashby et 
al , 1989; Barnes et al, 1990; Hoyer et al, 1989; Watling et al , 1989). 
The synthesis of selective and potent receptor antagonists has made possible 
the detailed study of the behavioural pharmacology of 5HT3 receptors: eg granisetron 
(Sanger and Nelson, 1989), ICS 205-930 (Richarson et al , 1985), LY278584 
(Robertson et al, 1990), MDL 72222 (Fozard, 1984), MDL 73147 (Sorenson et 
al , 1989), ondansetron (Butler et al, 1988), renzapride (Sanger, 1987), 
Zacopride (Smith et al, 1988). The 5HT3 receptor is different from the other 5HT 
receptor subtypes in that it is not linked to a G protein but is activated by an ion 
channel which increases the conductance of monovalent cations (Peters and Lambert, 
1989). Radioligand binding studies using tritiated [H3] 5HT3 receptor antagonists 
have shown that 5HT3 receptors are distributed in the cortex, amygdala, 
hippocampus, accumbens, septum, thalamus and hypothalamus, whilst the 
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cerebellum is almost devoid of specific 5HT3 sites. Also when compared with the 
other 5HT receptor subtypes, the 5HT3 receptors exhibit a ten times lower density 
in the brain (Barnes et al, 1990, 1989; Kilpatrick et al,1987; Peroutka and Hamik 
1988; Robertson et al, 1990; Waeber et al, 1988, 1990; Watling et al, 1988, 
1 9 8 9 ) . 
Costall et al, (1987) have shown that a 5HT3 receptor antagonist GR 
38032F [ondansetron] injected into the nucleus accumbens or administered 
peripherally, inhibited the hyperlocomotion induced by acute intra-accumbens 
injection of lO^g amphetamine in the rat, and also hyperactivity induced following 
persistent intra-accumbens infusion of dopamine into the rat or marmoset. 
Ondansetron has no known affinity for other neurotransmitter sites and does not 
interact with dopamine receptors (Brittain et al, 1987), therefore Costall et al , 
(1987) attribute the blocking of hyperactivity by this drug to 5HT3 receptor 
antagonism. Ondansetron and amphetamine were administered bilaterally to the 
nucleus accumbens of the rat and it would seem likely that 5HT3 receptor blockade 
in this area was responsible for the decrement in the amphetamine-induced 
hyperactive response. In addition, ondansetron was administered peripherally and 
this also reduced the hyperactivity caused by the intra-accumbens injection of 
amphetamine or the infusion of dopamine. This may also have resulted from 5HT3 
receptor blockade in the nucleus accumbens although other regions could not be ruled 
out. Injection of ondansetron into either the left or right amygdala in rats receiving 
unilateral dopamine infusion to the left amygdala inhibited hyperactivity, a finding 
which demonstrates inter-hemispheric communication in the regulation of 
locomotor activity in the limbic system and provides evidence of 5HT involvement in 
the hyperactive response. Thus a specific, potent 5HT3 antagonist, when 
administered into the amygdala, nucleus accumbens or peripherally, blocked either 
amphetamine or dopamine induced hyperactivity in a manner similar to that of a 
dopamine antagonist. This study (Costall et al, 1987), demonstrated important 
differences between the action of ondansetron and proven antipsychotic agents such 
as fluphenazine, haloperidol and sulpiride. Ondansetron did not reduce activity levels 
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in normal untreated animals, nor did it reduce raised limbic dopamine activity to 
levels below control values, which is in marked contrast to the depressant effects of 
dopamine antagonist antipsychotic agents which depress all forms of motor activity. 
Such a profile might indicate that ondansetron may be able to restore dopamine 
activity to normal levels. Another distinction between the action of ondansetron and 
antipsychotic agents relates to the prolonged increases in locomotor activity seen on 
discontinuation of neuroleptic-dopamine treatment which appear to reflect dopamine 
receptor sensitivity (Rupniak et al, 1983). After discontinuation of ondansetron-
dopamine treatment activity levels remained at control levels. In addition, 
ondansetron reduced the 'rebound' hyperactivity seen following the discontinuation of 
haloperidol-dopamine treatment. Taken together these findings indicate a role for 
5HT3 in the modulation of dopamine or amphetamine-induced locomotor responses. 
Interestingly and paradoxically, ondansetron failed to antagonise hyperactivity 
following the peripheral administration of amphetamine (Costall et al, 1987; Van 
der Hoek and Cooper ,1990). Furthermore, higher doses of many of the 5HT3 
antagonists show a reduced ability to reverse intra-accumbens dopamine-induced 
hyperactivity (Costall et al, 1990). Costall at al, (1987) attribute the failure of 
ondansetron to antagonise peripherally administered amphetamine-induced 
behaviours to its inability to affect striataly-mediated behaviours. The mesolimbic 
system has been shown to be involved in the activation of amphetamine-induced 
locomotor behaviours (Pijnenburg and Van Rossum 1973) and peripherally 
administered ondansetron has been shown to block hyperactivity following injection 
of amphetamine into the nucleus accumbens, this would indicate that some reduction 
in locomotor activity might have been expected. Costall et al, (1987) do not report 
the amphetamine dose administered peripherally. The findings reported would be 
expected if the dose administered was high enough to initiate stereotyped behaviours, 
the results are ambiguous particularly with respect to lower doses of amphetamine 
where the predominant behaviours are locomotor. 
Certainly the ability of ondansetron to reduce locomotor activity following 
central administration of either dopamine or amphetamine indicates a facilitatory 
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role for 5HT on dopamine transmission, and supports the findings that injections of 
5HT into the nucleus accumbens increases locomotor activity (Pijnenburg et al , 
1975; Costall et al, 1979; Makanjuola et al, 1980). In addition, the 5HT3 receptor 
agonist 2-methyl-5-HT increased amphetamine-induced hyperactivity, but not 
normal activity, and this effect was antagonised by ondansetron (Costall et al, 
1987). As few overt behavioural changes are noted following the administration of 
5HT3 receptor antagonists to normal undrugged animals (Hagan et al , 1987) it 
would appear that the normal activity of this system is low, but that this may change 
as a consequence of dysfunction within the mesolimbic dopamine system (Costall et 
a l , 1987). 
It would seem that there is convincing evidence in both rats and primates that 
the 5HT3 receptor antagonists can exhibit a modulatory effect on the hyperactivity 
response following raised mesolimbic dopamine activity. How this relates to 
effective antipsychotic activity remains to be seen. Ondansetron has been reported to 
possess antipsychotic action in uncontrolled trials (De Veaugh-Geiss et al, 1990), 
although results from the only double-blind placebo-controlled study in acute 
schizophrenia, to date, were inconclusive (Meltzer, 1991). 
In view of the fact that strong evidence suggests that 5HT3 receptors are 
strongly implicated in taking a modulatory role In the hyperactivity following raised 
mesolimbic dopamine activity and the intriguing reports that 5HT3 antagonists do 
not block hyperactivity following peripherally administered amphetamine, the aim 
of this present study was to use a selective 5HT3 antagonist, ondansetron (Brittain 
et al, 1987), and investigate its action on the spatiotemporal aspects of open-field 
locomotion and on behaviours induced following treatment with 3.5mg/kg 
amphetamine. 
6.2 Materials and methods 
Animals. Male wistar rats weighing 350 - 450 g (bred in the University 
animal house facilities) were used. Rats were housed in groups of six on a 12 hour 
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light dark cycle and allowed free access to food and water. The groups to be tested 
were allowed at least three days acclimation in a temperature-regulated room 
adjacent to the laboratory. Each animal was tested only once in the open field. 
Drugs. The following drugs were used and all doses are expressed as the salt: 
d-amphetamine sulphate (sigma) 3.5 mg/kg dissolved in phosphate buffered saline; 
ondansetron (donated by Glaxo) 0.05, 0.1, 0.5, 1.0 mg/kg. dissolved in phosphate 
buffered saline and stored in neutral glass containers. Amphetamine and saline were 
injected intraperitoneally (IP) immediately before testing in the open field. 
Ondansetron or vehicle was injected subcutaneously (SC) 30 minutes prior to the 
injection of either amphetamine or saline. 
Experimental procedure. Animals were randomly assigned to a treatment group 
(n=9 per group). Rats received a S C injection of vehicle or ondansetron before being 
placed in the open field. They were removed after 30 minutes, given amphetamine or 
saline IP and replaced in the open field where they remained for 105 minutes. 
Apparatus. The experiment used 4 circular open fields (75cm diameter x 30cm 
in height, see Chapter 2 for a detailed description). The apparatus used for the 
analysis of behaviour is described in Chapter 5. 
Data collection. Chapter 2 provides a detailed description of the procedure used 
to obtain automated measures of locomotor activity. Chapter 5 provides information 
on the methods employed in the behavioural analysis. 
Data analysis. Data obtained from the image analysis of locomotor activity 
were analysed using analysis of variance (ANOVA) with treatment (drug dose) the 
between subjects factor and 5 minute session intervals the repeated within subjects 
factor. Differences were evaluated using the Newman-Keuls multiple range test 
(Howell 1992). Vehicle-amphetamine groups were compared with vehicle-saline 
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groups and ondansetron pre-treated groups were compared with vehicle-
amphetamine groups. Data derived from the behavioural analysis of video tapes, were 
analysed using PRIMER (Carr et al, 1990) - See Chapter 5. 
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6.3 Results 
Computer assisted image analysis of locomotor behaviour. 
Distance moved The total distance moved during the 105 minute test session 
was not significantly affected by pre-treatment with ondansetron (F(4,41) = 2.007 
p> .1). Figure 6.1 shows the total distance moved across the session by all 
amphetamine treated groups and by ail vehicle treated groups. Figure 6.2 shows the 
distance moved by amphetamine treated animals pre-treated with ondansetron (0 -
I.Omg/kg). This figure clearly demonstrates a significant main effect of time on the 
distance moved for all groups (F(20,800) =36.668 p< .0001). Examination of this 
effect revealed that although pre-treatment with ondansetron tended to increase the 
distance moved under amphetamine between session intervals 5-40 minutes post-
injection with amphetamine, the effect was not significant. Between session 
intervals 55-95 minutes animals pre-treated with 0.1, 0.5, & 1.0 mg/kg 
ondansetron made significantly less horizontal movement than vehicle amphetamine 
treated rats. During the final 10 minutes of the test session these animals travelled a 
similar distance to vehicle-amphetamine treated animals. In marked contrast, 
animals pre-treated with the lowest dose of ondansetron (0.05mg/kg) covered a 
significantly greater distance than vehicle-amphetamine treated rats during some 
session intervals. At session interval 55 minutes animals treated with the lowest 
dose of ondansetron moved a significantly greater distance than vehicle amphetamine 
treated animals, however, between session intervals 60-80 minutes there was no 
significant difference between these two groups on this measure. At session intervals 
85-105 pre-treatment with 0.05 mg/kg ondansetron again resulted in a significant 
increase in distance moved (Newman-Keuls p< .05). 
Proportion of length 4 trips. Figure 6.3 shows the proportion of length 4 
trips made by all amphetamine treated groups. Pre-treatment with ondansetron did 
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not significantly affect the total proportion of length 4 trips made by amphetamine 
treated animals (F(4,40) = 0.497 NS). 
Effect of time in ttie proportion of lengtfi 4 trips. There was a significant effect of 
time on the proportion of length 4 trips (F(20,800) =13.276 p< .0001). Figure 
6.4 shows the proportion of length 4 trips for all amphetamine treatment groups 
across the 105 minute test session. Newman-Keuls multiple range tests conducted on 
the means at each session interval, revealed that there was no significant difference 
in the proportion of length 4 trips made by any of the treatment groups between 
session intervals 5-35 minutes. Between session intervals 40-45 minutes, and also 
at session interval 55 minutes, animals pre-treated with an intermediate dose of 
ondansetron (0.5mg/kg), made a significantly increased proportion of length 4 
trips. Paradoxically, at session interval 65 minutes, animals pre-treated with 
ondansetron approximately 0.5mg/kg above or below the intermediate dose made 
significantly less length 4 trips than vehicle-amphetamine treated animals. 
In addition the ANOVA revealed a significant Dose x Session Interval 
interaction (F(80,800) = 1.417 p<0.01). Figure 6.5 and figure 6.6 show the 
cumulative perceritage for both distance moved and the proportion of length 4 trips 
over the entire test session. Both graphs show clearly the facilitatory effect of pre-
treatment with ondansetron in the early session intervals on both measures. 
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Figure 6.1 
The total distance moved across the 105 min test session by 
rats (n = 9) treated with 3.5 mg/kg amphetamine and pre-treated 
with vehicle or 0.05-1.0 mg/kg ondansetron. 
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Figure 6.2 
Distance moved at each of the 5 min time intervals by rats (n 
9) treated with 3.5 mg/kg amphetamine and pre-treated with 
vehicle or 0.05-1.0 mg/kg ondansetron. 
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Figure 6.3 
Proportion of lengtli 4 trips over the 105 min test session by 
rats (n = 9) treated with 3.5.mg/l<g amphetamine and pre-treated 
with vehicle or 0.05-1.0 mg/kg ondansetron. 
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Figure 6.4 
Proportion of legtli 4 trips made at each 5 min session interval 
by rats (n = 9) treated with 3.5 mg/kg amphetamine and pre-
treated with vehicle or 0.05-1.0 mg/kg ondansetron. 
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Figure 6.5 
Each session interval shows the cumulative percentage of the 
total distance moved by rats (n = 9) treated with 3.5 mg/kg 
amphetamine and pre-treated with vehicle or 0.05-1.0 mg/kg 
ondansetron. 
TIME 
Figure 6.6 
Each session interval shows the cumulative percentage of the 
total number of length 4 trips by rats (n = 9) treated with 3.5 
mg/kg amphetamine and pre-treated with vehicle or 0.05-1.0 
mg/kg ondansetron. 
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Behavioural analysis. 
Figure 6.7 siiows tlie effect of ondansetron pre-treatment on eacli of tlie 
befiavioural categories. Tlie results of tfie one-way ANOSIIVI indicated tiiat tliere was a 
significant difference in thie beliaviours exfiibited by treatment groups. The sample 
statistic (Global R) = 0.108 p< .023. Examination of the differences between 
treatment groups revealed that pre-treatment with 0.1, 0.5, or 1.0 mg/kg 
ondansetron resulted in a significant difference in behavioural categories compared 
with vehicle-amphetamine treated animals. See Table 6.1. 
Table 6.1. Significance levels of vehicle-amphetamine groups compared with 
ondansetron pre-treated groups. 
Veh-Amph 0 .05mg/kg O . l m g / k g 0 . 5 m g / k g 1.0 mg/kg 
v e r s u s Ondansetron Ondansetron Ondansetron Ondansetron 
3 37.16 36.80 38.76 
NS p<0.003 p<0.01 p<0.01 
Veh-Amph v 0.1 mg/kg ondansetron. Compared with vehicle-amphetamine treated 
animals, pre-treatment with 0.1 mg/kg ondansetron resulted in an increase in 
Locomotion without Pause between session intervals 30-40 minutes, but by 
session interval 45 min there was a decline in locomotion. Rearing In the Open 
was unaffected by pre-treatment with O.lmg/kg ondansetron. Rearing against 
the Wall occurred earlier in the test session than for vehicle-amphetamine treated 
animals and appeared to be associated with the period at which maximum levels of 
locomotor activity occurred. Pre-treatment with 0.1 mg/kg ondansetron increased 
Head-Swaying behaviour from session interval 45 min and was markedly 
increased in these animals between session intervals 45-90 min. In addition to an 
increase in Head-Swaying behaviour these animals also made snout contact earlier 
in the test session (30 min), and maintained an increase in Head-Down posture 
throughout the remainder of the test session. Table 6.2 shows the results of the 
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similarities terms analysis (SIMPER), which revealed that an increase in H e a d -
Sway ing behaviour between session intervals 50-70 min contributed to the first 
30% difference between these two treatment groups. An increase in snout contact 
between session intervals 60-100 min also contributed to the first 30% difference 
between the two groups. The SIMPER also revealed that a decrease in pausing during 
the early locomotor phase of the amphetamine response occurred following pre-
treatment with 0.1 mg/kg ondansetron, and this contributed to the significant 
difference between the two groups. The commencement of locomotor activity for 
animals pre-treated with ondansetron occurred 15 minutes into the test session, 
earlier than for animals treated with vehicle-amphetamine. This earlier onset of 
locomotor activity also contributed to the first 30% difference between the two 
groups. 
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Figure 6.7 
The percentage of animals exhibiting each of the behavioural 
categories during the 105-min observation period by rats (n = 
9 per group) injected with vehicle-saline (red), Vehicle-
amphetamine (green), 0.05 mg/kg ondansetron + 3.5 mg/kg 
amphetamine (dark blue), 0.1 mg/kg ondansetron + 3.5 mg/kg 
amphetamine (yellow), 0.5 mg/kg ondansetron + 3.5 mg/kg 
amphetamine (magenta), 1.0 mg/kg ondansetron + 3.5 mg/kg 
amphetamine (light blue). 
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Table 6.2. Percentage (ABUND) of behaviours in group A (O. lmg/kg ondansetron) and group B (vehicle-amphetamine). Behaviours are listed in order 
of their contribution (di) to the average dissimilarity d(= 37.16) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) 
to d reaches 30%. 
TIME BEHAVIOUR ABUNDA ABUNDB a(i) SD(di) d(i)/SD(di) Zdi% 
65 head-s 0.78 0.22 .55 .41 1.36 1.49 
70 head-s 0.78 0.22 .55 .41 1.36 2 .97 
75 head-s 0.78 0.33 .51 .43 1.19 4 .33 
65 loco 0.22 0.67 .50 .42 1.19 5.68 
60 head-s . 0.67 0.22 .50 . .42 1.19 7.01 
55 head-s 0.67 0.22 .50 .42 1.19 8.35 
75 loco+p 0.33 0.78 .49 .42 1.18 9.68 
90 head-d 0.67 0.33 .48 .43 1.10 10.96 
70 loco+p 0.44 0.89 .46 .43 1.07 12.20 
90 head-s 0.78 0.44 .46 .44 1.05 13.44 
40 loco+p 0.44- 0.78 .45 .43 1.05 14.66 
95 ioco+p 0.44 0.89 .45 .42 1.07 15.88 
95 still 0.56 0.11 .45 .42 1.07 17.10 
35 loco 0.56 0.22 .45 .43 1.04 18.32 
35 loco+p 0.44 0.78 .45 .43 1.04 19.54 
50 head-s 0.56 0.11 .45 .42 1.08 20.75 
75 still 0.56 0.11 .45 .42 1.07 21.96 
15 loco+p 0.67 0.44 .44 .44 1.02 23 .16 
60 head-d 0.56 0.22 .44 .42 1.05 24.35 
85 head-d 0.56 0.33 .44 .43 1.02 25.44 
95 head-d 0.56 0.33 .44 .43 1.02 26.72 
80 head-s 0.67 0.44 .44 .43 1.02 27.91 
70 head-d 0.56 0.44 .43 .43 1.00 29.07 
100 head-d 0.56 0.44 .43 .43 1.00 30.23 
Veh-Amph v 0.5mg/kg ondansetron. Pre-treatment with 0.5mg/l<g ondansetron 
increased locomotor activity earlier in the test session, with the majority of 
ondansetron treated animals engaging in Locomotion at session interval 10 min. In 
addition pre-treatment with 0.5 mg/kg ondansetron resulted in a marked decrease in 
pausing between session intervals 35-65 min compared with vehicle-amphetamine 
treated animals. Rearing in the Open was unaffected by treatment with 
ondansetron. Like animals treated with 6.1 mg/kg ondansetron. Rearing against 
the Wail appeared to be associated with the period of peak locomotor activity and 
consequently occurred earlier than for vehicle-amphetamine treated animals. Pre-
treatment with 0.5 mg/kg ondansetron resulted in an increase in Head-Swaying 
between session intervals 50-75 min. There was also a marked increase in snout 
contact between session intervals 55-85 min, with this group displaying the 
greatest increase in Head-Down posture of all the treatment groups. Table 6.3 
shows the results of the SIMPER, which revealed that an earlier onset of locomotion, 
and an associated decrease in pausing during locomotor bouts following pre-
treatment with ondansetron accounted for the first 6% difference between the two 
groups. An increase in Head-Swaying and snout contact between session intervals 
55-85 min also accounted for the first 30% difference between these two treatment 
groups. 
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Table 6.3. Percentage (ABUND) of behaviours in group A (0.5mg/kg ondansetron) and group B (vehicle-amphetamine). Behaviours are listed in order 
of their contribution (di) to the average dissimilarity d(= 36.80) between the two groups, with a cut-off when the cumulative % contribution (Idi%) 
to d reaches 30%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) a(i)/SD(di) Idi% 
10 loco+p 0.78 0.11 .63 .41 1.54 1.72 
40 loco+p 0.11 0.78 .61 .39 1.56 3.37 
40 loco 0.67 0.11 .55 .43 1.28 4.87 
65 loco 0.22 0.67 .52 .44 1.18 6.27 
60 head-d 0.67 0.22 .52 .43 1.19 7.67 
65 head-s 0.67 0.22 .51 .43 1.19 9.06 
70 head-s 0.67 0.22 .51 .43 1.19 10.44 
85 head-d 0.67 0.33 .49 .45 1.10 11.77 
75 head-s 0.67 0.33 .49 .44 1.10 13.10 
15 loco+p 0.78 0.44 .47 .45 1.04 14.38 
85 still 0.56 0.11 .47 .44 1.07 15.66 
80 loco+p 0.44 0.89 .47 .44 1.07 16.93 
80 still 0.56 0.11 .47 .44 1.07 18.20 
30 loco+p 0.44 0.78 .46 .44 1.04 19.46 
65 head-d 0.67 0.44 .46 .45 1.02 20.72 
70 head-d 0.67 0.44 .46 .45 1.02 21.97 
75 head-d 0.67 0.44 .46 .45 1.02 23.22 
80 head-d 0.67 0.44 .46 .45 1.02 24.47 
55 head-d 0.56 0.22 .46 .44 1.05 25.72 
85 loco+p 0.44 0.78 .46 .44 1.04 26.97 
60 head-s 0.56 0.22 .45 .43 1.05 28.21 
50 loco+p 0.44 0.67 .45 .44 1.02 29.44 
95 head-s 0.56 0.33 .45 .44 1.00 30.66 
Veh-Amph v 1.0 mg/kg ondansetron. The onset of locomotor activity occurred 
earlier following pre-treatment with 1.0 mg/kg ondansetron, unlike groups treated 
with the two lower doses of ondansetron, pre-treatment with 1.0 mg/kg did not 
result in a decrease in pausing during locomotor bouts. Animals pre-treated with the 
maximum dose of ondansetron showed an increase in Rearing against the Wall 
during the early session intervals, unlike other treatment groups, a small 
proportion of animals continued to Rear in the Open throughout the 105. minute 
test session. Pre-treatment with 1.0 mg/kg resulted in increased Head-Swaying 
behaviour between session intervals 60-65 min, thereafter Head-Swaying 
occurred in fewer animals than in the vehicle-amphetamine treatment group. Pre-
treatment with 1.0 mg/kg ondansetron also resulted in an increase in Head-Down 
posture (snout contact) between session intervals 35-65 min. Table 6.4 shows the 
results of the SIMPER analysis. An increase in locomotor activity early in the test 
session, and a decline in locomotor activity between session intervals 65-100 min 
contributed to the first 30% difference between the two treatment groups. In 
addition, an increase in Head-Down (snout contact) and Head-Swaying between 
session intervals 65-70 min and a subsequent decrease in both these behaviours in 
the final 20 minutes of the test session contributed to the first 30% difference 
between these two groups. 
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Table 6.4. Percentage (ABUND) of behaviours in group A (I.Omg/kg ondansetron) and group B (vehicle-amphetamine). Behaviours are listed in order 
of their contribution (di) to the average dissimilarity d(= 38.76) between the two groups, with a cut-off when the cumulative % contribution (Zdi%) 
to d reaches 25%. 
TIME BEHAVIOUR ABUNDA ABUNDB d(i) SD(di) d(i)/SD(ai) Zdi% 
95 loco+p 0.22 0.89 .64 .42 1.54 1.65 
95 still 0.78 0.11 .64 .42 1.54 3.31 
65 loco 0.00 0.67 .61 .44 • 1.38 4.87 
105 head-d 0.22 0.67 .53 .45 1.18 6.24 
65 still 0.56 0.00 .51 .46 1.09 7.55 
15 loco+p 0.89 0.44 .50 .47 1.07 8.83 
105 head-s 0.44 0.89 .50 .46 1.07 10.11 
100 loco+p 0.44 0.89 .49 .46 1.07 11.37 
100 still 0.56 0.11 .49 .46 1.07 12.63 
10 loco+p 0.56 0.11 .48 .45 1.07 13.87 
75 still 0.56 0.11 .48 .45 1.07 15.11 
85 still 0.56 0.11 .48 .45 1.07 17.57 
75 loco+p 0.44 0.78 .47 .45 1.04 18.81 
85 loco+p 0.44 0.78 .47 .45 1.04 20.02 
100 head-s 0.44 • 0.67 .47 .46 1.02 21.23 
5 sniff 0.44 0.67 .47 .46 1.02 22.44 
65 head-s 0.56 0.22 .46 .44 1.05 23.64 
65 head-d 0.56 0.44 .45 .45 1.00 24.84 
70 head-d 0.56 0.44 .45 .45 1.00 26.01 
85 head-s 0.44 0.44 .45 .45 1.00 27 .18 
6.4 Discussion 
In agreement with previous reports (Costall et al, 1987; Van der Hbekand 
Cooper, 1990) ondansetron failed to reduce the total distance moved over the 105 
minute test session following peripheral administration of amphetamine. 
Interestingly, administration of a 5HT3 antagonist 30 minutes before peripherally 
administered amphetamine was not entirely without effect. All doses of ondansetron 
tested tended to increase locomotor behaviour in the first 45 minutes of the session 
in an inverse dose-related manner, although this increase in activity was not 
significant at the time of peak drug action, differences between the means approached 
significance. It is apparent that ondansetron administered at a dose between 0.1-1.0 
mg/kg facilitated the expression of locomotor activity 30-60 minutes following 
administration of amphetamine. These findings are somewhat in contrast to the action, 
of peripherally administered ondansetron (0.1-1.0 mg/kg) on amphetamine 
administered directly to the nucleus accumbens, which significantly reduced 
hyperactivity over a 100 minute test period 
More notably, in the latter half of the test session animals pre-treated with 
0.1-1.0 mg/kg ondansetron showed a significant reduction in the distance moved 
during each of the session intervals. Perhaps of greatest interest is the effect of 
ondansetron (0.05-1 .Omg/kg) on length 4 trips. In common with the atypical 
antipsychotics, clozapine and sulpiride, tested within this animal model, ondansetron 
failed to reduce the thigmotaxic perimeter circling associated with hyperactivity. In 
marked contrast to clozapine and sulpiride, ondansetron (0.5mg/kg) succeeded in 
potentiating the proportion of length 4 trips during session intervals 40-45 
minutes and at 55 minutes, an increase unlikely to be related to a general increase 
in locomotor activity as during these session intervals locomotor activity was 
declining toMevels below those exhibited by vehicle-amphetamine treated animals. 
One explanation for the increase in thigmotaxic patrolling seen following pre-
treatment with an intermediate dose of ondansetron is that a decline in locomotor 
activity caused by possible 5HT3 receptor antagonism may allow latent stereotyped 
behaviours to be elicited. This appeared to be manifest initially as an increase in 
Ondansetron 1 
stereotyped forms of locomotion, whicfi was followed by an increase in head-swaying 
behaviour, and finally resulted in an increase in head-down posture (snout contact) 
during the final part of the test session. It would appear that amphetamine animals 
pre-treated with ondansetron at a dose between 0.1 -I.Omg/kg exhibit an increase 
in some forms of stereotyped behaviours which appear sequentially, firstly as a 
decrease in pausing resulting in increased levels of locomotion, followed by a short 
period in which the locomotor route taken by the animal became increasingly 
stereotyped, then locomotor activity diminished, to be replaced by head-swaying 
behaviour, and finally the head posture of the animal changed and the snout dropped 
to make contact with the floor surface of the open field. The blockade of a 51-IT 
facilitatory effect on locomotor behaviours, may allow other subtypes of 5HT 
receptors to exert a greater influence on dopamine mediated behaviours. For 
example, head swaying is mediated by both 5HT1a receptors and striatal dopamine 
(see Curzon, 1990), and it seems that this behaviour is 'unmasked' following 5HT3 
antagonism of an amphetamine-induced locomotor response. 
The effect of 5HT receptors on locomotor behaviours is complex and 
experimental findings have often been contradictory. Evidence supports either a 
facilitatory or inhibitory action. For example 5HT receptor antagonists have been 
shown to potentiate dopamine-induced locomotor behaviour (Dourish, 1982), or 
inhibit dopamine dependant locomotion (Warbritton et al, 1978; Jones et al, 1981). 
5HT3 antagonists have been clearly shown to block amphetamine-induced locomotion 
when amphetamine is administered solely to the nucleus accumbens. A more general 
distribution of amphetamine within brain structures appears to allow for more 
complex interactions between 5HT and dopamine to influence response output. It is 
interesting to note that at higher doses many 5HT3 receptor antagonists show 
reduced effectiveness, resulting in a bell shaped dose response curve (Costall et al, 
1990). The reasons for the loss of activity are not clear but Elarnes et al, (1992) 
speculate that the loss may be a consequence of additional pharmacological 
interactions, a view entirely consistent with the speculation that changinjg 5HT3 
'tone' on locomotor behaviours may allow other 5HT-dopamine interactions to 
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influence beliaviour. In the current study the bell shaped dose response curve which 
has been reported by several researchers was clearly evident. Animals pre-treated 
with the lowest dose of ondansetron (0.05mg/kg) showed no significant effect on 
amphetamine-induced behaviours, whilst animals treated with the highest dose of 
ondansetron showed less effect on amphetamine-induced behaviours than animals 
treated with an intermediate dose of 0.1 - 0.5 mg/kg ondansetron. Van der Hoek and 
Cooper (1990) found no effect following pre-treatment with 0.03 mg/kg 
ondansetron in animals treated with 3 mg/kg amphetamine and this would agree with 
the present findings in which a similar dose (0.05mg/kg) had no significant effect 
on amphetamine-induced behaviours. 
Examining locomotor behaviour in greater detail has provided evidence that 
although the net amount of amphetamine-induced hyperactivity does not change, the 
temporal characteristics of locomotion are altered following 5HT3 antagonism. 
Several authors have reported that photocell beam counts fail to detect changes in the 
length of locomotion (Fink and Smith 1979, 1980: Fray et al, 1980; Krsiak et al, 
1970) and this could well account for studies using photocell beam measures of 
locomotor activity failing to detect changes in the locomotor response following 
treatment with ondansetron and peripherally administered amphetamine. The 
current method of measuring locomotion also detected an increase in the stereotyped 
nature of amphetamine-induced locomotion, midway through the test session. Clearly 
further work is required to examine the effect of 5HT3 antagonists on locomotor 
behaviours, although the findings of the present study reinforce the view that the 
study of both the temporal and spatial aspects of amphetamine-induced open field 
locomotion provide a more accurate 'picture' of this behaviour and has the potential 
to detect more subtle changes in the response following pre-treatment with 
compounds which interact with amphetamine-induced hyperactivity. 
Summary 
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This experiment examined the effect of the 5HT3 receptor antagonist, 
ondansetron, on amphetamine-induced behaviours. The findings showed that animals 
pre-treated with ondansetron demonstrated an increase in some forms of stereotyped 
behaviours which appeared sequentially. This was manifest first as a decrease in 
pausing resulting in increased levels of locomotion, followed by a period mid-session 
in which the locomotor route taken by the animal became increasingly stereotyped. 
Finally, locomotor activity diminished to be replaced by an increase in head-swaying 
and head-down posture (snout contact). 
It would appear that latent behaviours are 'unmasked' following 5HT3 
antagonism of an amphetamine-induced locomotor response. This is seen as an 
example of behavioural competition whereby blocking a facilitatory effect of 5HT3 
on a dopamine-mediated behaviour allows other subtypes of 5HT receptors to exert 
a greater influence on amphetamine-induced behaviours. 
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Chapter Seven. 
General discussion and conclusions. 
7.1 Amphetamine-induced stereotyped locomotion. 
The findings of the current series of experiments show that rats given 
amphetamine at doses between 1 and 4 mg/l<g became hyperactive, and that with 
increasing dose, the route tal<en by the animal became perseverative. The 
categorisation of fonward movement into a series of trip-lengths using contrast 
based image analysis, and specially written software (Kenyon, 1991) enabled a 
complete quantification of the distinctive changes that occurred in the spatial 
distribution of locomotion seen under each dose of the drug (see Chapter 3). This is 
in direct contrast to previous research which had been unsuccessful in fully 
quantifying these locomotor changes (eg Lat, 1965; Schiorring, 1979; Mueller et 
al, 1989a, 1989b). In the current series of experiments it was found that 
maximum levels of locomotion were induced following 4 mg/kg amphetamine, and 
that animals given the drug at doses higher than this produced less locomotion. The 
increase in perimeter circling measured as an increase in length 4 trips paralleled 
the increase in hyperactivity, with maximum levels of length 4 trips also observed 
following 4 mg/kg amphetamine. Indicating that contrary to the findings of Mueller 
et al, (1989b) maximum levels of stereotyped locomotion were observed under 4 
mg/kg amphetamine. The proportion of length 4 trips declined in animals given 
amphetamine at the higher dose of 5 mg/kg. 
It is hypothesised that the stereotyped nature of locomotion seen following 
intermediate doses of amphetamine reflects a link be^veen the locomotor output 
mediated by the nucleus accumbens and stereotyped behaviours which are mediated 
by the caudate-putamen. As the dose of amphetamine increases the behavioural 
output of these two systems becomes increasingly antagonistic, and it would appear 
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that stereotyped locomotion, measured as an increase in- length 4 trips, is an 
attempt by the animal to resolve this conflict when the output from the caudate-
putamen is insufficient to override the locomotor activity mediated by the nucleus 
accumbens. 
7.2 Stereotyped locomotion and snout contact. 
Categorisation of the behaviours elicited in rats following administration of 
1-5 mg/kg amphetamine showed that a change in head-posture occurred with 
increasing dose of amphetamine. The head of the rat dropped below a horizontal 
plane until the snout came into contact with the open field floor. This abnormal 
posture was associated with a decline in fonward progression which occurred 
following treatment with the highest doses (4 or 5 mg/kg) of the drug. 
The categorisation of behavioural elements was made in such a way as to 
support the proposed model of locomotion, thus the main interest focused on snout 
contact, rearing and locomotion (see Chapter 5), using an adaptation of the method 
proposed by Fray et al. (1980). An attempt was made to examine the role of snout 
contact on the development of length 4 trips by manipulating contact with the 
surface of the open field by altering the shape of the perimeter. The findings 
indicated that an open field with a circular perimeter wall allowed for the 
development of locomotor activity more quickly, and for peak levels of activity to 
be achieved eariier in the test session, than when these animals were tested in a 
field with a square perimeter wall. 
Despite finding significant differences in locomotion and stereotyped 
locomotion in open fields with different shaped perimeters there was no significant 
difference in any other behaviours measured, although there was some evidence to 
suggest that there was a trend for animals treated with 4 mg/kg amphetamine to 
engage in head-down posture eariier in the circular field. The square wall surface 
periodically broke the animal's snout contact with the floor of the arena. Certainly 
future work should investigate this aspect of behaviour, particulariy in relation to 
the link between snout contact and forward progression. Furthermore, it is clear 
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that an increase in the proportion of length 4 trips associated with amphetamine-
induced hyperactivity was not an artefact of the circular nature of the perimeter 
wall, as dose-related increases in this measure of stereotyped locomotion were 
found in both types of open field. The findings suggest that the unbroken circular 
perimeter wall facilitated the expression of stereotyped locomotion and led to an 
earlier induction of perseverative locomotor routes. 
It is interesting to note that many researchers have reported the influence 
that environment plays in the expression of behaviour following administration of 
amphetamine (eg Oades, 1985; Szechtman, 1982; Robbins et al, 1990). It is 
probable that the differences in locomotor responses seen in different shaped fields 
would not have been detected using conventional photocell beam measures, and was 
detected as a direct consequence of the sensitivity of a contrast based image 
detection system, which tracked the exact position of the animal. 
As a consequence of these studies into the dose response characteristics of 
amphetamine-induced locomotion and stereotyped locomotion it was decided that 4 
or 5 mg/kg of the drug led to a less robust measure of length 4 trips, which was 
readily disrupted by factors such as field shape. Subsequent studies used a dose of 
3.5mg/kg amphetamine. Furthermore, this dose (3.5mg/kg) was close to the dose 
at which maximum levels of locomotion were observed and it was clear that this 
would allow for the detection of a facilitatory or inhibitory effect of drug 
interactions within this model. 
7.3 Interaction of antipsychotic drugs and stereotyped locomotion. 
Treatment with the atypical antipsychotics clozapine and sulpiride 30 min 
before administration of 3.5mg/kg amphetamine had no significant effect on 
measures of stereotyped locomotion, despite showing a considerable capacity to 
reduce amphetamine-induced hyperactivity (see chapter 4). This finding" is in 
agreement with the actions of atypical antipsychotic drugs on other amphetamine-
induced behaviours where they have been shown not to antagonise stereotyped 
behaviours, and in some reports to even potentiate some stereotyped behaviours 
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(Robertson and MacDonald, 1984,1985). In contrast, the classical antipsychotic 
drug haloperidol brought about a marked reduction in both locomotion and 
stereotyped locomotion, again an effect which is entirely consistent with this drug's 
ability to block other amphetamine-induced behaviours. Furthermore, it seems 
unlikely that a decline in length 4 trips following haloperidol was associated with a 
general decline in activity. The dose of amphetamine was chosen specifically to 
•ensure that not all hyperactivity was eliminated following pre-treatment.with 
antipsychotic drugs, and that the locomotion remaining following pretreatment 
with haloperidol showed a noticeable decline in the proportion of length 4 trips in 
marked contrast to equivalent levels of locomotion following pretreatment with 
both clozapine and sulpiride, which remained stereotyped in nature. 
In addition to focusing attention on dopamine receptor antagonists with 
established antipsychotic action it was necessary to examine the action of putative 
antipsychotic agents within the proposed model system. It is increasingly evident 
that many non-dopaminergic compounds have antipsychotic potential, and serotonin 
(5HT) as well as dopamine influences the behavioural response following 
treatment with amphetamine. Many 5HT antagonists are known to block 
amphetamine-induced hyperactivity, and this is often seen as support for their 
antipsychotic potential (see Chapter 6). Currently much interest has focused on 
the influence of 5HT3 receptors on hyperactivity seen following stimulation of the 
mesolimbic system with either dopamine or amphetamine (Costall et al. 1987). A 
5HT3 antagonist seemed an appropriate drug with which to further examine the 
potential of this proposed model system, particularly as a 5HT3 antagonist 
(ondansetron) had been found to antagonise hyperactivity following direct 
administration of amphetamine into the mesolimbic system but not following 
peripheral administration of amphetamine (Costall et al, 1987, Van der Hoek and 
Cooper, 1990). 
A study examining the effects of the 5HT3 antagonist ondansetron on 
hyperactivity and stereotyped locomotion following intra-peritoneal injection of 
amphetamine was able to shed light on some of these paradoxical findings and at the 
General Discussion 1 
same time provide support for tine claim that this model system provides a more 
sensitive and complete measurement of locomotor activity, providing information 
not detectable using conventional photocell beam measures. 
The results showed that pre-treatment with ondansetron facilitated 
locomotor activity early in the test session resulting in a decline in pausing and 
potentiated stereotyped locomotion, this drug was also found to increase head 
swaying and the head down posture seen following treatment with higher doses of 
amphetamine but rarely seen in animals treated with 3.5 mg/kg amphetamine. The 
D2 specific antagonist, sulpiride, was also found to potentiate head swaying and the 
head down posture adopted by amphetamine treated animals, confirming other 
reports that sulpiride potentiates some aspects of amphetamine-induced 
stereotyped behaviour ( Robertson and MacDonald, 1985; Sharp et al, 1986). 
The current studies have shown that locomotion is not a unitary behaviour, 
rather it is a complex phenomenon which changes both quantitatively and 
qualitatively following treatment with amphetamine, and has the capacity to become 
stereotyped in a manner similar to other behaviours which are seen to 'fragment' 
following treatment with amphetamine. 
It is hypothesised that the measurement of increases in locomotion and 
stereotyped locomotion can be seen as a model of both raised mesolimbic and 
caudate-putamen function and as such has the capacity to identify drugs which 
interact with either one or both of these systems. Drugs which fail to antagonise the 
stereotyped aspects of amphetamine-induced locomotion, despite a marked 
capability to reduce locomotion are most likely to have a reduced capacity to induce 
extrapyramidal side-effects. Further work is clearly required to examine the 
nature of open field hyperactivity following direct intracerebral administration of 
either amphetamine or dopamine to various regions particularly the nucleus 
accumbens, amygdala, and caudate-putamen. Fink and Smith (1980) suggest that 
amphetamine-induced locomotor activity depends on the 'mass action' of the central 
dopamine systems whilst Kelly and Moore (1976) produced a behaviour analogous 
to stereotyped locomotion by unilateral depletion of dopamine from the head of the 
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caudate, which determined the direction of rotation of locomotion in amphetamine 
treated rats whilst depletion of dopamine from the nucleus accumbens determined 
its rate. This is similar to the current proposal that stereotyped aspects of 
amphetamine-induced locomotion depend on both structures. Robbins et al, 
(1990), describe an interesting unpublished study whereby they injected 
amphetamine into the nucleus accumbens and the head of the caudate-putamen and 
compared a full dose to either structure with half the dose administered to both 
structures. Their findings are similar to those of the current investigation in that 
the strongest effects were obtained when amphetamine was administered to both 
structures and the behaviours which seemed to be most affected were head swaying, 
head down posture and locomotion. It would be interesting to examine the effects of 
combined nucleus accumbens and caudate-putamen bilateral micro injection on 
components of unconditioned behaviour, particularly with respect to the spatial 
distribution of open-field locomotion as described in the present model system. 
Another explanation for the finding that both ondansetron and sulpiride 
bring about a reduction in amphetamine-induced locomotion whilst at the same 
time increasing the amount of stereotyped head behaviours, and in the case of 
ondansetron, potentiating the stereotyped nature of locomotion for a short period 
before stereotyped head movements were induced, could be that pre-treatment with 
either of these drugs brings about a leftwards shift of the behavioural dose 
response curve. 
Figure 7.1(a) shows the behavioural dose response curve for 3 to 5 mg/kg 
amphetamine, and (b) for each intermediate dose of antipsychotic tested. The 
behavioural profile seen in animals given 3.5mg/kg amphetamine and pre-treaited 
with either ondansetron or sulpiride resembles the behavioural profile of animals 
given a higher dose of amphetamine. Certainly the profile of animals pre-treated 
with 20mg/kg sulpiride (see Figure 7.1b) is very similar to that of animals 
treated with the higher dose of 5mg/kg amphetamine (see Figure 7.1a). Sharpe et 
al, (1986) argue that the prolongation of the dopamine releasing effects of 
amphetamine following pretreatment with sulpiride does not correspond to that of a 
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Figure 7.1 
(a) Behaviours elicited in rats treated with saline (SAL) or 3 -
5mg/kg amphetamine. 
(b) Behaviours elicited in rats treated with an intermediate 
dose (see chapters 4 & 6) of haloperidol (HAL), Clozapine (CLOZ), 
Ondansetron (OND), or sulpiride (SULP). 
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higher dose of amphetamine. Findings from the current investigation suggest that 
this may well be the case, indicating that the behavioural effects of amphetamine-
treated rats pre-treated with sulpiride or ondansetron represent a change in the 
relative outputs of the ventral and dorsal striatum rather than a blocking of 
behaviour per se. 
The current series of experiments examined the interaction of antipsychotic 
drugs on rats given 3.5mg/kg amphetamine. At this dose both maximum levels of 
locomotion and perseverative locomotor routes were observed. Thus an 
enhancement of the effects of amphetamine led to stereotyped head behaviours. 
Treatment with a lower dose of amphetamine (eg 2mg/kg), where perseverative 
locomotor routes are minimal, may possibly lead to induction of stereotyped 
locomotion, resulting in an increase in the proportion of length 4 trips. 
Treatment with the low dose of 5mg/kg clozapine prior to 3.5mg/kg 
amphetamine did in fact lead to an increase in both locomotion and length 4 trips 
for some of the session intervals, reinforcing the view that these antipsychotic 
drugs enhance, rather than block, the action of amphetamine. 
7.5 Proposal for future studies not adequately addressed by the 
current investigation. 
Temporal aspects of contrast based image analysis: The animal model of 
amphetamine-induced unconditioned behaviour has focused on the spatial 
characteristics of open-field locomotion yet personal observations have noted that 
temporal aspects of locomotor behaviour are an important component of the 
amphetamine response and readily manipulated by drug treatment. Direct 
observation and classification of locomotor behaviour into ambulation which 
occurred continuously and forward progression which occurred with frequent 
pauses lasting longer than 3 seconds, showed quite clearly that pre-treatment with 
ondansetron significantly reduced pausing between bouts of locomotion early in the 
test session. The classification of locomotor behaviour by direct observation is 
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somewhat unsatisfactory. An aim of the present investigation was to incorporate 
measures of temporal, in addition to spatial, aspects of amphetamine-indliced 
locomotor behaviour using contrast based image analysis, time did not permit 
analysis of temporal measures derived from the tracking system. Furthermore, 
rats were unavailable for further studies although much of the information 
required to undertake this task had already been collected and was stored both on 
video tape and on computer. The future development of trip lengths as a measure of 
stereotyped locomotion should attempt to quantify both the temporal and the spatial 
aspects of the behaviour. Paulus and Geyer (1991) found that both temporal and 
spatial scaling exponents used to assess the acute behavioural effects of various 
psychoactive substances on unconditioned motor behaviour provided a dose-
dependent, sensitive and distinctive 'fingerprint' for each of the substances tested. 
Personal observations in the present series of experiments suggest that temporal 
aspects of interactions between antipsychotic drugs and amphetamine-induced 
locomotion do indeed discriminate drugs. 
Snout contact: Past work in our laboratory (Kenyoh et al, 1981, 1983) examined 
the disruption of maternal retrieving in rodents following perioral anaesthesia. 
These authors injected lidocaine into the mystacial pads of rats. The mystacial pads 
are an area of the snout innervated by the infra-orbital nerve (Greene, 1955; 
Vincent, 1912, 1913), which is a principal branch of the trigeminal nerve 
serving the snout and lips, and consists of the external nasal and superior labial 
branches of the trigeminal nerve, which innervate the side of the nose, the snout 
and the lips (Greene, 1955). Injection of lidocaine into the mystatial pads renders 
the snout anaptic (Thor and Ghisselli, 1975). The majority of the cells in the main 
sensory nucleus of the trigeminal system send their axons to the contralateral side 
of the brain where they join with the medial lemiscus and terminate in the medial 
part of the ventral posterior medial nucleus of the thalamus (see Kelly, 1985). 
This proprioceptive information serves as the initial step in generating a sensory 
perception of the world, whereby these perceptions from several sensory systems. 
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including that outlined above, are integrated and related to higher motor 
behaviours. 
The work of Teitelbaum et al, (see Cooper and Dourish, 1990) has shown 
that apparently unrelated stereotyped acts produced by apomorphine in rats consist 
of a mixture of snout contact, forward progression and turning and are established 
as a result of changing levels of these three behaviours. 
Future work sets out to extend these findings and examine the relationship 
between forward progression, turning and snout contact on the development of 
amphetamine-induced behaviours particularly in relation to locomotion and 
stereotyped locomotion. 
The procedure adopted by Kenyon et al, (1981, 1983) of inducing perioral 
anaesthesia by injecting lidocaine into the mystacial pads could be adapted for use 
in the study of the interaction of snout contact and forward progression following 
treatment with amphetamine. Experiments would be conducted to examine the 
function of sensory input from the snout area via the trigeminal system on the 
development of locomotion and turning behaviour following treatment with 
amphetamine. The development of amphetamine-induced hyperactivity could be 
assessed following unilateral or bilateral injection of lidocaine into the mystacial 
pads of the rat prior to treatment with amphetamine. 
Construct validity: In the introduction (section 1.3) it is proposed that animal 
models which address issues of predictive, face and construct validity offer a better 
way forward in the development of models of schizophrenia (see Ellenbroek and 
Cools, 1990). Despite this claim the present study has failed to examine the 
construct validity of the proposed model system and has examined only problems 
relating to the reliability, predictive and face validity of amphetamine-induced 
locomotion and stereotyped locomotion. Clearly future studies should attempt to 
examine the underlying constructs relating to open-field measures. The 
environmental stimulus provided by placing animals in an open field following 
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treatment with amphetamine could be examined in terms of both 'stress' and 
'exploration'. 
There is evidence that stressful environmental conditions produce 
stereotypy in laboratory animals (Meyer-Holzapel, 1968; Ridley and Baker, 
1982; Fentress, 1983), although Robbins et al, (1990) argue that stereotyped 
behaviours are most likely to be elicited under conditions involving high levels of 
arousal having no external focus or cause. For example, exposure to stressors such 
as electric shock or changes in temperature do not appear to lead to stereotyped 
behaviour whereas treatments such as rearing or housing in isolation, mild tail 
pinch and even amphetamine all lead to the induction of stereotyped behaviour yet 
lack strong exteroceptive properties. 
It is important to develop an understanding of schizophrenia alongside 
models which include genetic and environmental factors which pre-dispose an 
individual to the chemical imbalance which is suggested to be the neurological 
correlate of psychosis. Antelman et al, (1980) propose that stress is an important 
aspect in any model of schizophrenia, including amphetamine. Therefore the aim of 
future research into open-field locomotion would examine the effect of stress on 
the spatial distribution of open-field locomotion. It is likely that contrast based 
image analysis has the capacity to detect subtle changes in open-field locomotor 
activity which would be missed using photocell beam measurement techniques. 
Several researchers (eg Sahakian et al., 1975; Sahakian and Robbins 
1977)have used animals reared in isolation as a model of raised dopamine function, 
therefore it would be possible to compare open field measures obtained from 
socially isolated animals with animals administered amphetamine. 
Serotonin and dopamine: The current study examined the effects of a 5HT3 
antagonist (ondansetron) on amphetamine-induced open-field locomotor behaviour. 
The findings of this study indicated that 5HT involvement in locomotor activity 
induced by amphetamine is complex and that blocking a 5HT3 synergistic effect on 
dopamine may allow other 5HT receptor mediated behaviours to be expressed. 
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Certainly 5HT1A receptors in addition to dopamine are known to be involved in head 
swaying (Luki et al, 1984), a behaviour which in the current investigation was 
shown to increase following antagonism of 5HT3 sites by ondansetron. Head swaying 
is known to significantly decrease following 6-OHDA lesions to the substantia 
nigra, ventral tegmentum and striatum but not the nucleus accumbens, suggesting 
that 5HT-dependent stereotyped head swaying is also dependent on dopamine 
(Andrews et al, 1982). Both SHTIa and 5HT1b agonists have anxiolytic and anti-
aggressive properties and there is some evidence to suggest that in combination 
they may have antipsychotic properties, particularly if administered with a D2 
blocking antipsychotic treatment such as sulpiride (see Gerlach, 1991). As both 
agonists and antagonists are available for 5HT1a receptors (see review by 
Middlemiss and Tricklebank, 1992, Luki, 1992), it may be fruitful to explore the 
effects of these in addition to studies involving 5HT3 and D2 receptor antagonism 
within this proposed model system. 
7 .6 C o n c l u s i o n s 
The experiments reported in this thesis (Chapters 3-6), provide 
convincing evidence that contrast based image analysis of drug-induced locomotion 
coupled with direct observation of behaviour analysed in terms of its similarity 
matrix (Clarke, 1993) is a powerful model of amphetamine-induced behaviours, 
which afford a detailed and integrated picture of the amphetamine response in 
rodents. 
It is proposed that measures which encompass this complexity will have 
greater utility in the study of drug interactions with amphetamine-induced 
behaviours. The findings relating to antipsychotic drug action and locomotion are 
interesting in that they have shown that stereotyped aspects of locomotion can be 
dissociated from locomotion by different classes of antipsychotic drug, supporting 
the claim that measures of stereotyped locomotion, for example length 4 trips, 
have the potential to be developed as an animal model of locomotor activity which 
will identify unsatisfactory antipsychotic drugs which have the capacity to 
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antagonise stereotyped locomotion and are therefore likely to produce 
extrapyramidal side effects. This model system is simple in that it is fully 
automated and measures a single behaviour (locomotion), which has been accepted 
by the majority of researchers as a model of raised mesolimbic dopamine activity 
and therefore a better animal model for schizophrenia and for the detection of 
dopamine receptor antagonists which are antipsychotic agents, without 
extrapyramidal side effects. 
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Glossary 
A c e t y l c h o l i n e A neurotransmitter, found in autonomic ganglia, 
postganglionic parasympathetic nerve terminals, the neuromuscular junction, the 
adrenal medulla, the central nervous system (CNS) and postganglionic sympathetic 
nerve terminals at sweat glands. Drugs which mimic the actions of acetylcholine 
are cholinomimetics and drugs which prevent the action of acetylcholine are called 
anticholinergics. Receptors are known as Muscarinic and Nicotinic. 
A d e n y l a t e c y c l a s e An effector enzyme regulated by G proteins which catalyses 
the production of the secondary messenger, cyclic 3'5-adenosine monophosphate 
(cyclic AMP) . 
A l p h a - m e t h y l - p a r a - t y r o s i n d s used experimentally to inhibit tyrosine 
hydroxylase, and thus to prevent the synthesis of all the catecholamines 
(noradrenalin, dopamine and adrenalin). 
( H - ) - A m p h e t a m i n e I s a potent dopamine-releasing substance. 
A p o m o r p h i n e Is a direct dopamine-receptor agonist. 
B e n z a m i d e s The substituted benzamides are a relatively new class of antisychotic 
drugs, chemically related to the antiemitic metoclopromide. The parent substance 
is procainamide. 
B e n z o d i a z e p i n e s A group of chemically related hypnotics, sedatives, 
anxiolytics and anticonvulsants, eg Diazepam. 
B u t y r o p h e n o n e A class of antipsychotic drugs not possessing tricyclic 
structure, chemically related to pethidine. These include, haloperidol, benperidol 
and droperidol. 
C a f f e i n e A powerful CNS stimulant, which blocks the action of adenosine 
receptors which are located on cell membranes in the CNS and peripheral nervous 
system. 
C h l o r p r o m a z i n e An antipsychotic drug which is the prototype of the 
phenothiazines. In addition to its antipsychotic action it possesses cardiovascular 
effects, anti-emetic action, induction of catatonia, and blocking of conditioned 
avoidance responses. Chlorpromazine also produces iatrogenic parkinsonism, an 
unwanted side effect of this drug. 
C h o l e c y s t o k i n i n ( C C K ) A neuroactive peptide which acts as a 
neurotransmitter. C C K has a heterogeneous distribution in the mammalian CNS, 
with a very high concentration in the cerebral cortex, hippocampus, the amygdala 
and septum. Significant amounts are also found in the hypothalamus, dorsal raphe 
nucleus, the caudate-putamen and ventral tegmentum. 
C l o z a p i n e Is a dibenzazepine with a tricyclic structure, having a piperazine 
sidechain. Clozapine does not cause cataleptic activity in animals and does not 
produce extrapyramidal side effects in man. Clozapine produces agranulocytosis in 
some patients. 
C y c l i c A M P A second messenger, which leads to the activation of kinases by 
phosphorylation. The phosphorylated kinases alter the activity of enzymes and 
structural proteins leading to cellular response. 
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D i b e n z a z e p i n e s Antipsychotic drugs with a tricyclic structure, although the 
centre ring differs from that of the phenothiazines and thioxanthines. The principle 
drug of this class is clozapine. 
D o p a m i n e A catecolamine neurotransmitter in the CNS and at some ganglia in 
the autonomic nervous system. Dopamine is a precursor of noradrenaline and 
adrenalin. Dopamine is made from the amino acid L-tyrosine which is hydroxylated 
by the enzyme tyrosine hydroxylase to L-dopa. 
D o p a m l n e - B e t a - h y d r o x y l a s e Dopamine is hydroxylated to form 
noradrenalin (norepinephrine) by the enzyme dopamine-beta-hydroxylase, which 
is associated with noradrenalin storage vesicles. It is a copper containing enzyme 
which requires molecular oxygen and ascorbic acid as a cofactor. 
F l u p h e n a z i n e An antisychotic drug of the phenothiazine class, possessing a 
piperazine sidechain. Amongst the most powerful of antipsychotic drugs,, however, 
fluphenazine has marked anti-emetic function and readily produces extrapyramidal 
side effects. 
G i u t a m a t e A dicarboxylic amino acid, associated with a number of metabolic 
processes within the cell. It is an important constituent of the diet. L-glutamic acid 
which is known to act as a neurotransmitter can be synthesised from glutamine by 
phosphate-activated glutaminase. 
G r a n i s e t r o n A potent 5-HT3 antagonist. 
H a i o p e r l d o l A n antisychotic drug of the butyrophenone class. Haloperidol lacks 
sedative properties, but has a marked propensity to cause extrapyramidal side 
effects. 
H o m o v a n i l i c a c i d (HVAy\ major metabolite of dopamine. 
K e t a n s e r i n A 5-HT2 antagonist. 
L - d o p a The precursor of dopamine. The rate limiting step in the synthesis of 
dopamine is the conversion of tyrosine into L-dopa. L-dopa is actively taken up into 
dopamine neurones in the CNS. where it is converted into dopamine by DOPA 
decarboxylase. 
L y s e r g i c a c i d d ie thy lamine (LSD) LSD is an ergot alkaloid which acts as a 
dopamine agonist It is a non-selective antagonist at 5-HT2 receptors. 
WIDE (Eve) An amphetamine derivitive. 
M D M A ( E c s t a s y ) (Methylenedioxymethamphetamine). An amphetamine 
derivative. 
2 - m e t h y l - 5 - H T A 5-HT3 agonist. 
M o r p h i n e An agonist at the mu-opiate receptor, distributed with particular 
high density in the brainstem, trigeminal nuclei, spinal cord, periaqueductal grey 
region, caudate-putamen, amygdala and cerebral cortex. 
M u s c a r i n i c R e c e p t o r s One of the two main types of cholinergic receptor. 
Muscarine was found to mimic the effect of parasympathetic-nerve stimulation, 
and the receptors on neuroeffector tissues with a parasympathetic nerve supply 
are known as muscarinic receptors. 
N e u r o t e n s i n (NT)ls a 13 amino acid residue peptide which was originally 
identified as a potent vasodilator. Areas of high concentration include the 
hypothalamus, basal ganglia, the interstitial nucleus of the stria terminalis, the 
limbic system and the dorsal region of the spinal cord. NT is proposed as having a 
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close association with dopamine neurones and the peptide can modify the effects of 
dopamine agonists on. motor activity. It has been suggested to exhibit a modulatory 
function in the mesolimbic system. 
Nicotinic Receptors. One of the two main types of cholinergic receptor. Nicotine 
mimics acetylcholine at ganglia in the autonomic nervous system, at the adrenal 
medulla and in parts of the CNS. 
Noradrena i in Noradrenalin (norepinephrine, norarternol) is a 
catecholamine neurotransmitter in post ganglionic sympathetic nerves and the C N S . 
Noradrenalin is released from the adrenal medulla. 
6-hydroxydopamlne (6-OHDA) Is a neurotoxin which is selectively 
taken up into catecholaminergic neurones. It causes degeneration of the neurones 
and is used experimentally to make selective lesions in neuronal systems which use 
catecholamines as neurotransmitters. 
Ondansetron (GR 38032F) A potent selective 5-HT3 antagonist. 
Phenothiazines The first agent to be successfully used as an antipsychotic 
agent (chlorpromazine) .The phenothiazines have a wide range of pharmacological 
actions which include antihistamine action, weak antagonism of 5-HT and 
acetylcholine. 
Phencyclidine (PCP) Commonly known as angre/dusf it is an antagonist at 
glutamate NMDA receptors. These are found in the hippocampus, basal ganglia, 
limbic system cerebral cortex, superior colliculus and vestibular nuclei. 
Phosphodiesterase Enzyme which when inhibited leads to effects similar 
to beta-adrenoceptor stimulation. 
Raclopr ide A substituted benzamide like sulpiride, but more potent and causing 
less prolactin riease. 
Reserpine Rauwolfia derivitive. Reduces sympathetic tone by noradrenalin 
depletion. Depletes brain noradrenalin, dopamine and 5-HT. Used in the treatment 
of hypertension and as an antipsychotic. Induces parkinsonism. 
Savoxepine A novel tricyclic compound with a higher affinity for hippocampal 
D2 than striatal D2 receptors. 
Scopolamine A psychedelic drug which acts by blocking post synaptic 
acetylcholine receptors. 
Serotonin (5-HT) 5-hydroxytryptamine (5-HT, serotonin) is a 
neurotransmitter in the CNS and in the myenteric plexus of the gut. 5-HT is a 
monoamine synthesised from the aromatic amino acid L-tryptophan, which is 
hydroxylated to 5-hydroxytryptophan by the enzyme tryptophan hydroxylase, 
found only in the cytoplasm of 5-HT neurones, and is the rate limiting enzyme in 
the synthesis of 5-HT. 
S u l p i r i d e One of the substituted benzamides. When tested in animals sulpiride 
shows only part of the spectrum of activity common to most antipsychotics, and was 
classed as an 'atypical' antipsychotic. The drug does not induce catalepsy in animals 
and does not antagonise the stereotyped behavioural effects of amphetamine and 
apomorphine. Sulpiride does produce Parkinson-like effects but these appear to be 
less than with other antipsychotic drugs. 
Th ior idaz ine An antipsychotic drug of the phenothiazine class, having a 
piperidine sidechain. This drug produces more sedative activity than the other 
phenothiazines and is claimed to produce fewer extrapyramidal side effects. 
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